Datasets:
ChatDOC
/
OCRFlux-pubtabnet-single

Dataset card Data Studio Files Community
image_name
stringlengths
68
68
type
stringclasses
2 values
gt_table
stringlengths
116
12.6k
c3bebfcb3faeaa222e62fb294fefc2e8cdbb21c1273918639ea5b65ca6e9e84d.png
simple
<table><tr><td>Gene</td><td>Forward primer</td><td>Backward primer</td><td>Size (bp)</td></tr><tr><td>GAPDH</td><td>GGTCGTATTGGGCGCCTGGTC</td><td>TGACGGTGCCATGGAATTTGCCA</td><td>148</td></tr><tr><td>KIFC1</td><td>TCTCTGGGTGGTAGTGCTAAGA</td><td>TAAGTCACTTCCTGTTGGCCTG</td><td>148</td></tr><tr><td>SOX4</td><td>GACCGGGACCTGGATTTTAACT</td><td>TGAAAACCAGGTTGGAGATGCT</td><td>133</td></tr><tr><td>PBX2</td><td>AAGTTCCAAGAGGAGGCAAACA</td><td>TCCTGAGAGATTGAAAGAGCCG</td><td>132</td></tr><tr><td>ESRRG</td><td>GCTATCCTGCAGCTGGTAAAGA</td><td>GCTATCCTGCAGCTGGTAAAGA</td><td>133</td></tr><tr><td>KDM5B</td><td>CCCTCAGACACATCCTATTCCG</td><td>CAGTCCACCTCATCTCCTTCTG</td><td>101</td></tr><tr><td>PTGS2</td><td>TGTATCCTGCCCTTCTGGTAGA</td><td>AAGGAGAATGGTGCTCCAACTT</td><td>85</td></tr><tr><td>EFNA1</td><td>GTGGCAAAATCACTCACAGTCC</td><td>CTATGTAGAACCCGCACCTCTG</td><td>91</td></tr><tr><td>BCL2</td><td>AGGATTGTGGCCTTCTTTGAGT</td><td>CGGTTCAGGTACTCAGTCATCC</td><td>113</td></tr><tr><td>SMAD4</td><td>TGTTGATGACCTTCGTCGCTTA</td><td>ATGCTCTGTCTTGGGTAATCCG</td><td>81</td></tr><tr><td>PHACTR3</td><td>TATGACAGGAGGGCAGACAAAC</td><td>GCTTGCTTGATGCATGTACCTC</td><td>118</td></tr><tr><td>C13orf27</td><td>TCAGGCTCAGCAGATGAAATGT</td><td>TCCAGTGGATTTTATGGGGAGC</td><td>85</td></tr><tr><td>PMEPA</td><td>CTGAGCCACTACAAGCTGTCTG</td><td>CTTCTGAGGACAGGGCATCTTC</td><td>85</td></tr><tr><td>OXGR1</td><td>ATCTTGAGGGTCATTCGGATCG</td><td>TGTCGCTGACCACCACATATAG</td><td>148</td></tr><tr><td>GPNMB</td><td>GTCACTGTGATCTCCCTCTTGG</td><td>TTTGCACGGTTGAGAAAGACAC</td><td>116</td></tr></table>
bbbeb327c6a6d4d78e31f169f0b5473609293e588a65fead99193a73f689b576.png
complex
<table><tr><td>Predictors</td><td>OR</td><td colspan="2">95% CI</td><td><i>p</i>-Value</td><td>Nagelkerke R<sup>2</sup></td></tr><tr><td>Perceived benefits of HSIV:</td><td></td><td colspan="2"></td><td></td><td rowspan="6">0.631</td></tr><tr><td>HSIV can prevent children from catching Influenza</td><td>2.367</td><td colspan="2">(1.272, 4.404)</td><td>0.007</td></tr><tr><td>Perceived barriers of HSIV:</td><td></td><td colspan="2"></td><td></td></tr><tr><td>The HSIV will cause unknown side effects to children</td><td>0.321</td><td colspan="2">(0.149, 0.691)</td><td>0.004</td></tr><tr><td>Motivating factors of vaccination taking:</td><td rowspan="2">3.675</td><td rowspan="2" colspan="2">(1.745, 7.742)</td><td rowspan="2">0.001</td></tr><tr><td>You would be more willing to give your children HSIV shots if the injection was cheap</td></tr></table>
48cf0b821dd67ebe2b979e947ca82e4911daf27845b6836fbb674220a8f8f563.png
simple
<table><tr><td></td><td>Desmopressin (n = 45)</td><td>Control (n = 45)</td><td><i>P</i></td></tr><tr><td>Propofol (mg)</td><td>830 (195)</td><td>780 (177)</td><td>0.2</td></tr><tr><td>Remifentanil (&#956;g)</td><td>1350 (235)</td><td>1785 (260)</td><td>&lt;0.001</td></tr><tr><td>Esmolol (mg)</td><td>15 (4.5)</td><td>40 (7.5)</td><td>&lt;0.001</td></tr><tr><td>Nicardipine (mg)</td><td>0.25 (0.06)</td><td>0.26 (0.07)</td><td>0.5</td></tr></table>
17c1c9241bd41b345de51d810f334037c6023e538637cfef196515c8c7547c37.png
complex
<table><tr><td rowspan="2">References</td><td colspan="4">SCI model</td><td rowspan="2">Methods</td><td rowspan="2">LncRNA expression changes</td></tr><tr><td>Animal</td><td>Method</td><td>Level</td><td>Sampling</td></tr><tr><td>35</td><td>Adult female SD rats (200&#8211;250 g)</td><td>Contusive spinal cord injury using an NYU impactor (10 g, 12.5 mm)</td><td>T10</td><td>1, 4 and 7 days post&#8208;SCI</td><td>RNA sequencing</td><td>1 dpo: 1 down, 6 up4 dpo: 5 down, 2 up7 dpo: 5 down, 2 up</td></tr><tr><td>33</td><td>Male ICR mice (20&#8211;25 g) aged 6&#8211;8 weeks</td><td>Multicenter Animal Spinal Cord Injury Study (MASCIS) Impactor weight&#8208;drop device(5 g, 25 mm)</td><td>T10</td><td>1 day, 3 days, 1 week and 3 weeks post&#8208;SCI</td><td>Microarray</td><td>1 dpo: 181 down, 164 up3 dpo: 290 down, 212 up1 wpo: 565 down, 326 up3 wpo: 40 down, 141 up</td></tr><tr><td>34</td><td>Adult female SD rats aged 12&#8211;14 weeks</td><td>Moderate contusion injury</td><td>T9</td><td>1, 3 and 6 months post&#8208;SCI</td><td>RNA sequencing</td><td>1mpo: 17 down, 120 up3mpo: 77 down, 162 up6mpo: 54 down, 125 up</td></tr></table>
a408b6c3a8dbd3a022d59e31952258b73b2fe0c509f8a0fe47dce713f518ef8f.png
complex
<table><tr><td>Characteristics of preliminary categories</td><td>Final categories</td><td colspan="2">1999/2000</td><td colspan="2">2005</td><td colspan="2">2010</td></tr><tr><td></td><td></td><td><i>n</i></td><td>%</td><td><i>n</i></td><td>%</td><td><i>n</i></td><td>%</td></tr><tr><td>Permanent work</td><td rowspan="2">Non-precarious employment (NP)</td><td rowspan="2">575</td><td rowspan="2">50.7</td><td rowspan="2">739</td><td rowspan="2">65.1</td><td rowspan="2">859</td><td rowspan="2">75.7</td></tr><tr><td> + no or low self-rated risk of future unemployment (regardless of previous unemployment)</td></tr><tr><td>Contingent work</td><td rowspan="2">Non-precarious employment (NP)</td><td rowspan="2">82</td><td rowspan="2">7.2</td><td rowspan="2">27</td><td rowspan="2">2.4</td><td rowspan="2">16</td><td rowspan="2">1.4</td></tr><tr><td> + no self-rated risk of future unemployment+ no previous unemployment</td></tr><tr><td>All others with contingent work AND/OR moderate to high self-rated risk of future unemployment AND/OR previous unemployment</td><td>Precarious employment (PE)</td><td>416</td><td>36.6</td><td>306</td><td>26.9</td><td>207</td><td>18.2</td></tr><tr><td>Unemployed</td><td>Precarious employment (PE)</td><td>62</td><td>5.5</td><td>63</td><td>5.6</td><td>53</td><td>4.7</td></tr><tr><td></td><td></td><td>1135</td><td>100</td><td>1135</td><td>100</td><td>1135</td><td>100</td></tr></table>
406c0171886c30f3fc19453aabb817aaa4790e744fe47da6cf5fb8ba13d61aef.png
complex
<table><tr><td></td><td colspan="2">Did not participate Patella lead level</td><td colspan="2">Participated Patella lead level</td></tr><tr><td>Characteristic</td><td>Low (<i>n</i> = 90)</td><td>High (<i>n</i> = 103)</td><td>Low (<i>n</i> = 15)</td><td>High (<i>n</i> = 16)</td></tr><tr><td>Mean age in years &#177; SD at MRSa</td><td>73.0 &#177; 6.2</td><td>78.0 &#177; 5.9</td><td>73.2 &#177; 4.7</td><td>80.7 &#177; 6.1</td></tr><tr><td>Mean years &#177; SD of education</td><td>15.3 &#177; 2.5</td><td>13.2 &#177; 2.6</td><td>16.3 &#177; 3.1</td><td>13.4 &#177; 2.6</td></tr><tr><td>Mean &#177; SD serum creatinine (mg/dL)</td><td>1.1 &#177; 0.5</td><td>1.1 &#177; 0.3</td><td>1.0 &#177; 0.2</td><td>1.2 &#177; 0.4</td></tr><tr><td>Mean &#177; SD systolic blood pressure (mmHg)</td><td>134 &#177; 16</td><td>134 &#177; 17</td><td>133 &#177; 15</td><td>135 &#177; 20</td></tr><tr><td>Diabetes, <i>n</i> (%)</td><td>7 (8)</td><td>5 (5)</td><td>0</td><td>1 (6)</td></tr><tr><td>Hypertension, <i>n</i> (%)</td><td>28 (31)</td><td>36 (35)</td><td>4 (27)</td><td>7 (44)</td></tr><tr><td>Taking hypertension medication, <i>n</i> (%)</td><td>9 (10)</td><td>15 (15)</td><td>1 (7)</td><td>6 (38)</td></tr><tr><td>Myocardial infarction, <i>n</i> (%)</td><td>0</td><td>6 (6)</td><td>0</td><td>1 (6)</td></tr><tr><td>Stroke, <i>n</i> (%)</td><td>0</td><td>3 (3)</td><td>0</td><td>1 (6)</td></tr><tr><td>Median (IQR) patella lead (&#956;g/g bone)</td><td>10 (6&#8211;14)</td><td>48 (44&#8211;60)</td><td>9 (5&#8211;15)</td><td>63 (43&#8211;86)</td></tr><tr><td>Median (IQR) tibia lead (&#956;g/g bone)</td><td>11 (7&#8211;17)</td><td>32 (24&#8211;41)</td><td>13 (9&#8211;17)</td><td>41 (38&#8211;59)</td></tr></table>
cb183b91b0829d4172441d1e23a57b1dada5c2a87c56880c64c35cea3d8c2b60.png
complex
<table><tr><td colspan="3">Sodium nitrite</td><td colspan="3">Sodium nitrate</td></tr><tr><td>Spiked level (<i>&#956;</i>g&#183;g<sup>&#8722;1</sup>)</td><td>Recovery (%)</td><td>SD</td><td>Spiked level (<i>&#956;</i>g&#183;g<sup>&#8722;1</sup>)</td><td>Recovery (%)</td><td>SD</td></tr><tr><td>50</td><td>96</td><td>13.68</td><td>50</td><td>96</td><td>7.13</td></tr><tr><td>100</td><td>100</td><td>9.64</td><td>100</td><td>96</td><td>16.65</td></tr><tr><td>150</td><td>98</td><td>9.12</td><td>150</td><td>100</td><td>3.28</td></tr><tr><td>200</td><td>101</td><td>3.19</td><td>200</td><td>98</td><td>6.76</td></tr></table>
7e2b7326855f54565729ba0de8c5c8c9dcd459881765a54ed56b5d8352aeb6a9.png
simple
<table><tr><td> </td><td>Other</td><td>Division</td><td>FN</td><td>FP</td></tr><tr><td>Other</td><td>935</td><td>69</td><td>66</td><td>85</td></tr><tr><td>Division</td><td>99</td><td>3395</td><td>31</td><td>68</td></tr><tr><td>FN/1:1</td><td>79</td><td>39</td><td>546</td><td>43</td></tr><tr><td>FP</td><td>17</td><td>7</td><td>28</td><td>1416</td></tr></table>
3bd9b587ec89681e754e1aded5e2b057c69130af4eda27b25cf1b6869acc8ade.png
simple
<table><tr><td>Descriptor</td><td>SVM</td><td>unSVM</td><td>Bagging</td><td>unBagging</td><td>asBagging</td><td>PRIFEAB</td></tr><tr><td>BCUT</td><td>98.2(0.1)</td><td>97.9(0.1)</td><td>97.6(0.1)</td><td>97.8(0.1)</td><td>68.3(0.4)</td><td>67.3(0.2)</td></tr><tr><td>CONST</td><td>98.2(0.1)</td><td>98.3(0.1)</td><td>98.2(0.1)</td><td>98.2(0.1)</td><td>65.3(0.5)</td><td>66.2(0.3)</td></tr><tr><td>PROP</td><td>98.1(0.1)</td><td>97.8(0.1)</td><td>97.6(0.1)</td><td>97.8(0.1)</td><td>70.3(0.3)</td><td>70.8(0.2)</td></tr><tr><td>TOPO</td><td>97.8(0.1)</td><td>98.2(0.0)</td><td>97.0(0.2)</td><td>97.5(0.1)</td><td>67.6(0.3)</td><td>67.7(0.3)</td></tr><tr><td>Average</td><td>98.1(0.1)</td><td>98.1(0.1)</td><td>97.6(0.1)</td><td>97.8(0.1)</td><td>67.9(0.4)</td><td>68.0(0.3)</td></tr></table>
e825d1adfd1a39b72806b3d56f7f74883ac4b5dc8504d935a22fe05d3df95b93.png
simple
<table><tr><td></td><td>N</td><td>n female</td><td>Age range</td></tr><tr><td>Tutor: Medical Doctor</td><td>1</td><td>0</td><td>51</td></tr><tr><td>Tutors: CO/AMO</td><td>3</td><td>0</td><td>41 &#8211; 65</td></tr><tr><td>Tutor: Nurse</td><td>1</td><td>1</td><td>35</td></tr><tr><td>Students: First year</td><td>3</td><td>1</td><td>19 &#8211; 28</td></tr><tr><td>Students: Second year</td><td>3</td><td>1</td><td>22 &#8211; 35</td></tr><tr><td>Students: Third year</td><td>4</td><td>1</td><td>23 &#8211; 30</td></tr></table>
6cf9fa469df7c9a67d1774890062c59eba16c889a859dba01898192fdc8d2fff.png
simple
<table><tr><td>Predictors</td><td><i>df</i></td><td>AIC<sub>c</sub></td><td>&#916;AIC<sub>c</sub></td><td><i>w</i><sub>i</sub></td></tr><tr><td>&#916; Latitude of the 80% diversity contour</td><td>3</td><td>&#8722;348.31</td><td>0.00</td><td>0.65</td></tr><tr><td>&#916; Eastern U.S. winter temperature</td><td>3</td><td>&#8722;345.14</td><td>3.17</td><td>0.13</td></tr><tr><td>Null</td><td>2</td><td>&#8722;344.74</td><td>3.57</td><td>0.11</td></tr><tr><td>Global temperature anomaly</td><td>3</td><td>&#8722;342.55</td><td>5.76</td><td>0.04</td></tr><tr><td>Northern hemisphere temperature anomaly</td><td>3</td><td>&#8722;342.42</td><td>5.88</td><td>0.03</td></tr><tr><td>Eastern U.S. temperature anomaly</td><td>3</td><td>&#8722;342.42</td><td>5.88</td><td>0.03</td></tr></table>
a17e926f2eb4a969ee51fb8ab7806abb9badc13db713dd7936e1d4dc00d3eef8.png
simple
<table><tr><td>Correction Method</td><td>Mean Error before Correction (mm)</td><td>Mean Error after Correction (mm)</td><td>Standard Deviation before Correction (mm)</td><td>Standard Deviation after Correction (mm)</td></tr><tr><td>Interpolation</td><td>2.737</td><td>0.325</td><td>2.781</td><td>0.549</td></tr><tr><td>Function (FFT)</td><td>2.737</td><td>0.400</td><td>2.781</td><td>0.581</td></tr></table>
60fa1e371e87f472a55126faf20aef3c6126a9551e0c08d1cd9c498a47018179.png
complex
<table><tr><td></td><td colspan="3">Test group*</td><td colspan="3">Active control group*</td><td colspan="3">Total</td></tr><tr><td></td><td>N</td><td>Mean</td><td>SD</td><td><i>N</i></td><td>Mean</td><td>SD</td><td><i>N</i></td><td>Mean</td><td>SD</td></tr><tr><td>Usefulness of</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Toothbrushing supplies</td><td>61</td><td>9.6</td><td>1.2</td><td>76</td><td>9.4</td><td>1.8</td><td>137</td><td>9.5</td><td>1.5</td></tr><tr><td>Printed postcard messages</td><td>54</td><td>7.2</td><td>3.6</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Voice telephone messages</td><td>49</td><td>6.4</td><td>3.9</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Overall satisfaction</td><td>61</td><td>9.5</td><td>1.1</td><td>76</td><td>9.5</td><td>0.9</td><td>137</td><td>9.5</td><td>0.9</td></tr></table>
e6b3e49dd19935c3ed272169619cdc05c96bddde05127dc50718bac0db4d25d8.png
simple
<table><tr><td>Old name*</td><td>New name*</td></tr><tr><td>N.CglI</td><td>H.CglI</td></tr><tr><td>N.NgoAVII</td><td>H.NgoAVII</td></tr></table>
f62fe39e36a1891dc767cf5d18e83b767b7a7be3c1b1c1aa7681f947e35a20aa.png
simple
<table><tr><td> Index </td><td> SS </td><td> df </td><td> MS </td><td> F </td><td> p </td></tr><tr><td> Pre-tests and post-tests of interaction </td><td> 34.16 </td><td> 1 </td><td> 17.08 </td><td> 0.10 </td><td> 0.900 </td></tr></table>
1c40140cfb9e98102459ffab5a1d052eba52b524bfd10e959607fc3cd83857b4.png
simple
<table><tr><td>Anterior wall</td><td> </td></tr><tr><td> TCC</td><td>16,5 &#956;m</td></tr><tr><td> Spectral estimation Burg </td><td>19,5 &#956;m</td></tr><tr><td> Spectral estimation Yule-Walker</td><td>21,3 &#956;m</td></tr><tr><td>Posterior wall</td><td> </td></tr><tr><td> TCC</td><td>16,5 &#956;m</td></tr><tr><td> Spectral estimation Burg</td><td>22,0 &#956;m</td></tr><tr><td> Spectral estimation Yule-Walker</td><td>17,0 &#956;m</td></tr></table>
01efa08cdf70280384b9f015c205e9f71e6c6b4f4fdbd9a157b45d424846263e.png
complex
<table><tr><td> </td><td> </td><td> </td><td><i>N</i> (%)</td></tr><tr><td rowspan="2">Age, years</td><td>Median</td><td>63.0</td><td></td></tr><tr><td>Range</td><td>33&#8211;81</td><td></td></tr><tr><td rowspan="2">Sex</td><td>Male</td><td></td><td>31 (70.5%)</td></tr><tr><td>Female</td><td></td><td>13 (29.5%)</td></tr><tr><td rowspan="3">ECOG performance status</td><td>0</td><td></td><td>24 (54.5%)</td></tr><tr><td>1</td><td></td><td>15 (34.1%)</td></tr><tr><td>2</td><td></td><td>5 (11.4%)</td></tr><tr><td rowspan="3">Primary site</td><td>Colon</td><td></td><td>22 (50.0%)</td></tr><tr><td>Rectum</td><td></td><td>20 (45.5%)</td></tr><tr><td>Colorectal</td><td></td><td>2 (4.5%)</td></tr><tr><td rowspan="5">Metastatic sites</td><td>Liver</td><td></td><td>31 (70.5%)</td></tr><tr><td>Lung</td><td></td><td>18 (40.9%)</td></tr><tr><td>Lymph nodes</td><td></td><td>8 (18.2%)</td></tr><tr><td>Other (mediastinum, pelvis, perineum)</td><td></td><td>4 (9.1%)</td></tr><tr><td>Peritoneum</td><td></td><td>2 (4.5%)</td></tr><tr><td rowspan="4">Number of target lesions</td><td>1</td><td></td><td>11 (25.0%)</td></tr><tr><td>2</td><td></td><td>12 (27.3%)</td></tr><tr><td>3</td><td></td><td>10 (22.7%)</td></tr><tr><td>4 or more</td><td></td><td>11 (25.0%)</td></tr><tr><td rowspan="4">Prior therapy</td><td>Surgery</td><td></td><td>38 (86.4%)</td></tr><tr><td>Radiotherapy</td><td></td><td>11 (25.0%)</td></tr><tr><td>Chemotherapy</td><td></td><td></td></tr><tr><td> Metastatic</td><td></td><td>44 (100.0%)</td></tr><tr><td rowspan="2">Time from initial diagnosis to inclusion, months</td><td>Median</td><td>17.0</td><td></td></tr><tr><td>Range</td><td>2.8&#8211;81.1</td><td></td></tr></table>
c2d517def650321af709d43bcdc07e838d2804f2e7f22f453d2fcd77c45f992c.png
complex
<table><tr><td rowspan="2">Host Strains with <i>rpoB</i> Alleles</td><td colspan="2">Cell Viability (&#177;SE) [% Plasmid Loss] Per Growth of Transformant at 42 &#176;C</td></tr><tr><td>[cII] <sup>a</sup></td><td>[cII-oop-pO94] <sup>b</sup></td></tr><tr><td>594 <sup>c</sup></td><td>&lt;0.001 (0.001) [100]</td><td>0.08 (0.03) [0]</td></tr><tr><td>594 <i>rpoB</i> B1</td><td>&lt;0.001 (&lt;0.0001) [100]</td><td>0.07 (0.01) [0]</td></tr><tr><td>594 <i>rpoB</i> B8</td><td>0.01 (&lt;0.0001) [78]</td><td>0.13 (0.03) [0]</td></tr><tr><td>594 <i>rpoB</i> C1</td><td>0.007 (0.10) [100]</td><td>0.36 (&lt;0.0001) [0]</td></tr><tr><td>594 <i>rpoB</i> C4</td><td>0.003 (0.010) [0]</td><td>0.07 (&lt;0.0001) [0]</td></tr><tr><td>594 <i>rpoB</i> C10</td><td>0.004 (0.001) [100]</td><td>1.00 (0.01) [0]</td></tr><tr><td>594 <i>rpoB</i> D2</td><td>0.38 (&lt;0.0001) [0]</td><td>0.10 (&lt;0.0001) [81]</td></tr><tr><td>594 <i>rpoB</i> D6</td><td>0.02 (0.01) [6]</td><td>0.03 (0.01) [86]</td></tr></table>
4bc97d0f32b5cbc58a598625d14664a515270452cfc158dcce2ee2078899049b.png
complex
<table><tr><td>Category of intervention</td><td>Effective interventions for nurse retention</td><td>Strength of evidence<sup>*</sup></td></tr><tr><td rowspan="4">A. Education and continuous professional development interventions</td><td>-Recruitment from, and training in, rural areas</td><td>Moderate [26]<sup>#</sup></td></tr><tr><td>-Targeted admission of students from rural background</td><td>Moderate [28]<sup>#</sup></td></tr><tr><td>-Early and increased exposure to rural practice during undergraduate studies</td><td rowspan="2"> </td></tr><tr><td>-Support for continuous professional development</td></tr><tr><td rowspan="3">B. Regulatory interventions</td><td>-Increased opportunities for recruitment to civil service</td><td rowspan="3">Low [25]<sup>#</sup></td></tr><tr><td>-Recognizing overseas qualifications</td></tr><tr><td>-Producing different types of health workers</td></tr><tr><td rowspan="2">C. Financial incentives</td><td rowspan="2">-Direct and indirect financial incentives (direct payments, service-requiring scholarships, educational loans with service requirements, loan repayment programs)</td><td>Moderate [24]<sup>#</sup></td></tr><tr><td>Low [25]</td></tr><tr><td rowspan="2">D. Personal and professional support</td><td>-General improvement in rural infrastructure (housing, roads, phones, water supplies, radio communication, etc.)</td><td>Strong [25]</td></tr><tr><td>-Supportive supervision (mentorship, preceptorship, clinical supervision)</td><td>Moderate [26]<sup>#</sup></td></tr><tr><td> </td><td>-Measures to reduce health workers&#8217; feeling of isolation (professional/specialist networks, telemedicine and telehealth)</td><td>Moderate [27]<sup>#</sup></td></tr></table>
f80070c9c2ac2cac06a9f4cb7910b68ec2130615aa2e8f183c64f6cbe70c8b16.png
complex
<table><tr><td rowspan="2">Brain region</td><td colspan="3">MR image</td><td colspan="3">PET image</td></tr><tr><td>Volume(mm<sup>3</sup>)</td><td>Mean voxel Activity concentration<sup>a</sup> (kBq&#183;mL<sup>&#8722;1</sup>)</td><td>Mean ROI activity(Bq)</td><td>Volume(mm<sup>3</sup>)</td><td>Mean voxelActivity concentration<sup>b</sup> (kBq&#183;mL<sup>&#8722;1</sup>)</td><td>Mean ROIactivity(Bq)</td></tr><tr><td>Left striatum</td><td>16.4</td><td>0.50</td><td>8.19</td><td>15.3</td><td>0.52</td><td>7.95</td></tr><tr><td>Right striatum</td><td>15.1</td><td>0.50</td><td>7.56</td><td>14.7</td><td>0.50</td><td>7.30</td></tr><tr><td>Hippocampus</td><td>26.4</td><td>0.50</td><td>13.22</td><td>26.8</td><td>0.50</td><td>13.38</td></tr><tr><td>Frontal cortex </td><td>46.1</td><td>0.50</td><td>23.03</td><td>48.6</td><td>0.50</td><td>24.13</td></tr><tr><td>Posterior cortex </td><td>49.6</td><td>0.50</td><td>24.80</td><td>48.9</td><td>0.49</td><td>23.96</td></tr><tr><td>Medulla oblongata</td><td>15.7</td><td>0.50</td><td>7.85</td><td>15.8</td><td>0.49</td><td>7.75</td></tr><tr><td>Cerebellum</td><td>86.7</td><td>0.50</td><td>43.35</td><td>86.0</td><td>0.49</td><td>42.14</td></tr></table>
5c35897036baa0d3aee5ee7084740f7215795795287b49ff1fb2c2b1a4c468ce.png
complex
<table><tr><td>Reaction type</td><td colspan="2">All reactions</td><td colspan="2">Reaction following GA<sup>b</sup></td></tr><tr><td> </td><td>N</td><td>% of all reactions<sup>a</sup></td><td>N</td><td>% of reaction types, where reaction followed GA</td></tr><tr><td>Nausea and/or vomiting</td><td>400</td><td>27.5%</td><td>295</td><td>73.8%</td></tr><tr><td>Pruritus</td><td>243</td><td>16.7%</td><td>232</td><td>95.5%</td></tr><tr><td>Constipation</td><td>155</td><td>10.6%</td><td>107</td><td>69.0%</td></tr><tr><td>Diarrhea (9/88 with vomiting)</td><td>88</td><td>6.0%</td><td>0</td><td>0.0%</td></tr><tr><td>Somnolence (without cardio-respiratory symptoms)</td><td>50</td><td>3.4%</td><td>34</td><td>68.0%</td></tr><tr><td>Respiratory depression (41)/arrest (3)</td><td>44</td><td>3.0%</td><td>43</td><td>97.7%</td></tr><tr><td>Candidiasis</td><td>41</td><td>2.8%</td><td>0</td><td>0.0%</td></tr><tr><td>Urinary retention</td><td>40</td><td>2.7%</td><td>37</td><td>92.5%</td></tr><tr><td>Rash</td><td>31</td><td>2.1%</td><td>3</td><td>9.7%</td></tr><tr><td>Hypokalemia</td><td>25</td><td>1.7%</td><td>0</td><td>0.0%</td></tr><tr><td>Hypotension</td><td>22</td><td>1.5%</td><td>9</td><td>40.9%</td></tr><tr><td>Hepatotoxicity(6)/increased transaminases (12)<sup>c</sup></td><td>18</td><td>1.2%</td><td>1</td><td>5.6%</td></tr><tr><td>Stomatitis</td><td>16</td><td>1.1%</td><td>0</td><td>0.0%</td></tr><tr><td>Myoclonus</td><td>15</td><td>1.0%</td><td>14</td><td>93.3%</td></tr><tr><td>Pancytopenia</td><td>13</td><td>&lt;1%</td><td>0</td><td>0.0%</td></tr><tr><td>Hyperglycemia</td><td>12</td><td>&lt;1%</td><td>0</td><td>0.0%</td></tr><tr><td>Hypertension</td><td>11</td><td>&lt;1%</td><td>2</td><td>18.2%</td></tr><tr><td>Allergic reactions</td><td>10</td><td>&lt;1%</td><td>3</td><td>30.0%</td></tr><tr><td>Pain (4/10 pain in jaw, 2/10 back pain)</td><td>10</td><td>&lt;1%</td><td>0</td><td>0.0%</td></tr><tr><td>Other reactions ( occurred &lt;10 times)</td><td>213</td><td>14.6%</td><td>65</td><td>30.5%</td></tr><tr><td>Total</td><td>1,457</td><td> </td><td>845</td><td>58.0%</td></tr></table>
807ae086788ae01bc3a546a8eefdd206953d14182f6d85e4969d1f9d10beed60.png
simple
<table><tr><td>Number of patients</td><td>Disease progression</td><td>Localized</td><td><i>P</i> Value</td></tr><tr><td>Age(Range)</td><td>57.19 (36.85-74.92)</td><td>60.61 (44.38-91.38)</td><td>0.1692</td></tr><tr><td>Median Time to Relapse (years)</td><td>1.59 (0.23-4.91)</td><td></td><td></td></tr><tr><td>Median Followup (years)</td><td>6.47 (4.53-13.84)</td><td></td><td></td></tr><tr><td>Sex</td><td></td><td></td><td></td></tr><tr><td> Male</td><td>21</td><td>22</td><td></td></tr><tr><td> Female</td><td>7</td><td>15</td><td>0.2898</td></tr><tr><td>Smoking Status</td><td></td><td></td><td></td></tr><tr><td> Yes</td><td>15</td><td>15</td><td></td></tr><tr><td> No</td><td>13</td><td>22</td><td>0.3256</td></tr><tr><td>Tumor Stage1<sup>1</sup></td><td></td><td></td><td></td></tr><tr><td> T2</td><td>6</td><td>15</td><td>0.1176</td></tr><tr><td> T3</td><td>22</td><td>22</td><td></td></tr><tr><td>Fuhrman Grade</td><td></td><td></td><td></td></tr><tr><td> Grade 1-2</td><td>7</td><td>22</td><td></td></tr><tr><td> Grade 3-4</td><td>21</td><td>15</td><td>*0.0066</td></tr></table>
532022de91064e1ba9ed8fab73d56079fd76f1a330ab6d9d4adde35bd8792f99.png
simple
<table><tr><td>Matrix</td><td>Original (&#956;g/kg)</td><td>Spiked (&#956;g/kg)</td><td>Determined (&#956;g/kg)</td><td>Recovery (%)1</td></tr><tr><td>Potato chips</td><td>53.2</td><td>100</td><td>151.2</td><td>98.0 &#177; 0.8</td></tr><tr><td>Chips (except potato chips)</td><td>&lt;LOQ</td><td>100</td><td>97.7</td><td>97.7 &#177; 1.0</td></tr><tr><td>Biscuits</td><td>21.7</td><td>100</td><td>119.3</td><td>97.6 &#177; 2.7</td></tr><tr><td>French fries</td><td>35.7</td><td>100</td><td>135.3</td><td>99.5 &#177; 3.2</td></tr><tr><td>Chocolate products</td><td>&lt;LOQ</td><td>100</td><td>96.7</td><td>96.7 &#177; 3.2</td></tr><tr><td>Breakfast cereals</td><td>9.7</td><td>100</td><td>117.3</td><td>107.6 &#177; 0.7</td></tr><tr><td>Tea products</td><td>13.3</td><td>100</td><td>107.8</td><td>94.5 &#177; 0.2</td></tr><tr><td>Seasoned laver</td><td>&lt;LOQ</td><td>100</td><td>102.7</td><td>102.7 &#177; 3.7</td></tr><tr><td>Nuts products</td><td>&lt;LOQ</td><td>100</td><td>105.0</td><td>105.0 &#177; 1.6</td></tr></table>
4b29edb33a357f23d0d93ec010de2648b2833188582e062e218bad3952eecd2c.png
simple
<table><tr><td>Subjects</td><td>Experimental (non obstructive CAD) group (n)</td><td>Control (obstructive CAD) Group (n)</td><td>P value*</td></tr><tr><td>Females</td><td>143</td><td>141</td><td>0.888</td></tr><tr><td>Males</td><td>99</td><td>101</td><td>0.906</td></tr></table>
f8ba4ee68d2bd983e795745eaf6236c7fe32786af6919046c9de32ae9f5b727c.png
simple
<table><tr><td> </td><td>Input level</td><td>Running speech (mean (dB SPL), SE (dB))</td><td>Isolation (mean (dB SPL), SE (dB))</td><td><i>t</i>-statistic, df</td><td><i>P</i> value</td><td>Critical <i>P</i> value</td></tr><tr><td> </td><td>55</td><td>85.66, 2.28</td><td>83.66, 2.51</td><td>4.437, 9</td><td>0.002*</td><td>0.017</td></tr><tr><td>Overall level</td><td>65</td><td>94.61, 2.38</td><td>92.72, 2.55</td><td>3.803, 9</td><td>0.004*</td><td>0.033</td></tr><tr><td> </td><td>75</td><td>101.97, 2.36</td><td>100.9, 2.66</td><td>1.173, 9</td><td>0.121</td><td>0.050</td></tr><tr><td> </td><td>55</td><td>86.35, 2.27</td><td>85.96, 2.31</td><td>4.234, 9</td><td>0.002*</td><td>0.017</td></tr><tr><td>Onset level</td><td>65</td><td>95.18, 2.35</td><td>94.93, 2.38</td><td>2.739, 9</td><td>0.023*</td><td>0.033</td></tr><tr><td> </td><td>76</td><td>102.48, 2.41</td><td>102.43, 2.44</td><td>0.446, 9</td><td>0.653</td><td>0.050</td></tr></table>
057478878be258be0adba4350f350c613e4c34774b3c4f0ff8dca2eae63b44d1.png
complex
<table><tr><td> Methods </td><td> FLAT </td><td> HTD </td><td> HTD-CS </td><td> HB </td><td> HB-CS </td><td> TPR </td><td> TPR-W</td></tr><tr><td colspan="8">Single-source </td></tr><tr><td>BIOGRID</td><td>0.2643</td><td>0.3759</td><td>0.4160</td><td>0.3385</td><td>0.4183</td><td>0.3902</td><td>0.4367</td></tr><tr><td>String </td><td>0.2203</td><td>0.2677</td><td>0.3135</td><td>0.2138</td><td>0.3007</td><td>0.2801</td><td>0.3048</td></tr><tr><td>PFAM BINARY</td><td>0.1756</td><td>0.2003</td><td>0.2482</td><td>0.1468</td><td>0.2407</td><td>0.2532</td><td>0.2738</td></tr><tr><td>PFAM LOGE</td><td>0.2044</td><td>0.1567</td><td>0.2541</td><td>0.0997</td><td>0.2847</td><td>0.3005</td><td>0.3160</td></tr><tr><td>Expr. </td><td>0.1884</td><td>0.2506</td><td>0.2889</td><td>0.2006</td><td>0.2781</td><td>0.2723</td><td>0.3053</td></tr><tr><td>Seq. sim. </td><td>0.1870</td><td>0.2532</td><td>0.2899</td><td>0.2017</td><td>0.2825</td><td>0.2742</td><td>0.3088</td></tr><tr><td colspan="8">Multisource (data fusion) </td></tr><tr><td>Kernel fusion </td><td>0.3220(22)</td><td>0.5401(44)</td><td>0.5492(32)</td><td>0.5181(53)</td><td>0.5505(32)</td><td>0.5034(29)</td><td>0.5592(28)</td></tr></table>
adfdc518efb80cf97de932cbaddef35efe769a99aed0f24ff5d7bad2c48cf9ff.png
simple
<table><tr><td></td><td>Odds Ratio</td><td>[95% Confidence Interval]</td><td>p-value</td></tr><tr><td>Age group</td><td>1.08</td><td>1.02 - 1.51</td><td>0.02</td></tr><tr><td>Family history of renal disease</td><td>1.12</td><td>0.76 - 1.45</td><td>0.05</td></tr><tr><td>School education</td><td>0.99</td><td>0.76 - 2.54</td><td>0.17</td></tr><tr><td>Physical inactivity</td><td>0.65</td><td>0.57 - 0.99</td><td>0.05</td></tr><tr><td>Hypertension</td><td>2.15</td><td>1.61 - 4.36</td><td>0.03</td></tr><tr><td>Diabetes</td><td>1.22</td><td>0.33 - 40.74</td><td>0.63</td></tr><tr><td>Obesity</td><td>1.33</td><td>1.05 - 1.98</td><td>0.04</td></tr></table>
05e530e6395d9281c68e01520e3d44fe4848c19d4bace49e3dd093e32c2c8744.png
complex
<table><tr><td>Source of variation</td><td>df</td><td>SSD</td><td>VC</td><td>% total</td><td><i>P</i></td></tr><tr><td colspan="6">1. Regions divided by rivers</td></tr><tr><td> Among regions</td><td>4</td><td>168.349</td><td>0.507</td><td>23.87</td><td>&lt;0.001</td></tr><tr><td> Among populations within regions</td><td>44</td><td>356.604</td><td>1.075</td><td>50.60</td><td>&lt;0.001</td></tr><tr><td> Within populations</td><td>297</td><td>161.099</td><td>0.542</td><td>25.53</td><td>&lt;0.001</td></tr><tr><td> Total</td><td>345</td><td>686.052</td><td>2.125</td><td></td><td></td></tr><tr><td colspan="6">2. Glaciated versus nonglaciated regions during Great Patagonian Glaciation</td></tr><tr><td> Among regions</td><td>1</td><td>10.703</td><td>&#8722;0.013</td><td>&#8722;0.68</td><td>n.s.</td></tr><tr><td> Among populations within regions</td><td>47</td><td>514.250</td><td>1.477</td><td>73.64</td><td>&lt;0.001</td></tr><tr><td> Within populations</td><td>297</td><td>161.099</td><td>0.542</td><td>27.04</td><td>&lt;0.001</td></tr><tr><td> Total</td><td>345</td><td>686.052</td><td>2.006</td><td></td><td></td></tr></table>
41fabb6c046a8eec5e57a1bdc44c7f4c7520305a599bfb00e650429801925cc8.png
simple
<table><tr><td>Amplified Region</td><td>Forward</td><td>Reverse</td></tr><tr><td><i>c-KIT </i>exon 8</td><td>5'-CAGCAGTCTGACCTATGGC -3'</td><td>5'-GCTCAGCTCCTGGACAGAAA-3'</td></tr><tr><td><i>c-KIT </i>exon 9</td><td>5'-GATTGATTGATTGATTTTCCTAG-3'</td><td>5'-GCAGGCAGAGCCTAAACATC-3'</td></tr><tr><td><i>c-KIT </i>exon 11</td><td>5'-CATTTGTTCTCTACCCTAAGTGCT-3'</td><td>5'-GTTCCCTAAAGTCATTGTTACACG-3'</td></tr><tr><td><i>c-KIT </i>exon 13</td><td>5'-CTGATTAAGTCGGATGCGGC-3'</td><td>5'-CAAGCACTGTCGCAATGG-3'</td></tr><tr><td><i>c-KIT </i>exon 17</td><td>5'-ATAGCAGCATTCTCGTGTTG-3'</td><td>5'-AACTAAAATCCTTCACTGGACTG-3'</td></tr><tr><td><i>PDGFRA </i>exon 12</td><td>5'-TTAATGGCTCTGATTGCTCAC-3'</td><td>5'-CACCCAGTGCTCATAACCTC-3'</td></tr><tr><td><i>PDGFRA </i>exon 14</td><td>5'-ACTGGTTTTGGTTCCCACAG -3'</td><td>5'-CAATGATTCGCAGCAACG-3'</td></tr><tr><td><i>PDGFRA </i>exon 18</td><td>5'-TAGCTCAGCCGTGGGTATG-3'</td><td>5'-CACATGAGCAGAGATGTCAGG-3'</td></tr></table>
52ef4c941df4e854e5cf74e0e427b0b19ec6672c82336e3976c9abb9decd7601.png
complex
<table><tr><td>Year range</td><td>No. records</td><td>Mortality (%)</td><td>Countries</td></tr><tr><td colspan="4"><i>An. arabiensis</i></td></tr><tr><td rowspan="3">Up to 2000 (first year = 1996)</td><td rowspan="3">3</td><td>Min 100</td><td rowspan="3">South Africa</td></tr><tr><td>Max 100</td></tr><tr><td><i>Mean 100</i></td></tr><tr><td rowspan="3">2001&#8211;2005</td><td rowspan="3">67</td><td>Min 75</td><td rowspan="3">Cameroon, Kenya, Madagascar, Mozambique, Nigeria, South Africa, Sudan, Tanzania</td></tr><tr><td>Max 100</td></tr><tr><td><i>Mean 95.6</i></td></tr><tr><td rowspan="3">2006&#8211;2010</td><td rowspan="3">218</td><td>Min 0</td><td rowspan="3">Burkina Faso, Cameroon, Chad, Ethiopia, Kenya, Mozambique, Senegal, Sudan, Tanzania, The Gambia, Uganda, Zambia, Zimbabwe</td></tr><tr><td>Max 100</td></tr><tr><td><i>Mean 79.3</i></td></tr><tr><td rowspan="3">2011&#8211;2015</td><td rowspan="3">161</td><td>Min 9</td><td rowspan="3">Ethiopia, Kenya, Malawi, Mali, South Africa, Senegal, Sudan, Tanzania, Uganda</td></tr><tr><td>Max 100</td></tr><tr><td><i>Mean 74.7</i></td></tr><tr><td colspan="4"><i>An. coluzzii</i></td></tr><tr><td rowspan="3">2001&#8211;2005</td><td rowspan="3">38</td><td>Min 19</td><td rowspan="3">Benin, Cameroon, Nigeria</td></tr><tr><td>Max 100</td></tr><tr><td><i>Mean 89.7</i></td></tr><tr><td rowspan="3">2006&#8211;2010</td><td rowspan="3">144</td><td>Min 0.9</td><td rowspan="3">Benin, Burkina Faso, Cameroon, Co&#770;te d&#8217;Ivoire, Ghana, Mali, Nigeria</td></tr><tr><td>Max 100</td></tr><tr><td><i>Mean 73.2</i></td></tr><tr><td rowspan="3">2011&#8211;2015</td><td rowspan="3">44</td><td>Min 1</td><td rowspan="3">Benin, Burkina Faso, Cameroon, Co&#770;te d&#8217;Ivoire, Mali, Mozambique, Liberia</td></tr><tr><td>Max 100</td></tr><tr><td><i>Mean 60.6</i></td></tr><tr><td colspan="4"><i>An. gambiae</i></td></tr><tr><td rowspan="3">Up to 2000 (first year = 1999)</td><td rowspan="3">10</td><td>Min 100</td><td rowspan="3">Zambia</td></tr><tr><td>Max 100</td></tr><tr><td><i>Mean 100</i></td></tr><tr><td rowspan="3">2001&#8211;2005</td><td rowspan="3">55</td><td>Min 27</td><td rowspan="3">Angola, Burundi, Cameroon, Equatorial Guinea, Mozambique, Nigeria, Uganda</td></tr><tr><td>Max 100</td></tr><tr><td><i>Mean 88.82</i></td></tr><tr><td rowspan="3">2006&#8211;2010</td><td rowspan="3">139</td><td>Min 0</td><td rowspan="3">Benin, Burkina Faso, Burundi, Cameroon, Congo, Ghana, Guinea, Kenya, Malawi, Mozambique, Uganda, Zambia</td></tr><tr><td>Max 100</td></tr><tr><td><i>Mean 75.2</i></td></tr><tr><td rowspan="3">2011&#8211;2015</td><td rowspan="3">48</td><td>Min 0</td><td rowspan="3">Cameroon, DRC, Ghana, Kenya, Mali, Tanzania, Uganda</td></tr><tr><td>Max 100</td></tr><tr><td><i>Mean 48.7</i></td></tr><tr><td colspan="4"><i>An. melas</i></td></tr><tr><td rowspan="3">All years (2005)</td><td rowspan="3">4</td><td>Min 100</td><td rowspan="3">Cameroon</td></tr><tr><td>Max 100</td></tr><tr><td><i>Mean 100</i></td></tr><tr><td colspan="4"><i>An. quadriannulatus</i></td></tr><tr><td rowspan="3">All years (2002)</td><td rowspan="3">1</td><td>Min 100</td><td rowspan="3">South Africa</td></tr><tr><td>Max 100</td></tr><tr><td><i>Mean 100</i></td></tr></table>
b06f5ae136f87bc075411a0dd941199edb2e5e91bb029e39de9ef6b4207f9285.png
complex
<table><tr><td></td><td colspan="3">Ukraine</td><td colspan="3">Kazakhstan</td><td colspan="3">Azerbaijan</td></tr><tr><td></td><td colspan="2">Respondents<sup>a</sup></td><td></td><td colspan="2">Respondents<sup>a</sup></td><td></td><td colspan="2">Respondents<sup>a</sup></td><td></td></tr><tr><td></td><td>without BA</td><td>with BA</td><td><i>p</i>-value</td><td>without BA</td><td>with BA</td><td><i>p</i>-value</td><td>without BA</td><td>with BA</td><td><i>p</i>-value</td></tr><tr><td>Valid N</td><td>871</td><td>70</td><td></td><td>693</td><td>237</td><td></td><td>817</td><td>115</td><td></td></tr><tr><td>Any co-morbidity, %</td><td>42.0</td><td>62.9</td><td>0.001</td><td>20.8</td><td>50.6</td><td>&lt; 0.001</td><td>51.4</td><td>77.4</td><td>&lt; 0.001</td></tr><tr><td>Hypertension, %</td><td>13.1</td><td>37.1</td><td>&lt; 0.001</td><td>21.6</td><td>40.1</td><td>&lt; 0.001</td><td>16.2</td><td>27.0</td><td>0.006</td></tr><tr><td>Diabetes, %</td><td>3.2</td><td>5.7</td><td>0.291</td><td>3.5</td><td>4.2</td><td>0.689</td><td>4.8</td><td>9.6</td><td>0.044</td></tr><tr><td>Cardiovascular disease, %</td><td>6.0</td><td>14.3</td><td>0.013</td><td>7.0</td><td>13.9</td><td>0.001</td><td>3.5</td><td>8.7</td><td>0.015</td></tr><tr><td>Abnormal blood lipids, %</td><td>4.3</td><td>10.0</td><td>0.039</td><td>10.0</td><td>17.3</td><td>0.004</td><td>1.0</td><td>3.5</td><td>0.050</td></tr><tr><td>Depression, %</td><td>0.5</td><td>1.4</td><td>0.322</td><td>0.4</td><td>0.8</td><td>0.607</td><td>1.7</td><td>3.5</td><td>0.263</td></tr><tr><td>Anxiety, %</td><td>0.2</td><td>0.0</td><td>1.000</td><td>0.6</td><td>0.4</td><td>1.000</td><td>2.6</td><td>3.5</td><td>0.758</td></tr><tr><td>Osteoporosis, %</td><td>0.6</td><td>1.4</td><td>0.374</td><td>1.5</td><td>2.5</td><td>0.384</td><td>0.5</td><td>0.9</td><td>1.000</td></tr><tr><td>Tuberculosis, %</td><td>0.5</td><td>1.4</td><td>0.321</td><td>2.2</td><td>1.7</td><td>0.794</td><td>0.7</td><td>7.0</td><td>&lt; 0.001</td></tr><tr><td>Pneumonia, %</td><td>18.9</td><td>38.6</td><td>&lt; 0.001</td><td>11.8</td><td>27.8</td><td>&lt; 0.001</td><td>5.5</td><td>12.2</td><td>0.009</td></tr><tr><td>Allergic rhinitis, %</td><td>3.6</td><td>15.7</td><td>&lt; 0.001</td><td>5.6</td><td>21.9</td><td>&lt; 0.001</td><td>6.9</td><td>20.9</td><td>&lt; 0.001</td></tr></table>
7d86d11100ebee3351cb48225c55062310d6ed00eeabeb31db1bab12bb8eef82.png
complex
<table><tr><td></td><td colspan="3">Australia</td><td colspan="3">Spain</td><td colspan="3">UK</td><td></td><td>Total</td></tr><tr><td>Predictor</td><td>No./total cases<sup>1</sup></td><td>%</td><td>OR<sup>2</sup> (95% CI)</td><td>No./total cases</td><td>%</td><td>OR (95% CI)</td><td>No./total cases</td><td>%</td><td>OR (95% CI)</td><td>%</td><td>Multivariate OR<sup>3</sup></td></tr><tr><td>Family history<sup>4</sup></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>0</td><td>7/500</td><td>1.4</td><td>1.0</td><td>13/696</td><td>1.9</td><td>1.0</td><td>20/1470</td><td>1.4</td><td>1.0</td><td>1.5</td><td>1.0</td></tr><tr><td>1</td><td>4/76</td><td>5.3</td><td>3.9 (1.1, 13.7)</td><td>3/35</td><td>8.6</td><td>4.9 (1.3, 18.2)</td><td>4/101</td><td>4.0</td><td>3.0 (1.0, 8.9)</td><td>5.2</td><td>3.8 (1.9, 7.5)</td></tr><tr><td>2+</td><td>3/20</td><td>15.0</td><td>12.4 (3.0, 52.3)</td><td>3/16</td><td>18.8</td><td>12.1 (3.1, 47.7)</td><td>7/15</td><td>46.7</td><td>63.4 (21.0, 19.8)</td><td>25.5</td><td>23.2 (11.3, 47.6)</td></tr><tr><td>No. of primaries<sup>5</sup></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>1</td><td>14/581</td><td>2.4</td><td>n/a</td><td>8/644</td><td>1.2</td><td>1.0</td><td>20/1495</td><td>1.4</td><td>1.0</td><td>1.3</td><td>1.0</td></tr><tr><td>2</td><td>0/14</td><td>0</td><td></td><td>6/80</td><td>7.5</td><td>6.5 (2.2, 19.1)</td><td>4/73</td><td>5.5</td><td>4.3 (1.4, 12.9)</td><td>6.5</td><td>5.4 (2.5, 11.6)</td></tr><tr><td>3+</td><td>0/1</td><td>0</td><td></td><td>5/23</td><td>21.7</td><td>22.1 (6.6, 74.2)</td><td>7/18</td><td>38.9</td><td>46.9 (16.5, 133.5)</td><td>29.3</td><td>32.4 (14.7, 71.2)</td></tr></table>
10246ad35deff509f26a006d4a4e03e7d1a999ee9659fcd93b2419e14b13f6c7.png
complex
<table><tr><td></td><td colspan="2">Untreated n. 77</td><td colspan="2">IFN-&#946; treated n.41</td><td colspan="2">p-value*</td></tr><tr><td><i>Time-varying covariates</i></td><td><i>Baseline</i></td><td><i>Change</i></td><td><i>Baseline</i></td><td><i>Change</i></td><td><i>Baseline</i></td><td><i>Change</i></td></tr><tr><td>Relapse rate**</td><td>0.2 &#177; 0.3</td><td>0.0 &#177; 0.4</td><td>0.7 &#177; 0.5</td><td>-0.1 &#177; 0.6</td><td>&lt;0.0001</td><td>0.37</td></tr><tr><td>EDSS</td><td>3.1 &#177; 1.7</td><td>0.4 &#177; 0.8</td><td>3.0 &#177; 1.8</td><td>0.4 &#177; 1.1</td><td>0.84</td><td>0.93</td></tr><tr><td>BDI</td><td>9.5 &#177; 7.7</td><td>1.3 &#177; 10.3</td><td>10.8 &#177; 9.2</td><td>2.2 &#177; 9.8</td><td>0.57</td><td>0.88</td></tr><tr><td>FSS</td><td>2.5 &#177; 1.8</td><td>1.1 &#177; 1.7</td><td>2.8 &#177; 1.9</td><td>1.2 &#177; 1.8</td><td>0.53</td><td>0.75</td></tr><tr><td>MMSE-c</td><td>28.5 &#177; 2.0</td><td>-0.6 &#177; 2.4</td><td>28.1 &#177; 3.7</td><td>-0.5 &#177; 2.5</td><td>0.78</td><td>0.70</td></tr><tr><td><i>MSQoL-54 Measures</i></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Physical health composite score</td><td>65.5 &#177; 21.4</td><td>-5.5 &#177; 17.2</td><td>65.1 &#177; 22.3</td><td>-9.1 &#177; 18.9</td><td>0.91</td><td>0.45</td></tr><tr><td>Mental health composite score</td><td>69.1 &#177; 19.8</td><td>1.2 &#177; 20.2</td><td>71.6 &#177; 18.2</td><td>-12.1 &#177; 19.1</td><td>0.54</td><td>0.006</td></tr><tr><td>Physical function</td><td>67.7 &#177; 35.8</td><td>-2.3 &#177; 14.7</td><td>69.5 &#177; 35.4</td><td>-8.8 &#177; 19.1</td><td>0.80</td><td>0.13</td></tr><tr><td>Health perceptions</td><td>47.5 &#177; 23.4</td><td>-3.0 &#177; 23.1</td><td>48.7 &#177; 22.7</td><td>-6.0 &#177; 26.9</td><td>0.76</td><td>0.64</td></tr><tr><td>Energy</td><td>47.7 &#177; 22.6</td><td>1.1 &#177; 23.0</td><td>47.0 &#177; 23.0</td><td>-1.2 &#177; 23.0</td><td>0.91</td><td>0.57</td></tr><tr><td>Role limitation-physical</td><td>67.6 &#177; 43.5</td><td>-4.6 &#177; 42.9</td><td>65.2 &#177; 40.7</td><td>-14.3 &#177; 41.8</td><td>0.48</td><td>0.52</td></tr><tr><td>Bodily pain</td><td>79.7 &#177; 25.7</td><td>-8.7 &#177; 30.9</td><td>74.0 &#177; 29.7</td><td>-8.1 &#177; 28.6</td><td>0.39</td><td>0.41</td></tr><tr><td>Sexual function</td><td>83.1 &#177; 26.6</td><td>-6.0 &#177; 35.6</td><td>81.5 &#177; 27.0</td><td>-12.0 &#177; 36.5</td><td>0.67</td><td>0.62</td></tr><tr><td>Social function</td><td>74.2 &#177; 23.3</td><td>-5.8 &#177; 23.4</td><td>74.4 &#177; 21.3</td><td>-10.0 &#177; 21.5</td><td>0.87</td><td>0.49</td></tr><tr><td>Health distress</td><td>70.8 &#177; 23.0</td><td>-2.0 &#177; 31.6</td><td>71.9 &#177; 20.4</td><td>-13.3 &#177; 24.0</td><td>0.98</td><td>0.06</td></tr><tr><td>Overall quality of life</td><td>67.5 &#177; 19.0</td><td>-1.0 &#177; 22.3</td><td>64.4 &#177; 18.8</td><td>-8.6 &#177; 24.3</td><td>0.46</td><td>0.17</td></tr><tr><td>Cognitive function</td><td>78.6 &#177; 20.6</td><td>-0.4 &#177; 23.0</td><td>82.4 &#177; 20.6</td><td>-12.2 &#177; 23.9</td><td>0.31</td><td>0.06</td></tr><tr><td>Emotional well-being</td><td>57.1 &#177; 22.8</td><td>5.4 &#177; 43.2</td><td>59.5 &#177; 16.7</td><td>-21.6 &#177; 42.5</td><td>0.65</td><td>0.014</td></tr><tr><td>Role limitation- emotional</td><td>70.6 &#177; 43.3</td><td>0.4 &#177; 27.2</td><td>78.9 &#177; 36.3</td><td>-6.4 &#177; 21.0</td><td>0.37</td><td>0.22</td></tr><tr><td>Satisfation with sexual function</td><td>60.4 &#177; 26.7</td><td>2.0 &#177; 34.9</td><td>54.3 &#177; 30.6</td><td>-3.7 &#177; 37.0</td><td>0.33</td><td>0.40</td></tr><tr><td>Change in health</td><td>47.1 &#177; 19.9</td><td>0.5 &#177; 21.3</td><td>50.6 &#177; 22.7</td><td>4.6 &#177; 35.5</td><td>0.43</td><td>0.36</td></tr></table>
726dfd87827af4e74c73a4a4dea3fbbbc750bee2045f3866936958bf5dbe3c4b.png
complex
<table><tr><td colspan="4">Primary antibodies</td><td colspan="4">Secondary antibodies</td></tr><tr><td>Antibody</td><td>Company</td><td>Tissue</td><td>Dilution</td><td>Antibody</td><td>Company</td><td>Tissue</td><td>Dilution</td></tr><tr><td>Brn-3a</td><td>Santa Cruz</td><td>Retina</td><td>1:100</td><td>Donkey anti-goat Alexa Fluor 488</td><td>Dianova</td><td>Retina</td><td>1:1000</td></tr><tr><td>C1q</td><td>Quidel</td><td>Retina</td><td>1:2500</td><td>Donkey anti-goat IgG Cy3</td><td>Abcam</td><td>Retina</td><td>1:750</td></tr><tr><td>C3</td><td>Cedarlane</td><td>Retina</td><td>1:500</td><td>Goat anti-rabbit IgG Cy 3</td><td>Linaris</td><td>Retina</td><td>1:500</td></tr><tr><td></td><td></td><td>Optic nerve</td><td>1:500</td><td></td><td></td><td>Optic nerve</td><td>1:500</td></tr><tr><td>C5b-9 (MAC)</td><td>Biozol</td><td>Retina</td><td>1:100</td><td>Donkey anti-mouse Dy Light 488</td><td>Dianova</td><td>Retina</td><td>1:250</td></tr><tr><td></td><td></td><td>Optic nerve</td><td>1:100</td><td>Goat anti-mouse Alexa Flour 488</td><td>Invitrogen</td><td>Optic nerve</td><td>1:500</td></tr><tr><td>MASP2</td><td>Biozol</td><td>Retina</td><td>1:400</td><td>Donkey anti-rabbit Alexa Fluor 555</td><td>Invitrogen</td><td>Retina</td><td>1:400</td></tr><tr><td></td><td></td><td>Optic nerve</td><td>1:100</td><td></td><td></td><td>Optic nerve</td><td>1:700</td></tr><tr><td>MBP</td><td>Millipore</td><td>Optic nerve</td><td>1:100</td><td>Goat anti-mouse Alexa Flour 488</td><td>Invitrogen</td><td>Optic nerve</td><td>1:500</td></tr></table>
e2f53f9adf3fbd9ea1a7e041ecd0be70cf539741ed67836646a0b73c5c5adbec.png
complex
<table><tr><td></td><td colspan="2">Control</td><td colspan="2">Minority frame</td><td colspan="2">Majority frame</td></tr><tr><td>Cookie acceptance</td><td>No</td><td>Yes</td><td>No</td><td>Yes</td><td>No</td><td>Yes</td></tr><tr><td>Low impulsivity</td><td>31% (14)</td><td>69% (31)</td><td>54% (37)</td><td>46% (32)</td><td>23% (13)</td><td>77% (43)</td></tr><tr><td><i>N</i></td><td colspan="2">45</td><td colspan="2">69</td><td colspan="2">56</td></tr><tr><td>High impulsivity</td><td>12% (5)</td><td>88% (38)</td><td>36% (14)</td><td>64% (25)</td><td>16% (6)</td><td>84% (32)</td></tr><tr><td><i>N</i></td><td colspan="2">43</td><td colspan="2">39</td><td colspan="2">38</td></tr><tr><td>Low risk</td><td>30% (11)</td><td>70% (26)</td><td>59% (31)</td><td>41% (22)</td><td>23% (10)</td><td>77% (34)</td></tr><tr><td><i>n</i></td><td colspan="2">37</td><td colspan="2">53</td><td colspan="2">44</td></tr><tr><td>High risk</td><td>16% (8)</td><td>84% (43)</td><td>36% (20)</td><td>64% (35)</td><td>18% (9)</td><td>82% (41)</td></tr><tr><td><i>n</i></td><td colspan="2">51</td><td colspan="2">55</td><td colspan="2">50</td></tr></table>
b5b72b492d701c48e4cf3a7da2bd339b7d4930a27f7ec6787b67d0074b543899.png
simple
<table><tr><td>BaP</td><td></td><td>XPA</td><td>XPC</td><td>ERCC4</td><td>ERCC5</td><td>ERCC1</td></tr><tr><td>0 &#956;M</td><td>RCC4-<i>VHL</i></td><td>1.00 &#177; 0.02</td><td>1.00 &#177; 0.14</td><td>1.00 &#177; 0.08</td><td>1.00 &#177; 0.10</td><td>1.00 &#177; 0.09</td></tr><tr><td></td><td>RCC4</td><td>0.94 &#177; 0.05</td><td>0.98 &#177; 0.12</td><td>0.98 &#177; 0.03</td><td>1.16 &#177; 0.11</td><td>1.09 &#177; 0.06</td></tr><tr><td>0.1 &#956;M</td><td>RCC4-<i>VHL</i></td><td>1.02 &#177; 0.04</td><td>1.04 &#177; 0.16</td><td>0.95 &#177; 0.08</td><td>0.98 &#177; 0.08</td><td>1.01 &#177; 0.02</td></tr><tr><td></td><td>RCC4</td><td>1.15 &#177; 0.05</td><td>1.17 &#177; 0.19</td><td>0.89 &#177; 0.02</td><td>1.21 &#177; 0.12</td><td>1.17 &#177; 0.09</td></tr></table>
ba8c228812b528a7ae0d75fc6786b2f87b48168dabef6f16943b04b2b640f082.png
simple
<table><tr><td>Federal state</td><td>Percentage Av positive in total (x/y) [95% CI]</td><td>Percentage Cv positive in total (x/y) [95% CI]</td><td>Percentage Ea positive in total (x/y) [95% CI]</td><td>Percentage Av + Cv positive (x/y) [95% CI]</td><td>Percentage Av + Ea positive (x/y) [95% CI]</td><td>Percentage Cv + Ea positive (x/y) [95% CI]</td><td>Percentage Av + Cv + Ea positive (x/y) [95% CI]</td></tr><tr><td>Hesse</td><td>19.1 (17/89)[11.5&#8211;28.8]</td><td>30.3 (27/89)[21.0&#8211;41.0]</td><td>71.9 (64/89)[61.4&#8211;80.9]</td><td>1.1 (1/89)[0.0&#8211;6.1]</td><td>11.2 (10/89)[5.5&#8211;19.7]</td><td>23.6 (21/89)[15.2&#8211;33.8]</td><td>4.5 (4/89)[1.2&#8211;11.1]</td></tr><tr><td>Rhineland-Palatinate</td><td>27.3 (33/121)[19.6&#8211;36.1]</td><td>25.6 (31/121)[18.1&#8211;34.4]</td><td>75.2 (91/121)[66.5&#8211;82.6]</td><td>0.8 (1/121)[0.0&#8211;4.5]</td><td>11.6 (14/121)[6.5&#8211;18.7]</td><td>15.7 (19/121)[9.7&#8211;23.4]</td><td>8.3 (10/121)[4.0&#8211;14.7]</td></tr><tr><td>Thuringia</td><td>8.4 (30/359)[5.7&#8211;11.7]</td><td>35.1 (126/359)[30.1&#8211;40.3]</td><td>66.9 (240/359)[61.7&#8211;71.7]</td><td>0.3 (1/359)[0.0&#8211;1.5]</td><td>3.6 (13/359)[1.9&#8211;6.1]</td><td>26.5 (95/359)[22.0&#8211;31.3]</td><td>2.2 (8/359)[1.0&#8211;4.3]</td></tr><tr><td>Total</td><td>14.1 (80/569)[11.3&#8211;17.2]</td><td>32.3 (184/569)[28.5&#8211;36.4]</td><td>69.4 (395/569)[65.5&#8211;73.2]</td><td>0.5 (3/569)[0.1&#8211;1.5]</td><td>6.5 (37/569)[4.6&#8211;8.9]</td><td>23.7 (135/569)[20.3&#8211;27.4]</td><td>3.9 (22/569)[2.4&#8211;5.8]</td></tr></table>
36670078cc13d905b24dc209d9a21e9859d2c46c28f90192554f70d9feca02f7.png
complex
<table><tr><td> </td><td> </td><td>Baseline</td><td>Two sessions</td><td>After pre-treatment</td><td>Start pain rehab treatment</td><td>Finish pain rehab treatment</td><td>6 months after T3</td></tr><tr><td> </td><td>Abbr.</td><td>T0<sup>a</sup></td><td> </td><td>T1</td><td>T2<sup>a</sup></td><td>T3<sup>a</sup></td><td>T4</td></tr><tr><td colspan="8">Covariates</td></tr><tr><td>Demographics patient</td><td> </td><td>x</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td colspan="8"><i>Primary outcome effect evaluation</i></td></tr><tr><td>Participation</td><td>USER-P</td><td>x</td><td> </td><td>x</td><td> </td><td>x</td><td>x</td></tr><tr><td colspan="8"><i>Secondary outcomes effect evaluation</i></td></tr><tr><td>Physical functioning/disability</td><td>PDI</td><td>x</td><td> </td><td> </td><td>x</td><td>x</td><td>x</td></tr><tr><td>Pain intensity</td><td>VAS</td><td>x</td><td> </td><td> </td><td>x</td><td>x</td><td>x</td></tr><tr><td>Main complaints</td><td>PSC</td><td>x</td><td> </td><td> </td><td>x</td><td>x</td><td>x</td></tr><tr><td>Drop-out/adherence</td><td> </td><td> </td><td> </td><td>#</td><td> </td><td>#</td><td> </td></tr><tr><td>Self-efficacy/perceived competence</td><td>GSE</td><td>x</td><td> </td><td>x</td><td> </td><td>x</td><td>x</td></tr><tr><td>Pain-specific self-efficacy scale</td><td>CPSS_V2</td><td>x</td><td> </td><td>x</td><td> </td><td>x</td><td>x</td></tr><tr><td colspan="8"><i>Cost-effectiveness evaluation</i></td></tr><tr><td>Cost questionnaire</td><td>Tic-P</td><td>x</td><td> </td><td> </td><td>x</td><td> </td><td>x</td></tr><tr><td>Productivity losses</td><td>SF-HLQ</td><td>x</td><td> </td><td> </td><td>x</td><td> </td><td>x</td></tr><tr><td>Quality of life/health status</td><td>SF-36</td><td>x</td><td> </td><td> </td><td>x</td><td>x</td><td>x</td></tr><tr><td colspan="8">Potential active ingredients MI</td></tr><tr><td>Stages of change</td><td>MPRCQ 2</td><td>x</td><td> </td><td>x</td><td> </td><td> </td><td> </td></tr><tr><td>MI integrity/fidelity</td><td> </td><td> </td><td>*</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td colspan="8">Potential moderators</td></tr><tr><td>Credibility and expectancy of the treatment</td><td>CEQ</td><td>x</td><td> </td><td>x</td><td>x</td><td> </td><td> </td></tr><tr><td>Motivation</td><td>TMQ</td><td>x</td><td> </td><td>x</td><td> </td><td> </td><td> </td></tr><tr><td>Depression</td><td>BDI</td><td>x</td><td> </td><td> </td><td>x</td><td>x</td><td> </td></tr><tr><td>Acceptance</td><td>AAQ-II</td><td>x</td><td> </td><td>x</td><td> </td><td>x</td><td> </td></tr><tr><td>Flexible goal-adjustment</td><td>FGA</td><td>x</td><td> </td><td>x</td><td> </td><td>x</td><td> </td></tr><tr><td colspan="8">Process evaluation</td></tr><tr><td>Satisfaction with (pre-)treatment</td><td> </td><td> </td><td> </td><td>x +</td><td> </td><td> </td><td> </td></tr><tr><td>Client-centeredness</td><td>CCCQ</td><td> </td><td> </td><td>x</td><td> </td><td> </td><td> </td></tr><tr><td>Feasibility</td><td> </td><td> </td><td> </td><td>+</td><td> </td><td> </td><td> </td></tr></table>
23a4c9b133d9651c69d3a425a8ae5c9f1eb4250fc16c6e6ea756acad88994c66.png
complex
<table><tr><td rowspan="2">Activity limitation</td><td colspan="2">No</td><td colspan="2">Some</td><td colspan="2">Profound</td></tr><tr><td>Percentage with health indicator<sup>a</sup></td><td>RR (95% CI)<sup>b</sup></td><td>Percentage with health indicator<sup>a</sup></td><td>RR (95% CI)<sup>b</sup></td><td>Percentage with health indicator<sup>a</sup></td><td>RR (95% CI)<sup>b</sup></td></tr><tr><td colspan="7">Health and well-being</td></tr><tr><td> Poor self-perceived health</td><td>2.2</td><td>1</td><td>27.4</td><td>1.33 (1.32&#8211;1.37)</td><td>64.8</td><td>2.78 (2.50&#8211;3.00)</td></tr><tr><td> Poor dental status</td><td>9.5</td><td>1</td><td>21.8</td><td>1.52 (1.40&#8211;1.65)</td><td>31.1</td><td>1.85 (1.68&#8211;2.03)</td></tr><tr><td> Pain or discomfort in musculoskeletal system</td><td>71.4</td><td>1</td><td>92.1</td><td>1.27 (1.25&#8211;1.29)</td><td>93.5</td><td>1.28 (1.26&#8211;1.31)</td></tr><tr><td> Headache</td><td>31.2</td><td>1</td><td>44.6</td><td>1.50 (1.43&#8211;1.57)</td><td>49.6</td><td>1.72 (1.61&#8211;1.83)</td></tr><tr><td> Fatigue</td><td>53.2</td><td>1</td><td>74.7</td><td>1.39 (1.35&#8211;1.43)</td><td>83.5</td><td>1.51 (1.47&#8211;1.56)</td></tr><tr><td> Dyssomnia</td><td>30.0</td><td>1</td><td>51.9</td><td>1.72 (1.64&#8211;1.80)</td><td>62.9</td><td>2.10 (1.98&#8211;2.23)</td></tr><tr><td> Psychological symptoms</td><td>29.9</td><td>1</td><td>49.5</td><td>1.69 (1.61&#8211;1.76)</td><td>61.6</td><td>2.11 (1.99&#8211;2.24)</td></tr><tr><td> Stress</td><td>14.0</td><td>1</td><td>33.7</td><td>2.46 (2.29&#8211;2.64)</td><td>55.3</td><td>4.05 (3.74&#8211;4.38)</td></tr><tr><td> Hypnotics/sedatives (prescription-only)</td><td>4.1</td><td>1</td><td>14.9</td><td>3.32 (2.92&#8211;3.77)</td><td>27.0</td><td>5.89 (5.08&#8211;6.84)</td></tr><tr><td> Hypnotics/sedatives (over-the-counter)</td><td>0.8</td><td>1</td><td>2.1</td><td>2.71 (1.97&#8211;3.71)</td><td>2.6</td><td>3.32 (2.10&#8211;5.26)</td></tr><tr><td> Analgesics (prescription-only)</td><td>11.9</td><td>1</td><td>35.7</td><td>2.89 (2.69&#8211;3.10)</td><td>54.0</td><td>4.32 (3.98&#8211;4.69)</td></tr><tr><td> Analgesics (over-the-counter)</td><td>34.7</td><td>1</td><td>43.0</td><td>1.30 (1.24&#8211;1.36)</td><td>40.6</td><td>1.28 (1.19&#8211;1.39)</td></tr><tr><td> Laxatives (prescription-only)</td><td>2.9</td><td>1</td><td>11.5</td><td>3.70 (3.19&#8211;4.30)</td><td>20.3</td><td>6.61 (5.53&#8211;7.89)</td></tr><tr><td> Laxatives (over-the-counter)</td><td>0.4</td><td>1</td><td>1.2</td><td>3.19 (2.05&#8211;4.97)</td><td>1.8</td><td>4.66 (2.59&#8211;8.40)</td></tr><tr><td> No sexual contact</td><td>26.2</td><td>1</td><td>37.8</td><td>1.19 (1.13&#8211;1.25)</td><td>51.4</td><td>1.30 (1.24&#8211;1.38)</td></tr><tr><td> Unsatisfied with sexual life</td><td>14.2</td><td>1</td><td>18.9</td><td>1.40 (1.29&#8211;1.53)</td><td>22.0</td><td>1.62 (1.41&#8211;1.85)</td></tr></table>
5893f666fdf2da87a8ac416ccf57340962b1e070e1c05ec1529689aeff9c4b71.png
simple
<table><tr><td></td><td>Mean growth rate (SD) non-manual social class</td><td>Mean difference (95% CI) manual vs. non-manual social class</td></tr><tr><td>Birth length, cm Growth rate, cm/month</td><td>50.173 (1.642)</td><td>&#8722;0.439 (&#8722;0.599 to &#8722;0.279)</td></tr><tr><td> 0&#8211;3 months</td><td>3.553 (0.241)</td><td>0.087 (0.016 to 0.158)</td></tr><tr><td> 3&#8211;12 months</td><td>1.626 (0.136)</td><td>&#8722;0.002 (&#8722;0.030 to 0.026)</td></tr><tr><td> 1&#8211;3 years</td><td>0.836 (0.071)</td><td>&#8722;0.015 (&#8722;0.026 to &#8722;0.005)</td></tr><tr><td> 3&#8211;10 years</td><td>0.531 (0.035)</td><td>&#8722;0.008 (&#8722;0.013 to &#8722;0.003)</td></tr></table>
4d58ad5975b1b9f847ae98a4409596bd1183c415e105939d3c862ea5eed1ebf1.png
simple
<table><tr><td>Method</td><td>Total number</td><td>Disorder number</td><td>Success rate</td></tr><tr><td>Subcutaneous injection of sesame oil</td><td>10</td><td>0</td><td>0.00%</td></tr><tr><td>Subcutaneous injection of DHEA</td><td>40</td><td>25</td><td>62.50%</td></tr></table>
98a917c013cbf2f40d7a1fca1991829d2947bf00f81fd3c735b6df089c1f0b1e.png
complex
<table><tr><td colspan="2">PBMS</td><td colspan="4">Comparison of PBMS parameters between study groups</td></tr><tr><td colspan="2">Domains</td><td>control</td><td>intervention</td><td>range</td><td>p</td></tr><tr><td> </td><td>Sub-domains</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td colspan="2">1 Attitude</td><td>3.5 (1.9)</td><td>3.0 (1.8)</td><td>0-9</td><td>.04*</td></tr><tr><td> </td><td>a: expectations regarding outcomes</td><td>1.8 (0.6)</td><td>1.6 (0.6)</td><td>0-3</td><td>.001*</td></tr><tr><td> </td><td>b: values of expected outcomes</td><td>1.8 (0.6)</td><td>1.8 (0.6)</td><td>0-3</td><td>.55</td></tr><tr><td colspan="2">2 Social norm</td><td>2.1 (1.2)</td><td>1.7 (1.0)</td><td>0-9</td><td>.006*</td></tr><tr><td> </td><td>a: assumed attitudes of important others</td><td>1.9 (0.6)</td><td>1.8 (0.7)</td><td>0-3</td><td>.28</td></tr><tr><td> </td><td>b: motivation to comply with these norms</td><td>1.1 (0.4)</td><td>1.0 (0.4)</td><td>0-3</td><td>.004*</td></tr><tr><td colspan="2">3 Control beliefs</td><td>3.2 (2.1)</td><td>2.9 (2.1)</td><td>0-9</td><td>.313</td></tr><tr><td> </td><td>a: assumed facilitators or barriers</td><td>1.6 (0.7)</td><td>1.4 (0.8)</td><td>0-3</td><td>.14</td></tr><tr><td> </td><td>b: perceived power of these factors</td><td>1.8 (0.6)</td><td>1.7 (0.7)</td><td>0-3</td><td>.42</td></tr><tr><td colspan="2">Intention estimate</td><td>8.9 (4.1)</td><td>7.5 (4.4)</td><td>0-27</td><td>.04*</td></tr></table>
8dae2664a4552b96ed75e889ec3b6cde0886afaf75768e215dc5dc95a6c3b1d1.png
simple
<table><tr><td>Objective</td><td>Control Group</td><td>Coadministration Group</td><td>Noninferiority Analysis</td></tr><tr><td>Primary objectives</td><td></td><td></td><td></td></tr><tr><td> HZ/su VRR (95% CI), %<sup>b</sup></td><td>n = 388</td><td>n = 382</td><td>...</td></tr><tr><td></td><td>97.9 (96.0&#8211;99.1)</td><td>95.8 (93.3&#8211;97.6)</td><td>ND</td></tr><tr><td> Noninferiority of anti-gE GMC<sub>Coadmin</sub> (95% CI), mIU/mL</td><td>n = 388</td><td>n = 382</td><td>GMC<sub>Control</sub>/GMC<sub>Coadmin</sub> (95% CI)<sup>c</sup></td></tr><tr><td>GMC</td><td>56848 (53 598&#8211;60 295)</td><td>52 861 (48 386&#8211;57 749)</td><td>ND</td></tr><tr><td>Adjusted GMC<sup>c</sup></td><td>56 247 (52 177&#8211;60 635)</td><td>52 152 (48 356&#8211;56 245)</td><td>1.08 (0.97&#8211;1.20)<sup>d</sup></td></tr><tr><td> Noninferiority of influenza GMT by strain (95% CI), 1/dilution</td><td>n = 394</td><td>n = 384</td><td>GMT<sub>Control</sub>/GMT<sub>Coadmin</sub> (95% CI)<sup>c</sup></td></tr><tr><td>GMT</td><td></td><td></td><td></td></tr><tr><td>A/H1N1</td><td>193.2 (170.2&#8211;219.4)</td><td>196.2 (172.2&#8211;223.5)</td><td>ND</td></tr><tr><td>A/H3N2</td><td>66.8 (60.4&#8211;74.0)</td><td>65.4 (59.0&#8211;72.5)</td><td>ND</td></tr><tr><td>B/Victoria</td><td>185.2 (168.0&#8211;204.1)</td><td>177.2 (161.6&#8211;194.2)</td><td>ND</td></tr><tr><td>B/Yamagata</td><td>423.3 (388.0&#8211;461.8)</td><td>433.7 (401.3&#8211;468.7)</td><td>ND</td></tr><tr><td>Adjusted GMT<sup>c</sup></td><td></td><td></td><td></td></tr><tr><td>A/H1N1</td><td>194.3 (173.0&#8211;218.1)</td><td>187.5 (166.7&#8211;210.8)</td><td>1.04 (0.88&#8211;1.22)<sup>d</sup></td></tr><tr><td>A/H3N2</td><td>65.9 (60.3&#8211;72.0)</td><td>63.7 (58.3&#8211;69.7)</td><td>1.03 (0.91&#8211;1.17)<sup>d</sup></td></tr><tr><td>B/Victoria</td><td>181.6 (166.7&#8211;197.8)</td><td>170.2 (156.1&#8211;185.6)</td><td>1.07 (0.95&#8211;1.20)<sup>d</sup></td></tr><tr><td>B/Yamagata</td><td>413.9 (383.4&#8211;446.8)</td><td>423.5 (392.0&#8211;457.5)</td><td>0.98 (0.88&#8211;1.09)<sup>d</sup></td></tr><tr><td>Secondary objectives</td><td></td><td></td><td></td></tr><tr><td> Noninferiority of influenza SCRs by strain (95% CI), %<sup>e</sup></td><td>n = 394</td><td>n = 384</td><td>SCR<sub>Control</sub> &#8211; SCR<sub>Coadmin</sub> (95% CI)<sup>f</sup></td></tr><tr><td>A/H1N1</td><td>60.9 (55.9&#8211;65.8)</td><td>60.4 (55.3&#8211;65.3)</td><td>0.50 (&#8722;6.36 to 7.35)<sup>d</sup></td></tr><tr><td>A/H3N2</td><td>35.3 (30.6&#8211;40.2)</td><td>35.4 (30.6&#8211;40.4)</td><td>&#8722;0.14 (&#8722;6.85 to 6.57)<sup>d</sup></td></tr><tr><td>B/Victoria</td><td>42.9 (37.9&#8211;47.9)</td><td>37.2 (32.4&#8211;42.3)</td><td>5.65 (&#8722;1.24 to 12.49)</td></tr><tr><td>B/Yamagata</td><td>37.6 (32.8&#8211;42.6)</td><td>40.1 (35.2&#8211;45.2)</td><td>&#8722;2.54 (&#8722;9.37 to 4.31)<sup>d</sup></td></tr></table>
b9a89a98610e3fd00f15f080823510bf627984236665c1a8a5a10cca9dbceb5a.png
complex
<table><tr><td></td><td colspan="4">Estimates</td><td colspan="6">Local adaptation contrasts</td></tr><tr><td>Measure (n)</td><td>Local scale (1)</td><td>Small scale (2)</td><td>Intermediate scale (3)</td><td>Large-scale (4)</td><td>1 vs. 2</td><td>1 vs. 3</td><td>1 vs. 4</td><td>1 + 2 vs. 3</td><td>1 + 2 vs. 4</td><td>1 + 2 + 3 vs. 4</td></tr><tr><td>Infectivity (<i>n</i> &gt; 1076)</td><td>0.662</td><td>0.586</td><td>0.711</td><td>0.663</td><td>NS</td><td>NS</td><td>NS</td><td>NS</td><td>NS</td><td>NS</td></tr><tr><td>Time to sporulation (<i>n</i> &gt; 667)</td><td>8.275</td><td>8.437</td><td>8.261</td><td>8.174</td><td>NS</td><td>NS</td><td>NS</td><td>NS</td><td>0.08</td><td>0.10</td></tr><tr><td>Aggressiveness (<i>n</i> &gt; 660)</td><td>3.156</td><td>3.092</td><td>3.196</td><td>3.238</td><td>NS</td><td>NS</td><td>NS</td><td>NS</td><td>0.04</td><td>0.07</td></tr><tr><td>Colony size (<i>n</i> &gt; 660)</td><td>2.201</td><td>2.012</td><td>2.356</td><td>2.294</td><td>NS</td><td>NS</td><td>NS</td><td>0.03</td><td>0.08</td><td>NS</td></tr><tr><td>Fitness 1 (<i>n</i> &gt; 660)</td><td>2.274</td><td>2.213</td><td>2.327</td><td>2.385</td><td>NS</td><td>NS</td><td>0.07</td><td>NS</td><td>0.01</td><td>0.02</td></tr><tr><td>Fitness 2 (<i>n</i> &gt; 660)</td><td>1.485</td><td>1.456</td><td>1.506</td><td>1.534</td><td>NS</td><td>NS</td><td>0.08</td><td>NS</td><td>0.01</td><td>0.02</td></tr><tr><td>Sexual spore production (<i>n</i> &gt; 342)</td><td>0.158</td><td>0.148</td><td>0.285</td><td>0.183</td><td>NS</td><td>0.08</td><td>NS</td><td>0.04</td><td>NS</td><td>NS</td></tr></table>
f7eaca424474eb4512baa954e6dc2284b58d74719b63da488112315f0fdeaf21.png
complex
<table><tr><td>Groups</td><td>UACR (mg/g)</td><td>Total</td></tr><tr><td>Normal albuminuria (NA) (<i>n</i> = 35)</td><td>UACR &lt; 30</td><td rowspan="3"><i>n</i> = 80</td></tr><tr><td>Microalbuminuria (MA) (<i>n</i> = 30)</td><td>30 &#8804; UACR &lt; 300</td></tr><tr><td>Clinical albuminuria (CA) (<i>n</i> = 15)</td><td>UACR &#8805; 300</td></tr><tr><td>Normal group (NC) (<i>n</i> = 80)</td><td>Non-diabetic subjects</td><td><i>n</i> = 80</td></tr></table>
3e76bcf11062f7b70828881372569e1d52f159fb1b202a18cb9315aa31cf8b8c.png
complex
<table><tr><td>Factors related to attitude</td><td>Number</td><td>Mean score</td><td>SD</td><td><i>P</i> &#8211; Value</td></tr><tr><td>Location</td><td>396</td><td>78.52</td><td>14.97</td><td></td></tr><tr><td>Rural</td><td>306</td><td>77.78</td><td>14.97</td><td rowspan="2"><i>P =</i> 0.066</td></tr><tr><td>Urban</td><td>90</td><td>81.02</td><td>13.74</td></tr><tr><td>Age</td><td>396</td><td>78.52</td><td>14.75</td><td></td></tr><tr><td>18&#8211;24 Years</td><td>24</td><td>82.96</td><td>13.28</td><td rowspan="5"><i>P</i> = 0.000</td></tr><tr><td>25&#8211;34 Years</td><td>89</td><td>83.74</td><td>14.74</td></tr><tr><td>35&#8211;44 Years</td><td>135</td><td>76.76</td><td>13.84</td></tr><tr><td>45&#8211;54 Years</td><td>115</td><td>77.72</td><td>14.78</td></tr><tr><td>55&#8211;60 Years</td><td>33</td><td>71.15</td><td>14.77</td></tr><tr><td>Gender</td><td>396</td><td>78.52</td><td>14.75</td><td></td></tr><tr><td>Male</td><td>73</td><td>82.97</td><td>15.26</td><td rowspan="2"><i>P</i> = 0.004</td></tr><tr><td>Female</td><td>323</td><td>77.51</td><td>14.46</td></tr><tr><td>Caste</td><td>396</td><td>78.52</td><td>14.75</td><td></td></tr><tr><td>Dalit</td><td>35</td><td>69.69</td><td>12.55</td><td rowspan="2"><i>P</i> = 0.000</td></tr><tr><td>Non Dalit</td><td>361</td><td>79.37</td><td>14.68</td></tr><tr><td>Provider&#8217;s Type</td><td>396</td><td>78.52</td><td>14.75</td><td></td></tr><tr><td>Dr/HA/AHW</td><td>87</td><td>82.64</td><td>15.10</td><td rowspan="3"><i>P</i> = 0.000</td></tr><tr><td>Nurse/ANM</td><td>94</td><td>85.59</td><td>13.45</td></tr><tr><td>FCHVs</td><td>215</td><td>73.75</td><td>13.40</td></tr></table>
472eea06e69a0a725aedc2ea8e070ac308a730e0277e21d5f43447de860f94ca.png
complex
<table><tr><td></td><td colspan="3">All patients</td><td colspan="3">CN-AML patients</td></tr><tr><td>Final model</td><td>HR</td><td>95% CI</td><td>P-value</td><td>HR</td><td>95% CI</td><td>P-value</td></tr><tr><td>Presence of unfavorable karyotype</td><td>2.54</td><td>1.56&#8211;4.12</td><td>&lt;0.001</td><td>NA</td><td>NA</td><td>NA</td></tr><tr><td>Presence of SNP-A lesion(s)</td><td>2.25</td><td>1.39&#8211;3.65</td><td>0.001</td><td>2.38</td><td>1.28&#8211;4.43</td><td>0.006</td></tr><tr><td>Presence of <i>NPM1</i> mutation</td><td>1.12</td><td>0.67&#8211;1.87</td><td>0.68</td><td>NA</td><td>NA</td><td>NA</td></tr><tr><td>Presence of <i>EVI1</i> overexpression</td><td>1.63</td><td>0.87&#8211;3.06</td><td>0.12</td><td>NA</td><td>NA</td><td>NA</td></tr><tr><td>Presence of <i>DNMT3A</i> mutation</td><td>NA</td><td>NA</td><td>NA</td><td>1.91</td><td>1.02&#8211;3.56</td><td>0.042</td></tr><tr><td>Presence of <i>IDH2</i>R140 mutation</td><td>NA</td><td>NA</td><td>NA</td><td>0.38</td><td>0.09&#8211;1.63</td><td>0.19</td></tr><tr><td>Randomization in the GO arm</td><td>0.75</td><td>0.49&#8211;1.13</td><td>0.17</td><td>0.51</td><td>0.27&#8211;0.98</td><td>0.043</td></tr></table>
0ab9ab9d8282f0117ae313059acf566de7858effe943bf0f9c053f36bcdf572c.png
complex
<table><tr><td rowspan="2">Closest taxon </td><td rowspan="2">Log inactivation</td><td colspan="4">Resistance (log<sub>10</sub>(CFU&#183;100 mL<sup>&#8722;</sup><sup>1</sup>))</td></tr><tr><td>Maximum</td><td>Treatment</td><td>Minimum </td><td>Treatment </td></tr><tr><td><i>A. hydrophila</i></td><td>0.84</td><td>10.43</td><td>TI 30 mg&#183;L<sup>&#8722;g</sup>/15 min</td><td>11.27</td><td>TII 20 mg&#183;L<sup>&#8722;g</sup>/0 min</td></tr><tr><td><i>E. coli</i></td><td>1.31</td><td>10.15</td><td>TI 8 mg&#183;L<sup>&#8722;g</sup>/30 min</td><td>11.45</td><td>TIII 8 mg&#183;L<sup>&#8722;g</sup>/30 min</td></tr><tr><td><i>E. coli</i> PD3</td><td>1.86</td><td>10.62</td><td>TIII 30 mg&#183;L<sup>&#8722;g</sup>/0 min</td><td>12.48</td><td>TI 30 mg&#183;L<sup>&#8722;g</sup>/0 min</td></tr><tr><td><i>E. coli</i> BL21</td><td>0.80</td><td>10.37</td><td>TI 8 mg&#183;L<sup>&#8722;g</sup>/0 min</td><td>11.18</td><td>TII 20 mg&#183;L<sup>&#8722;g</sup>/0 min</td></tr><tr><td><i>E. cloacae</i></td><td>0.81</td><td>10.38</td><td>TIII 30 mg&#183;L<sup>&#8722;g</sup>/30 min</td><td>11.19</td><td>TIII 8 mg&#183;L<sup>&#8722;g</sup>/0 min</td></tr></table>
47627a4e95a2baf011823c702c1f6673b6d4b3f064fe363e0a8b4d848e10cc94.png
simple
<table><tr><td>Characteristic</td><td>EBT (<i>n</i> = 7)</td><td>3DRT (<i>n</i> = 14)</td><td>IMRT (<i>n</i> = 11)</td><td><i>P</i></td></tr><tr><td>Age (mean &#177; SD)</td><td>60.4 &#177; 17.4</td><td>58.2 &#177; 12.0</td><td>52.3 &#177; 7.6</td><td>0.32</td></tr><tr><td>Sex (female%)</td><td>100</td><td>29</td><td>64</td><td>0.007</td></tr><tr><td>Race (Caucasian%)</td><td>85.7</td><td>64.2</td><td>63.6</td><td>0.55</td></tr><tr><td>ECOG (mean &#177; SD)</td><td>0.21 &#177; 0.41</td><td>0.17 &#177; 0.39</td><td>0.20 &#177; 0.42</td><td>0.84</td></tr><tr><td>Pre-RT CEA (median (range) ng/mL)</td><td>4.5 (1.5&#8211;15.5)</td><td>7.4 (1.5&#8211;168.1)</td><td>3.7 (1.5&#8211;11.9)</td><td>0.35<sup>&#8727;</sup></td></tr><tr><td>Pre-RT tumor volume (median (range) cm<sup>3</sup>)</td><td>13.1 (0.9&#8211;26.4)</td><td>25.2 (6.3&#8211;119.0)</td><td>6.1 (1.9&#8211;76.6)</td><td>0.11<sup>&#8727;</sup></td></tr><tr><td>Time between pre-RT MRI and RT start (mean &#177; SD days)</td><td>20 &#177; 11</td><td>22 &#177; 10</td><td>34 &#177; 31</td><td>0.30</td></tr><tr><td>Number. T3 (%)</td><td>5 (71)</td><td>12 (86)</td><td>8 (73)</td><td>0.66</td></tr><tr><td>Number T4 (%)</td><td>0 (0)</td><td>2 (14)</td><td>0 (0)</td><td>0.25</td></tr><tr><td>Number N0 (%)</td><td>4 (57)</td><td>4 (29)</td><td>3 (27)</td><td>0.36</td></tr><tr><td>Number N1 (%)</td><td>3 (43)</td><td>8 (57)</td><td>6 (55)</td><td>0.82</td></tr><tr><td>Number N2 (%)</td><td>0 (0)</td><td>2 (14)</td><td>0 (0)</td><td>0.25</td></tr><tr><td>Distance of tumor from anal verge (mean &#177; SD cm)</td><td>6.2 &#177; 1.9</td><td>8.4 &#177; 5.0</td><td>5.4 &#177; 2.5</td><td>0.80</td></tr></table>
2153ceb42b9bdde752a5de70835760f5c6d7e7ef61b7b34530a23e2830e936a4.png
simple
<table><tr><td>Characteristics</td><td>Fresh frozen tissue (%)</td><td>Paraffin-embedded tissue (%)</td></tr><tr><td>Gender</td><td> </td><td> </td></tr><tr><td>Male</td><td>103 (66)</td><td>88 (56)</td></tr><tr><td>Female</td><td>53 (34)</td><td>70 (44)</td></tr><tr><td>Age (years)</td><td> </td><td> </td></tr><tr><td>&lt;70</td><td>48 (32)</td><td>59 (37)</td></tr><tr><td>&#8805;70</td><td>104 (68)</td><td>99 (63)</td></tr><tr><td>Location</td><td> </td><td> </td></tr><tr><td>Colon</td><td>98 (63)</td><td>77 (49)</td></tr><tr><td>Rectum</td><td>57 (37)</td><td>81 (51)</td></tr><tr><td>Stage</td><td> </td><td> </td></tr><tr><td>I</td><td>20 (14)</td><td>25 (16)</td></tr><tr><td>II</td><td>73 (50)</td><td>61 (39)</td></tr><tr><td>III</td><td>34 (23)</td><td>40 (25)</td></tr><tr><td>IV</td><td>18 (12)</td><td>31 (20)</td></tr><tr><td>Differentiation</td><td> </td><td> </td></tr><tr><td>Well/moderately</td><td>110 (73)</td><td>107 (68)</td></tr><tr><td>Poorly</td><td>40 (27)</td><td>50 (32)</td></tr></table>
89c67e5d4a4b184127b31a62218c0bc755ab784115457e4ca6cb1b78974ce97b.png
complex
<table><tr><td></td><td></td><td>All patients</td><td colspan="2">Anti-CCP</td><td><i>P </i>value</td></tr><tr><td></td><td></td><td></td><td>Negative</td><td>Positive</td><td></td></tr><tr><td>Age</td><td>&lt;50*</td><td>45 (75%)</td><td>8 (17.8%)</td><td>37 (82.2%)</td><td>NS</td></tr><tr><td></td><td>&#8805;50</td><td>15 (25%)</td><td>2 (13.3%)</td><td>13 (86.7%)</td><td></td></tr><tr><td>Sex</td><td>female</td><td>54 (90%)</td><td>9 (16.7%)</td><td>45 (83.3%)</td><td>NS</td></tr><tr><td></td><td>male</td><td>6 (10%)</td><td>1 (16.7%)</td><td>5 (83.3%)</td><td></td></tr><tr><td>Duration</td><td>&lt;6m</td><td>3 (5%)</td><td>1 (33.3%)</td><td>2 (66.7%)</td><td>NS</td></tr><tr><td></td><td>&#8805;6m</td><td>57 (95%)</td><td>9 (15.8%)</td><td>48 (84.2%)</td><td></td></tr><tr><td>Smoking</td><td>yes</td><td>5 (8.3%)</td><td>1 (20%)</td><td>4 (80%)</td><td>NS</td></tr><tr><td></td><td>no</td><td>55 (91.7%)</td><td>9 (16.4%)</td><td>46 (83.6%)</td><td></td></tr><tr><td>CRP</td><td>&lt;18 *</td><td>26 (43.3%)</td><td>7 (26.9%)</td><td>19 (73.1%)</td><td>NS</td></tr><tr><td></td><td>&#8805;18</td><td>34 (56.7%)</td><td>3 (8.8%)</td><td>31 (91.2%)</td><td></td></tr><tr><td>RF</td><td>+ve</td><td>43 (71.7%)</td><td>4 (9.3%)</td><td>39 (90.7%)</td><td>0.02</td></tr><tr><td></td><td></td><td></td><td>6 (35%)</td><td>11 (65%)</td><td></td></tr><tr><td>ESR-1</td><td>&lt;32 *</td><td>14 (23.3%)</td><td>5 (35.7%)</td><td>9 (64.3%)</td><td>0.04</td></tr><tr><td></td><td>&#8805;32</td><td>46 (76.7%)</td><td>5 (10.9%)</td><td>41 (89.1%)</td><td></td></tr><tr><td>ANA</td><td>+ve</td><td>22 (36.7%)</td><td>0 (0%)</td><td>22 (100%)</td><td>0.03</td></tr><tr><td></td><td>-ve</td><td>38 (63.3%)</td><td>10 (40.8%)</td><td>28 (59.2%)</td><td></td></tr><tr><td>AKA</td><td>+ve</td><td>31 (52%)</td><td>3 (10%)</td><td>28 (90%)</td><td></td></tr><tr><td></td><td>-ve</td><td>29 (48%)</td><td>17 (59%)</td><td>12 (41%)</td><td>0.05</td></tr><tr><td>Grade of activity (DAS)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> - Mild or moderete</td><td></td><td>25 (41.7%)</td><td>9 (31.6%)</td><td>16 (68.4%)</td><td>0.001</td></tr><tr><td> - Severe</td><td></td><td>35 (58.3%)</td><td>1 (9.8%)</td><td>34 (90.2%)</td><td></td></tr><tr><td>Larsen score</td><td>&lt;35*</td><td>19 (31.7%)</td><td>6 (10%)</td><td>13 (21.7%)</td><td>0.05</td></tr><tr><td></td><td>&#8805;35</td><td>41(68.3%)</td><td>4 (6.7%)</td><td>37 (61.7%)</td><td></td></tr><tr><td>HLA-<i>DRB1*04</i></td><td>+ve</td><td>21 (35%)</td><td>2 (9.5%)</td><td>19 (90.5%)</td><td>NS</td></tr><tr><td></td><td>-ve</td><td>39 (65%)</td><td>8 (20.5%)</td><td>31 (79.5%)</td><td></td></tr><tr><td>HLA-<i>RB1*01</i></td><td>+ve</td><td>27 (45%)</td><td>5 (19%)</td><td>22 (81%)</td><td>NS</td></tr><tr><td></td><td>-ve</td><td>33 (55%)</td><td>5 (15%)</td><td>28 (85%)</td><td></td></tr></table>
2bba4c29f3f6c1670fcee3b6c1659da8dab28034e4fc4c9eb2ab3dc832caa2dc.png
simple
<table><tr><td>Characteristics</td><td>Synbiotics (<i>n</i> = 43)</td><td>Placebo (<i>n</i> = 42)</td><td><i>p</i>-Value</td></tr><tr><td>Sex *</td><td></td><td></td><td></td></tr><tr><td> Male</td><td>7 (16.3)</td><td>5 (11.9)</td><td>0.533</td></tr><tr><td> Female</td><td>36 (83.7)</td><td>37 (88.1)</td><td></td></tr><tr><td>Age (years) <sup>&#966;</sup></td><td>29.5 &#177; 8.34</td><td>27.5 &#177; 6.5</td><td>0.368</td></tr><tr><td>Ethnicity *</td><td></td><td></td><td></td></tr><tr><td> Malay</td><td>36 (83.7)</td><td>38 (90.5)</td><td>0.332</td></tr><tr><td> Non-Malay</td><td>7 (16.3)</td><td>4 (9.5)</td><td></td></tr><tr><td>Weight (kg) <sup>&#966;</sup></td><td>59.4 &#177; 11.7</td><td>58.7 &#177; 12.6</td><td>0.911</td></tr><tr><td>Height (m) <sup>&#966;</sup></td><td>1.59 &#177; 0.09</td><td>1.59 &#177; 0.09</td><td>0.738</td></tr><tr><td>BMI (kg/m<sup>2</sup>) <sup>&#966;</sup></td><td>23.6 &#177; 4.1</td><td>23.6 &#177; 4.1</td><td>0.578</td></tr><tr><td>Waist circumference (cm) <sup>&#966;</sup></td><td>80.0 &#177; 9.5</td><td>80.0 &#177; 9.5</td><td>0.977</td></tr></table>
89e80e1f26c7ef4f439e47fa9815aed670e0815e1db00a5d444d5b20d371f15b.png
simple
<table><tr><td></td><td></td><td>Germany</td><td>Greece</td><td>Norway</td><td>Spain</td><td>Sweden</td><td>UK</td></tr><tr><td>Absenteeism, hours/week</td><td>n</td><td>187</td><td>249</td><td>233</td><td>131</td><td>196</td><td>132</td></tr><tr><td></td><td></td><td>3.2 (8.8)</td><td>1.5 (5.1)</td><td>0.9 (4.7)</td><td>2.1 (7.1)</td><td>0.7 (3.4)</td><td>0.4 (2.7)</td></tr><tr><td>Presenteeism (work hours lost/week due to reduced productivity while working)</td><td>n</td><td>158</td><td>252</td><td>231</td><td>122</td><td>178</td><td>118</td></tr><tr><td></td><td></td><td>5.7 (8.6)</td><td>5.1 (7.7)</td><td>6.7 (6.2)</td><td>4.7 (8.2)</td><td>7.7 (7.5)</td><td>3.5 (6.6)</td></tr><tr><td>Lost work productivity score*</td><td>n</td><td>189</td><td>248</td><td>231</td><td>120</td><td>196</td><td>131</td></tr><tr><td></td><td></td><td>16.7 (22.6)</td><td>12.3 (17.3)</td><td>18.1 (16.9)</td><td>17.1 (26.9)</td><td>17.0 (16.1)</td><td>9.1 (16.4)</td></tr></table>
8f8e6e01a3582ae7b0a0c882525d582133f939fddc569fdfdb03bfb956636926.png
complex
<table><tr><td rowspan="2">Phylogenetic Group</td><td colspan="10">A</td><td rowspan="2" colspan="3">B</td></tr><tr><td colspan="5">A1</td><td colspan="4">A2</td><td>A3</td></tr><tr><td>Predicted CDS</td><td>EhV-84</td><td>EhV-86</td><td>EhV-88</td><td>EhV-145</td><td>EhV-164</td><td>EhV-201</td><td>EhV-203</td><td>EhV-207</td><td>EhV-208</td><td>EhV-99B1</td><td>EhV-202</td><td>EhV-18</td><td>EhV-156</td></tr><tr><td>hypothetical protein</td><td>27</td><td>3</td><td>4</td><td>7</td><td>8</td><td>4</td><td>4</td><td>9</td><td>9</td><td>6</td><td>18</td><td>9</td><td>6</td></tr><tr><td>putative endonuclease</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>2</td><td></td><td></td><td></td></tr><tr><td>putative membrane protein</td><td></td><td>2</td><td></td><td>1</td><td>1</td><td></td><td></td><td></td><td></td><td>4</td><td></td><td></td><td></td></tr><tr><td>putative transposase</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>1</td><td></td><td></td><td></td></tr><tr><td>putative DUF814 domain containing protein</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>1</td><td></td><td></td><td></td></tr><tr><td>zinc finger protein</td><td></td><td></td><td></td><td></td><td></td><td></td><td>1</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>putative ribonuclease</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>1</td><td>1</td></tr><tr><td>glycosyltransferase family 29 (sialyltransferase)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>1</td><td>1</td></tr><tr><td>Total</td><td>27</td><td>5</td><td>4</td><td>8</td><td>9</td><td>4</td><td>5</td><td>9</td><td>9</td><td>15</td><td>18</td><td>11</td><td>8</td></tr></table>
d9c59573b9ad1fe058339bffef81c349fefcd297cf972544d0f9a22924653e02.png
simple
<table><tr><td>study</td><td><i>y</i><sub><i>i</i>1</sub></td><td><i>y</i><sub><i>i</i>2</sub></td><td><i>n</i><sub><i>i</i>1</sub></td><td><i>n</i><sub><i>i</i>2</sub></td><td><i>p</i><sub><i>i</i>1</sub></td><td><i>p</i><sub><i>i</i>2</sub></td></tr><tr><td>1</td><td>14</td><td>14</td><td>131</td><td>136</td><td>0.1068</td><td>0.1029</td></tr><tr><td>2</td><td>21</td><td>17</td><td>385</td><td>134</td><td>0.0545</td><td>0.1268</td></tr><tr><td>3</td><td>14</td><td>24</td><td>57</td><td>48</td><td>0.2456</td><td>0.5000</td></tr><tr><td>4</td><td>6</td><td>18</td><td>38</td><td>40</td><td>0.1579</td><td>0.4500</td></tr><tr><td>5</td><td>12</td><td>35</td><td>1011</td><td>760</td><td>0.0118</td><td>0.0460</td></tr><tr><td>6</td><td>138</td><td>175</td><td>1370</td><td>1336</td><td>0.1007</td><td>0.1310</td></tr><tr><td>7</td><td>15</td><td>20</td><td>506</td><td>524</td><td>0.0296</td><td>0.0382</td></tr><tr><td>8</td><td>6</td><td>2</td><td>108</td><td>103</td><td>0.0555</td><td>0.0194</td></tr><tr><td>9</td><td>65</td><td>40</td><td>153</td><td>102</td><td>0.4248</td><td>0.3921</td></tr></table>
3e62911ddaf3a4d3f260b125c47b3a0d98ae59af5b916d5969651bb0ad2da449.png
complex
<table><tr><td rowspan="2"></td><td rowspan="2">Exposure time [min]</td><td colspan="3">HIV-1 titer [TCID<sub>50</sub>/ml] after exposure to uncoated and coated coverslip and after washing with 0.49 ml of PBS</td><td rowspan="2">HIV-1 titer reduction<sup><i>a</i></sup></td><td rowspan="2"><i>p</i>-value<sup><i>b</i></sup></td></tr><tr><td>Coverslip #1</td><td>Coverslip #2</td><td>Coverslip #3</td></tr><tr><td rowspan="2">Uncoated coverslip</td><td>5</td><td>3981</td><td>3981</td><td>3981</td><td>-</td><td>-</td></tr><tr><td>20</td><td>3981</td><td>1000</td><td>3981</td><td>-</td><td>-</td></tr><tr><td rowspan="2">Coated coverslip by heat polymerization</td><td>5</td><td>251</td><td>1259</td><td>1000</td><td>79 %</td><td>&lt;0.001</td></tr><tr><td>20</td><td>316</td><td>251</td><td>316</td><td>90 %</td><td>&lt;0.05</td></tr><tr><td rowspan="2">Coated coverslip by photopolymerization</td><td>5</td><td>63</td><td>63</td><td>63</td><td>98 %</td><td>&lt;0.001</td></tr><tr><td>20</td><td>0</td><td>20</td><td>0</td><td>99.8 %</td><td>&lt;0.05</td></tr></table>
b7b1ea725f95297c323bdba5d2fb5f0852ace7e37eb8d72c7de5fdcb6f1a7c47.png
simple
<table><tr><td>Gender</td><td>Functional dyspepsia</td><td>Organic dyspepsia</td><td>Total</td></tr><tr><td>Male</td><td>72 </td><td>40</td><td>112</td></tr><tr><td>Female</td><td>120</td><td>64</td><td>184</td></tr><tr><td>Total</td><td>192</td><td>104</td><td>296</td></tr></table>
4c1a255b4ee781b18b935ac56c71cf078528f58a30e06c42ddb15ff16473fa20.png
simple
<table><tr><td>Names</td><td>Sequence (5&#8242;&#8211;3&#8242;)</td><td>T<sub>m</sub> (&#176;C)</td><td><i>M</i>w</td></tr><tr><td><i>Osa-miR156</i></td><td>UGA CAG AAG AGA GUG AGC AC</td><td>57.3</td><td>6279</td></tr><tr><td>(<i>Biotin</i>)<i>-miD156rk</i></td><td>(Biotin)-A CGT GCT CAC TCT CTT CTG TCA</td><td>60.5</td><td>6587+</td></tr><tr><td>(<i>DIG</i>)<i>-miD156rk</i></td><td>(DIG)-A CGT GCT CAC TCT CTT CTG TCA</td><td>60.5</td><td>6587+</td></tr><tr><td><i>miD156</i></td><td>TGA CAG AAG AGA GTG AGC AC</td><td>57.3</td><td>6201+</td></tr><tr><td><i>miD156</i>(<i>&#8722;1</i>)</td><td>TGA gAG AAG AGA GTG AGC AC</td><td>55.4</td><td>6241</td></tr><tr><td><i>miD156</i>(<i>&#8722;3</i>)</td><td>aGA CAG gAG gGA GTG AGC AC</td><td>57.4</td><td>6242</td></tr><tr><td><i>miD156</i>(<i>&#8722;5</i>)</td><td>aGA CAG gAG tGA GTc AGC gC</td><td>59.5</td><td>6193+</td></tr><tr><td><i>let-7a</i></td><td>UGA GGU AGU AGG UUG UAU AGU U</td><td>46.1</td><td>7244</td></tr><tr><td>(<i>Biotin</i>)<i>-let-7rk</i></td><td>(Biotin)-ACA ACT ATA CAA CCT ACT ACC TCA</td><td>52.6</td><td>7166+</td></tr><tr><td>(<i>DIG</i>)<i>-let-7rk</i></td><td>(DIG)-ACA ACT ATA CAA CCT ACT ACC TCA</td><td>52.6</td><td>7166+</td></tr></table>
6d02c5980c337b8074aefabd60713573fa48441fba6141e2f9129dd0a7a571e9.png
simple
<table><tr><td>Test microorganisms</td><td>Inhibition zone diameter (mm) &#165;</td><td>MIC (&#956;g/ml)</td><td>MIC of penicillin (&#956;g/ml)</td></tr><tr><td><i>Bacillus subtilis</i> MTCC 736</td><td>25 &#177; 1.0</td><td>2.0</td><td>0.5</td></tr><tr><td><i>Bacillus circulans</i> MTCC 8074</td><td>23 &#177; 1.2</td><td>3.0</td><td>0.5</td></tr><tr><td><i>Bacillus megaterium</i> MTCC 8075</td><td>26 &#177; 1.5</td><td>2.0</td><td>0.5</td></tr><tr><td><i>Staphylococcus aureus</i> MTCC 96</td><td>31 &#177; 0.9</td><td>0.5</td><td>0.25</td></tr><tr><td><i>Staphylococcus aureus</i> (Clinical isolate)</td><td>30 &#177; 0.9</td><td>0.5</td><td>0.25</td></tr><tr><td><i>Micrococcus luteus</i> MTCC 2987</td><td>25 &#177; 1.3</td><td>2.0</td><td>0.5</td></tr><tr><td><i>Mycobacterium phlei</i> MTCC 1724</td><td>25 &#177; 1.0</td><td>2.0</td><td>0.5</td></tr><tr><td><i>Mycobacterium smegmatis</i> MTCC 6</td><td>21 &#177; 0.5</td><td>3.0</td><td>1.0</td></tr><tr><td><i>Escherichia coli</i> MTCC 739</td><td></td><td>ND</td><td>ND</td></tr><tr><td><i>Klebsiela pneumoniae</i> MTCC 3040</td><td></td><td>ND</td><td>ND</td></tr><tr><td><i>Pseudomonas aeruginosa</i> MTCC 2453</td><td></td><td>ND</td><td>ND</td></tr></table>
47c204c2838c69c03d047f567a0e67561e63584249cb074fcc271a3e1fd714bc.png
complex
<table><tr><td> </td><td colspan="2">6-11y (n=3,033)</td><td colspan="2">12-19y (n=5,432)</td><td colspan="2">20-50y (n=7,635)</td><td colspan="2">&#8805;51y (n=6,752)</td><td> </td></tr><tr><td>Category<sup>1</sup></td><td>calories</td><td>% total</td><td>calories</td><td>% total</td><td>calories</td><td>% total</td><td>calories</td><td>% total</td><td>p-value</td></tr><tr><td>Grain-based desserts</td><td>139</td><td>6.9</td><td>131</td><td>5.8</td><td>129</td><td>5.5</td><td>134</td><td>7.1</td><td>&lt;0.001</td></tr><tr><td>Yeast breads</td><td>129</td><td>6.4</td><td>143</td><td>6.3</td><td>145</td><td>6.1</td><td>150</td><td>7.9</td><td>&lt;0.001</td></tr><tr><td>Pizza</td><td>119</td><td>5.9</td><td>169</td><td>7.5</td><td>109</td><td>4.6</td><td>41</td><td>2.2</td><td>&lt;0.001</td></tr><tr><td>Reduced fat milk</td><td>112</td><td>5.6</td><td>81</td><td>3.6</td><td>48</td><td>2.0</td><td>43</td><td>2.3</td><td>&lt;0.001</td></tr><tr><td>Chicken and chicken mixed dishes</td><td>104</td><td>5.2</td><td>140</td><td>6.2</td><td>141</td><td>6.0</td><td>91</td><td>4.8</td><td>&lt;0.001</td></tr><tr><td>Soda, energy and sports drinks</td><td>94</td><td>4.7</td><td>187</td><td>8.2</td><td>161</td><td>6.8</td><td>58</td><td>3.0</td><td>&lt;0.001</td></tr><tr><td>Pasta and pasta mixed dishes</td><td>93</td><td>4.6</td><td>84</td><td>3.7</td><td>84</td><td>3.6</td><td>58</td><td>3.1</td><td>&lt;0.001</td></tr><tr><td>Potato/corn/other chips</td><td>71</td><td>3.5</td><td>83</td><td>3.7</td><td>61</td><td>2.6</td><td>37</td><td>1.9</td><td>&lt;0.001</td></tr><tr><td>Ready-to-eat cereals</td><td>71</td><td>3.5</td><td>62</td><td>2.7</td><td>40</td><td>1.7</td><td>45</td><td>2.4</td><td>&lt;0.001</td></tr><tr><td>Dairy desserts</td><td>69</td><td>3.4</td><td>53</td><td>2.3</td><td>46</td><td>2.0</td><td>56</td><td>3.0</td><td>&lt;0.001</td></tr><tr><td>Sausage, franks, bacon and ribs</td><td>60</td><td>3.0</td><td>49</td><td>2.2</td><td>59</td><td>2.5</td><td>52</td><td>2.7</td><td>&lt;0.001</td></tr><tr><td>Whole milk</td><td>60</td><td>3.0</td><td>42</td><td>1.8</td><td>27</td><td>1.1</td><td>17</td><td>0.9</td><td>&lt;0.001</td></tr><tr><td>Candy</td><td>57</td><td>2.9</td><td>62</td><td>2.7</td><td>50</td><td>2.1</td><td>38</td><td>2.0</td><td>&lt;0.001</td></tr><tr><td>Beef and beef mixed dishes<sup>2</sup></td><td>55</td><td>2.8</td><td>89</td><td>3.9</td><td>102</td><td>4.3</td><td>82</td><td>4.4</td><td>&lt;0.001</td></tr><tr><td>Fruit drinks</td><td>55</td><td>2.7</td><td>57</td><td>2.5</td><td>37</td><td>1.5</td><td>18</td><td>0.9</td><td>&lt;0.001</td></tr><tr><td>Mexican mixed dishes</td><td>50</td><td>2.5</td><td>81</td><td>3.6</td><td>85</td><td>3.6</td><td>35</td><td>1.9</td><td>&lt;0.001</td></tr><tr><td>Regular cheese</td><td>50</td><td>2.5</td><td>57</td><td>2.5</td><td>61</td><td>2.6</td><td>43</td><td>2.3</td><td>0.039</td></tr><tr><td>Fried white potatoes</td><td>48</td><td>2.4</td><td>62</td><td>2.7</td><td>57</td><td>2.4</td><td>31</td><td>1.7</td><td>&lt;0.001</td></tr><tr><td>Quickbreads</td><td>32</td><td>1.6</td><td>44</td><td>1.9</td><td>61</td><td>2.6</td><td>44</td><td>2.3</td><td>&lt;0.001</td></tr><tr><td>Nuts/seeds and nut/seed mixed dishes</td><td>30</td><td>1.5</td><td>28</td><td>1.2</td><td>41</td><td>1.7</td><td>52</td><td>2.7</td><td>&lt;0.001</td></tr><tr><td>Egg and egg mixed dishes</td><td>27</td><td>1.3</td><td>30</td><td>1.3</td><td>43</td><td>1.8</td><td>43</td><td>2.3</td><td>&lt;0.001</td></tr><tr><td>Rice and rice mixed dishes</td><td>26</td><td>1.3</td><td>34</td><td>1.5</td><td>55</td><td>2.3</td><td>32</td><td>1.7</td><td>&lt;0.001</td></tr><tr><td>Burgers<sup>2</sup></td><td>25</td><td>1.2</td><td>45</td><td>2.0</td><td>36</td><td>1.5</td><td>16</td><td>0.8</td><td>&lt;0.001</td></tr><tr><td>Alcoholic beverages</td><td>0</td><td>0.0</td><td>18</td><td>0.8</td><td>125</td><td>5.3</td><td>66</td><td>3.5</td><td>&lt;0.001<sup>4</sup></td></tr><tr><td>Others<sup>3</sup></td><td>436</td><td>21.7</td><td>437</td><td>19.2</td><td>558</td><td>23.6</td><td>612</td><td>32.3</td><td>-</td></tr></table>
c1850a45927f5864b5e17d9ee87fa456795620f166793cfa6980325ae654ce70.png
simple
<table><tr><td>Parameter</td><td>All subjects%</td><td>M%</td><td>F%</td><td>P</td></tr><tr><td>Living with one&#8217;s family</td><td>63.1</td><td>78.6</td><td>51.5</td><td>&lt;0.001**</td></tr><tr><td>Regular exercise</td><td>61.7</td><td>84.1</td><td>44.5</td><td>&lt;0.001**</td></tr><tr><td>Smokes cigarettes</td><td>19.7</td><td>13.6</td><td>24.2</td><td>0.023</td></tr><tr><td>Consumed alcoholic beverages</td><td>36.1</td><td>39.3</td><td>33.7</td><td>NS</td></tr><tr><td>Experienced drugs</td><td>16.4</td><td>17.0</td><td>15.9</td><td>0.01*</td></tr></table>
6c5fd2a091a8e4ac7db53dbb1542f3740baa4d3d99e255266496b8456202818b.png
simple
<table><tr><td> </td><td>OMG</td><td>SG</td><td><i>p</i>value</td><td>OBG</td><td><i>p</i>value</td></tr><tr><td>BV/TV (%)</td><td>16.38 &#177; 5.69</td><td>29.47 &#177; 6.52*</td><td>0.001</td><td>22.39 &#177; 5.26*</td><td>0.005</td></tr><tr><td>Tb. Th (&#956;m)</td><td>48.96 &#177; 8.64</td><td>85.36 &#177; 9.35*</td><td>0.001</td><td>72.96 &#177; 7.37*</td><td>0.002</td></tr><tr><td>Tb. N (L/mm)</td><td>1.69 &#177; 0.16</td><td>2.05 &#177; 0.16*</td><td>0.005</td><td>1.89 &#177; 0.11*</td><td>0.008</td></tr><tr><td>Tb. Sp (&#956;m)</td><td>763.85 &#177; 138.24</td><td>369.42 &#177; 102.34*</td><td>0.001</td><td>587.56 &#177; 185.21*</td><td>0.008</td></tr><tr><td>ES/BS (%)</td><td>18.27 &#177; 4.82</td><td>9.50 &#177; 4.42*</td><td>0.007</td><td>14.27 &#177; 4.23**</td><td>0.044</td></tr><tr><td>Oc. N (L/mm<sup>2</sup>)</td><td>0.26 &#177; 0.08</td><td>0.10 &#177; 0.06*</td><td>0.001</td><td>0.20 &#177; 0.05**</td><td>0.039</td></tr><tr><td>O. Pm (%)</td><td>30.35 &#177; 6.32</td><td>18.84 &#177; 6.47**</td><td>0.030</td><td>31.13 &#177; 5.08</td><td>-</td></tr><tr><td>L. Pm (%)</td><td>15.03 &#177; 1.26</td><td>8.63 &#177; 1.09*</td><td>0.001</td><td>16.98 &#177; 3.25**</td><td>0.041</td></tr><tr><td>BFR/BV (%/year)</td><td>36.85 &#177; 6.23</td><td>58.27 &#177; 7.03*</td><td>0.002</td><td>61.23 &#177; 13.91*</td><td>0.001</td></tr></table>
5560376ab999413dba5540a87bfbef5d99bcd9b5e1732c0e4ffe40caf21bfd93.png
complex
<table><tr><td rowspan="2">Variable</td><td colspan="2">Experiment 1</td><td colspan="2">Experiment 2</td></tr><tr><td>controls</td><td>db cAMP</td><td>controls</td><td>db cAMP</td></tr><tr><td colspan="5">Hypothalamus</td></tr><tr><td><i>ADCYAP1</i></td><td>0.56&#177;0.02</td><td>0.78&#177;0.02*</td><td>0.41&#177;0.02</td><td>0.59&#177;0.02</td></tr><tr><td><i>GHRH#</i></td><td>0.51&#177;0.04</td><td>1.39&#177;0.05**</td><td>0.38&#177;0.05</td><td>0.72&#177;0.08*</td></tr><tr><td><i>CRH#</i></td><td>0.94&#177;0.03</td><td>1.53&#177;0.06*</td><td>0.66&#177;0.02</td><td>0.97&#177;0.05*</td></tr><tr><td><i>POMC</i></td><td>0.81&#177;0.01</td><td>1.00&#177;0.01*</td><td>0.46&#177;0.03</td><td>1.81&#177;0.01**</td></tr><tr><td><i>PC1#</i></td><td>0.33&#177;0.02</td><td>0.80&#177;0.05*</td><td>0.64&#177;0.04</td><td>0.99&#177;0.01*</td></tr><tr><td><i>PC2#</i></td><td>0.35&#177;0.02</td><td>0.55&#177;0.03</td><td>0.71&#177;0.02</td><td>0.82&#177;0.01</td></tr><tr><td colspan="5">Pituitary gland</td></tr><tr><td><i>GHRHR#</i></td><td>0.72&#177;0.01</td><td>0.95&#177;0.01*</td><td>0.45&#177;0.01</td><td>0.46&#177;0.01</td></tr><tr><td><i>GH#</i></td><td>0.50&#177;0.02</td><td>1.20&#177;0.01**</td><td>0.39&#177;0.01</td><td>0.84&#177;0.03*</td></tr><tr><td><i>CRHR</i></td><td>0.59&#177;0.03</td><td>0.62&#177;0.03</td><td>0.59&#177;0.01</td><td>0.75&#177;0.08</td></tr><tr><td><i>POMC#</i></td><td>0.49&#177;0.02</td><td>1.13&#177;0.01*</td><td>0.42&#177;0.01</td><td>0.82&#177;0.01*</td></tr><tr><td><i>TRHR</i></td><td>0.51&#177;0.01</td><td>0.58&#177;0.03</td><td>0.39&#177;0.02</td><td>0.53&#177;0.01</td></tr><tr><td><i>TSH</i></td><td>1.44&#177;0.04</td><td>1.49&#177;0.02</td><td>0.66&#177;0.04</td><td>0.88&#177;0.03</td></tr><tr><td colspan="5">Liver</td></tr><tr><td><i>GHR#</i></td><td>0.55&#177;0.01</td><td>1.06&#177;0.03**</td><td>0.86&#177;0.01</td><td>0.93&#177;0.05</td></tr><tr><td><i>IGF-1#</i></td><td>0.50&#177;0.01</td><td>1.14&#177;0.01**</td><td>0.57&#177;0.01</td><td>1.10&#177;0.02*</td></tr></table>
53a5a560327d5433f4b6a5a8bed131a819063b0497bce64c175649f75c5929ac.png
simple
<table><tr><td></td><td>SOD (% of Control)</td><td>Catalase (% of Control)</td><td>Glutathione Reductase (% of Control)</td><td>Glucose-6-phosphate Dehydrogenase (% of Control)</td></tr><tr><td>BDP 2 &#956;g</td><td>135 &#177; 2</td><td>136 &#177; 3</td><td>134 &#177; 3</td><td>132 &#177; 3</td></tr><tr><td>BDP 5 &#956;g</td><td>105 &#177; 3</td><td>102 &#177; 4</td><td>103 &#177; 3</td><td>127 &#177; 4</td></tr><tr><td>BDP 10 &#956;g</td><td>192 &#177; 5</td><td>204 &#177; 7</td><td>183 &#177; 2</td><td>237 &#177; 2</td></tr></table>
90d074576aeaa72c6a8bf9d0531c415da446f1cf3927f8dfbe2d2aa1c8f9b1d2.png
simple
<table><tr><td>Use diversity</td><td>D. sisso</td><td>A. modesta</td><td>A. nilotica</td><td>C. desidua</td><td>M. boxifolia</td><td>Z. nummularia</td><td>M. nigra</td><td>M. azidarach</td><td>W. coagulans</td><td>R. stricta</td><td>Total</td><td>Rank</td></tr><tr><td>Construction</td><td>5</td><td>2</td><td>3</td><td>1</td><td>2</td><td>3</td><td>4</td><td>3</td><td>1</td><td>1</td><td>25</td><td>2</td></tr><tr><td>Agriculture</td><td>4</td><td>2</td><td>2</td><td>3</td><td>2</td><td>2</td><td>2</td><td>1</td><td>1</td><td>1</td><td>20</td><td>5</td></tr><tr><td>Firewood</td><td>3</td><td>4</td><td>3</td><td>2</td><td>3</td><td>2</td><td>3</td><td>2</td><td>2</td><td>2</td><td>26</td><td>1</td></tr><tr><td>Fodder</td><td>2</td><td>3</td><td>3</td><td>2</td><td>2</td><td>3</td><td>3</td><td>2</td><td>3</td><td>1</td><td>24</td><td>3</td></tr><tr><td>Medicinal</td><td>1</td><td>3</td><td>3</td><td>3</td><td>2</td><td>2</td><td>1</td><td>2</td><td>3</td><td>3</td><td>23</td><td>4</td></tr><tr><td>Total</td><td>15</td><td>14</td><td>14</td><td>11</td><td>11</td><td>12</td><td>13</td><td>10</td><td>10</td><td>8</td><td> </td><td> </td></tr><tr><td>Rank</td><td>1</td><td>2</td><td>2</td><td>5</td><td>5</td><td>4</td><td>3</td><td>6</td><td>6</td><td>7</td><td> </td><td> </td></tr><tr><td>Market price in US$/Kg</td><td>0.6</td><td>0.5</td><td>0.5</td><td>0.2</td><td>0.53</td><td>0.4</td><td>0.4</td><td>0.2</td><td>0.9</td><td>0.8</td><td> </td><td> </td></tr></table>
6ebbe616b4664e86bc78707ad68aa20f079225b1ad06e26e6eeb18d85a4c69c0.png
complex
<table><tr><td rowspan="2">Group</td><td rowspan="2">n</td><td colspan="2">Expression of ELF</td></tr><tr><td>High</td><td>Low</td></tr><tr><td>Normal liver tissues</td><td>20</td><td>20(100.0%)</td><td>0(0.0%)</td></tr><tr><td>Adjacent tissues*</td><td>84</td><td>65(77.4%)</td><td>19(22.6%)</td></tr><tr><td>HCC tissues*<sup>#</sup></td><td>84</td><td>40(47.6%)</td><td>44(52.4%)</td></tr></table>
3c8cb483e8d8cce96c1982f922a50163f22511aa3f9bb4f30504645124778f67.png
complex
<table><tr><td rowspan="2">Externality category</td><td colspan="2">UK</td><td colspan="2">USA</td><td colspan="2">Germany</td></tr><tr><td>&#8364; million</td><td>&#8364; per kg a.i.</td><td>&#8364; million</td><td>&#8364; per kg a.i.</td><td>&#8364; million</td><td>&#8364; per kg a.i.</td></tr><tr><td>Pesticides in drinking water</td><td>217</td><td>9.06</td><td>851</td><td>2.00</td><td>137</td><td>5.15</td></tr><tr><td>Pollution incidents, fish deaths and monitoring costs</td><td>15</td><td>0.68</td><td>122</td><td>0.29</td><td>39</td><td>1.47</td></tr><tr><td>Biodiversity and wildlife losses</td><td>23</td><td>1.01</td><td>157</td><td>0.37</td><td>5</td><td>0.18</td></tr><tr><td>Cultural, landscape and tourism</td><td>90</td><td>3.98</td><td>nd</td><td>nd</td><td>nd</td><td>nd</td></tr><tr><td>Bee colony losses</td><td>2</td><td>0.08</td><td>109</td><td>0.26</td><td>2</td><td>0.04</td></tr><tr><td>Acute effects of pesticides on human health</td><td>2</td><td>0.08</td><td>127</td><td>0.30</td><td>21</td><td>0.80</td></tr><tr><td>Totals</td><td>349</td><td>15.5</td><td>1366</td><td>3.2</td><td>202</td><td>7.6</td></tr></table>
5e830b7476ac83b729ee5dc576a7820385e70da9602c5309a8727156fd2b4bbf.png
simple
<table><tr><td></td><td>ABTS (&#956;mol/mL)</td><td>DPPH (&#956;mol/mL)</td><td>FRAP (mmol/mL)</td></tr><tr><td>Raw hydrolysate supernatant</td><td>5.34 &#177; 1.29</td><td>0.18 &#177; 0.08</td><td>0.60 &#177; 0.04</td></tr><tr><td>After ultrasound treatment</td><td>5.92 &#177; 0.96</td><td>0.27 &#177; 0.07</td><td>0.73 &#177; 0.04</td></tr><tr><td>After autoclaving</td><td>7.03 &#177; 1.34</td><td>0.24 &#177; 0.05</td><td>0.79 &#177; 0.05</td></tr></table>
55bd195b11158447aefad7db6e93f1b6ce7ecd4290e352ff3db09f9d23d6c23d.png
simple
<table><tr><td>ADAPT-ITT phase</td><td>Methodology</td></tr><tr><td>1. Assessment</td><td>Conducted focus groups/needs assessment with Community Advisory Board (CAB)</td></tr><tr><td>2. Decision</td><td>Decision regarding type of intervention was pre-determined by evidence base; however, decisions regarding characteristics of the intervention (equipment and study structure) were made.</td></tr><tr><td>3. Administration</td><td>Theater testing was conducted during the CAB focus groups with patient stakeholders prior to intervention implementation.</td></tr><tr><td>4. Production</td><td>A draft of the tailored intervention was presented to the CAB for further feedback and approval.</td></tr><tr><td>5. Topical experts</td><td>The study team specifically recruited topical experts for CAB membership; see Table 2.</td></tr><tr><td>6. Integration</td><td>CAB input was integrated into the final adapted version of the intervention; the telehealth software company revised the software to reflect CAB recommendations.</td></tr><tr><td>7. Training</td><td>Both clinical and installation experts received training with regard to study structure and equipment use.</td></tr><tr><td>8. Testing</td><td>A pilot test of the intervention was conducted with 10 patients to identify &#8220;hands-on&#8221; challenges requiring adaptation; a focus group was then held with 4 of those patients to further explore these challenges and solutions</td></tr></table>
0264075355def2526025f8c633e2a65543d782831aeda5f69ba5d577bb7c3324.png
complex
<table><tr><td rowspan="2"></td><td colspan="4">MRI (+)</td><td colspan="2">MRI (&#8722;)</td><td colspan="3"><i>p</i> Value</td></tr><tr><td colspan="2">Systematic cores <i>n</i> = 2696 (A)</td><td colspan="2">Targeted cores <i>n</i> = 345 (B)</td><td colspan="2">Systematic cores <i>n</i> = 3542 (C)</td><td>A vs B</td><td>A vs C</td><td>B vs C</td></tr><tr><td>Cores of cancer, n (%)</td><td>333</td><td>(12.3)</td><td>108</td><td>(31.3)</td><td>355</td><td>(10.0)</td><td>&lt;0.0001</td><td>0.004</td><td>&lt;0.0001</td></tr><tr><td>Cores including GP 4 or more, n (%)</td><td>229</td><td>(8.4)</td><td>80</td><td>(23.1)</td><td>210</td><td>(5.9)</td><td>&lt;0.0001</td><td>0.0001</td><td>&lt;0.0001</td></tr><tr><td>Median percentage of core length involved by cancer (IQR)</td><td>30</td><td>(10&#8211;60)</td><td>50</td><td>(20&#8211;70)</td><td>20</td><td>(10&#8211;50)</td><td>0.0011</td><td>0.10</td><td>&lt;0.0001</td></tr></table>
7d9aebaadb881aa4e517d55ff1889719b4863403a5402700cae5423bdf5fb8a2.png
simple
<table><tr><td></td><td>Healthy Controls (<i>n</i> = 50)</td><td>Patients (<i>n</i> = 50)</td><td><i>p</i>-Value</td></tr><tr><td>Gender female&#8212;<i>n</i> (%)</td><td>15 (30.0%)</td><td>17 (34.0%)</td><td>0.83</td></tr><tr><td>Age&#8212;median years (p 25&#8211;75)</td><td>59 (50&#8211;68)</td><td>60 (51&#8211;69)</td><td>0.47</td></tr><tr><td>Serum sCD154&#8212;median ng/mL (p 25&#8211;75)</td><td>0.98 (0.80&#8211;1.46)</td><td>1.79 (1.22&#8211;3.56)</td><td>&lt;0.001</td></tr></table>
f679e38dd445c9b9520b5a0ca5ba84f44485043bcbc950372ba0edbc1ce52144.png
simple
<table><tr><td>PFT and Polygraphy (during withdrawal)</td><td><i>n</i> = 15</td></tr><tr><td>FEV1/FVC (%)</td><td>79.5 &#177; 7.4</td></tr><tr><td>FEV1 (%)</td><td>69.2 &#177; 16.4</td></tr><tr><td>FVC (%)</td><td>70.2 &#177; 17.3</td></tr><tr><td>AHI (n/h)</td><td>53.5 &#177; 26.9</td></tr><tr><td>RT &lt; 90% (%)</td><td>21.8 &#177; 24.2</td></tr><tr><td>ODI &#8805; 4% (n/h)</td><td>42.1 &#177; 39.5</td></tr></table>
8f28c08723dd38a71ae6150ee0869a55139444c238239c3a3b17cd2f5653ebe7.png
simple
<table><tr><td>No.</td><td>Species</td><td>GenBank accession No.</td><td>Locality</td><td>Voucher ID</td></tr><tr><td>1</td><td><i>Cyrtodactylus badenensis</i></td><td>KF929505</td><td>Vietnam, Tay Ninh Prov.</td><td>KIZ13689</td></tr><tr><td>2</td><td><i>C. bansocensis</i></td><td>KU175573</td><td>Laos, Khammouane Prov.</td><td>VNUF&#8211;R.2015.20</td></tr><tr><td>3</td><td><i>C. bansocensis</i></td><td>KU175574</td><td>Laos, Khammouane Prov.</td><td>NUOL-R-2015.21</td></tr><tr><td>4</td><td><i>C. bobrovi</i></td><td>KT004368</td><td>Vietnam, Hoa Binh Prov.</td><td>IEBR-A.2015.30</td></tr><tr><td>5</td><td><i>C. bobrovi</i></td><td>KT004369</td><td>Vietnam, Hoa Binh Prov.</td><td>VNMN-A.2015.61</td></tr><tr><td>6</td><td><i>C. calamei</i></td><td>KX064043</td><td>Laos, Khammouane Prov.</td><td>NUOL-R-2015.22</td></tr><tr><td>7</td><td><i>C. calamei</i></td><td>KX064044</td><td>Laos, Khammouane Prov.</td><td>VNUF-R.2015.28</td></tr><tr><td>8</td><td><i>C. cryptus</i></td><td>KF169971</td><td>Vietnam, Quang Binh Prov.</td><td>PNKB3</td></tr><tr><td>9</td><td><i>C. cryptus</i></td><td>KF169972</td><td>Vietnam, Quang Binh Prov.</td><td>PNKB4</td></tr><tr><td>10</td><td><i>C. cryptus</i></td><td>KX064038</td><td>Laos, Khammouane Prov.</td><td>VNUF-R.2014.69</td></tr><tr><td>11</td><td><i>C. elok</i></td><td>HM888478</td><td>Malaysia</td><td>ZMMU-RAN1991</td></tr><tr><td>12</td><td><i>C. darevskii</i></td><td>HQ967221</td><td>Laos, Khammouane Prov.</td><td>ZISP-FN256</td></tr><tr><td>13</td><td><i>C. darevskii</i></td><td>HQ967223</td><td>Laos, Khammouane Prov.</td><td>ZISP-FN223</td></tr><tr><td>14</td><td><i>C. hinnamnoensis</i></td><td>KX064045</td><td>Laos, Khammouane Prov.</td><td>IEBR-A.2013.89</td></tr><tr><td>15</td><td><i>C. hinnamnoensis</i></td><td>KX064046</td><td>Laos, Khammouane Prov.</td><td>IEBR-A.2013.90</td></tr><tr><td>16</td><td><i>C. hinnamnoensis</i></td><td>KX064047</td><td>Laos, Khammouane Prov.</td><td>VNUF-R.2015.11</td></tr><tr><td>17</td><td><i>C. hinnamnoensis</i></td><td>KX064048</td><td>Laos, Khammouane Prov.</td><td>VNUF-R.2015.3</td></tr><tr><td>18</td><td><i>C. hinnamnoensis</i></td><td>KX064049</td><td>Laos, Khammouane Prov.</td><td>NUOL-R-2015.9</td></tr><tr><td>19</td><td><i>C. lomyenensis</i></td><td>KJ817436</td><td>Laos, Khammouane Prov.</td><td>IEBR-KM2012.54</td></tr><tr><td>20</td><td><i>C. lomyenensis</i></td><td>KP199942</td><td>Laos, Khammouane Prov.</td><td>IEBR-KM2012.52</td></tr><tr><td>21</td><td><i>C. interdigitalis</i></td><td>KX077901</td><td>Laos, Khammouane Prov.</td><td>VNUF-R.2014.50</td></tr><tr><td>22</td><td><i>C. jaegeri</i></td><td>KT004364</td><td>Laos, Khammouane Prov.</td><td>IEBR-A.2013.55</td></tr><tr><td>23</td><td><i>C. jaegeri</i></td><td>KT004365</td><td>Laos, Khammouane Prov.</td><td>NUOL-R.2013.1</td></tr><tr><td>24</td><td><i>C. jaegeri</i></td><td>KT004366</td><td>Laos, Khammouane Prov.</td><td>VFU-TK914</td></tr><tr><td>25</td><td><i>C.</i>cf. <i>jarujini</i></td><td>KX077907</td><td>Laos, Bolikhamxay Prov.</td><td>VNUF-R.2015.7</td></tr><tr><td>26</td><td><i>C. khammouanensis</i></td><td>HM888467</td><td>Laos, Khammouane Prov.</td><td>ZISP-FN191</td></tr><tr><td>27</td><td><i>C. khammouanensis</i></td><td>HM888469</td><td>Laos, Khammouane Prov.</td><td>ZISP-FN257</td></tr><tr><td>28</td><td><i>C. kingsadai</i></td><td>KF188432</td><td>Vietnam, Phu Yen Prov.</td><td>IEBR-A.2013.3</td></tr><tr><td>29</td><td><i>C.</i>cf. <i>martini</i></td><td>KF929537</td><td>China, Yunnan Prov.</td><td>KIZ201103</td></tr><tr><td>30</td><td><i>C. multiporus</i></td><td>HM888472</td><td>Laos, Khammouane Prov.</td><td>ZISP-FN3</td></tr><tr><td>31</td><td><i>C. multiporus</i></td><td>HM888471</td><td>Laos, Khammouane Prov.</td><td>ZISP-FN2</td></tr><tr><td>32</td><td><i>C. otai</i></td><td>KT004370</td><td>Vietnam, Hoa Binh Prov.</td><td>IEBR-A.2015.26</td></tr><tr><td>33</td><td><i>C. otai</i></td><td>KT004371</td><td>Vietnam, Hoa Binh Prov.</td><td>IEBR-A.2015.27</td></tr><tr><td>34</td><td><i>C. puhuensis</i></td><td>KF929529</td><td>Vietnam, Thanh Hoa Prov.</td><td>KIZ11665</td></tr><tr><td>35</td><td><i>C.</i>aff. <i>pulchellus</i></td><td>HQ967202</td><td>Malaysia</td><td>ZMMU-R-12643-3</td></tr><tr><td>36</td><td><i>C.</i>aff. <i>pulchellus</i></td><td>HQ967203</td><td>Malaysia</td><td>ZMMU-R-12643-4</td></tr><tr><td>37</td><td><i>C. pageli</i></td><td>KJ817431</td><td>Laos, Vientiane Prov.</td><td>ZFMK91827</td></tr><tr><td>38</td><td><i>C. pageli</i></td><td>KX077902</td><td>Laos, Vientiane Prov.</td><td>NQT2010.36</td></tr><tr><td>39</td><td><i>C. pageli</i></td><td>KX077903</td><td>Laos, Vientiane Prov.</td><td>NQT2010.37</td></tr><tr><td>40</td><td><i>C. phongnhakebangensis</i></td><td>KF929526</td><td>Vietnam, Quang Binh Prov.</td><td>PNKB2011.30</td></tr><tr><td>41</td><td><i>C. phongnhakebangensis</i></td><td>KF929527</td><td>Vietnam, Quang Binh Prov.</td><td>PNKB2011.32</td></tr><tr><td>42</td><td><i>C. pseudoquadrivirgatus</i></td><td>KF169963</td><td>Vietnam, Thua Thien - Hue Prov.</td><td>ITBCZ3001</td></tr><tr><td>43</td><td><i>Cyrtodactylus</i>sp. 1</td><td>KP199949</td><td>Vietnam, Da Nang, Ba Na</td><td>ZMMU-R-13095-2</td></tr><tr><td>44</td><td><i>C. quadrivirgatus</i></td><td>HM888465</td><td>Malaysia</td><td>ZMMU-RAN1989</td></tr><tr><td>45</td><td><i>C. quadrivirgatus</i></td><td>HM888466</td><td>Malaysia</td><td>ZMMU-RAN1990</td></tr><tr><td>46</td><td><i>C. roesleri</i></td><td>KF929532</td><td>Vietnam, Quang Binh Prov.</td><td>PNKB2011.34</td></tr><tr><td>47</td><td><i>C. roesleri</i></td><td>KF929531</td><td>Vietnam, Quang Binh Prov.</td><td>PNKB2011.3</td></tr><tr><td>48</td><td><i>C. rufford</i></td><td>KU175572</td><td>Laos, Khammouane Prov.</td><td>VFU-R.2015.14</td></tr><tr><td>49</td><td><i>C. sommerladi</i></td><td>KX064039</td><td>Laos, Khammouane Prov.</td><td>IEBR-A.2015.37</td></tr><tr><td>50</td><td><i>C. sommerladi</i></td><td>KX064040</td><td>Laos, Khammouane Prov.</td><td>VNUF-R.2013.22</td></tr><tr><td>51</td><td><i>C. sommerladi</i></td><td>KX064041</td><td>Laos, Khammouane Prov.</td><td>VNUF-R.2013.87</td></tr><tr><td>52</td><td><i>C. sommerladi</i></td><td>KX064042</td><td>Laos, Khammouane Prov.</td><td>IEBR-A.2015.39</td></tr><tr><td>53</td><td><i>C. spelaeus</i></td><td>KP199947</td><td>Laos, Vientiane Prov.</td><td>ZMMU-R-13980-3</td></tr><tr><td>54</td><td><i>C. spelaeus</i></td><td>KP199948</td><td>Laos, Vientiane Prov.</td><td>ZMMU-R-13980-1</td></tr><tr><td>55</td><td><i>C. soudthichaki</i></td><td>KX077904</td><td>Laos, Khammouane Prov.</td><td>NUOL-R-2015.5</td></tr><tr><td>56</td><td><i>C. soudthichaki</i></td><td>KX077905</td><td>Laos, Khammouane Prov.</td><td>VFU-R.2015.18</td></tr><tr><td>57</td><td><i>C. soudthichaki</i></td><td>KX077906</td><td>Laos, Khammouane Prov.</td><td>IEBR-A.2015.34</td></tr><tr><td>58</td><td><i>C. teyniei</i></td><td>KJ817430</td><td>Laos, Khammouane Prov.</td><td>IEBR-KM2012.77</td></tr><tr><td>59</td><td><i>C. teyniei</i></td><td>KP199945</td><td>Laos, Khammouane Prov.</td><td>IEBR-KM2012.77</td></tr><tr><td>60</td><td><i>C. vilaphongi</i></td><td>KJ817434</td><td>Laos, Luang Prabang Prov.</td><td>NUOL-R-2013.5</td></tr><tr><td>61</td><td><i>C. vilaphongi</i></td><td>KJ817435</td><td>Laos, Luang Prabang Prov.</td><td>IEBR-A.2013.103</td></tr><tr><td>62</td><td><i>C. wayakonei</i></td><td>KJ817438</td><td>Laos, Luang Nam Tha Prov.</td><td>ZFMK91016</td></tr><tr><td>63</td><td><i>C. wayakonei</i></td><td>KP199950</td><td>Laos, Luang Nam Tha Prov.</td><td>ZMMU-R-13981-1</td></tr><tr><td>64</td><td><i>Cyrtodactylus thathomensis</i>sp. nov.</td><td>MG791873</td><td>Laos, Xiangkhouang Prov.</td><td>ZMMU-R-14919-1</td></tr><tr><td>65</td><td><i>Cyrtodactylus thathomensis</i>sp. nov.</td><td>MG791874</td><td>Laos, Xiangkhouang Prov.</td><td>ZISP 29731</td></tr><tr><td>66</td><td><i>Cyrtodactylus thathomensis</i>sp. nov.</td><td>MG791875</td><td>Laos, Xiangkhouang Prov.</td><td>ZMMU R-15384</td></tr></table>
8d3e8e32f36fde5f92b8c3a59e289c6a90207264a62644fc6e7c255e1768f8a1.png
complex
<table><tr><td><i>Clinicopathologic Characteristics</i></td><td></td></tr><tr><td colspan="2"><i>Age at diagnosis (years)</i></td></tr><tr><td> <i>Median (range)</i></td><td>62 (30&#8211;80)</td></tr><tr><td colspan="2"><i>Histology (n (%))</i></td></tr><tr><td> <i>Ductal</i></td><td>44 (90%)</td></tr><tr><td> <i>Lobular</i></td><td>5 (10%)</td></tr><tr><td colspan="2"><i>Histologycal grade (n (%))</i></td></tr><tr><td> <i>I and II</i></td><td>39 (80%)</td></tr><tr><td> <i>III</i></td><td>10 (20%)</td></tr><tr><td colspan="2"><i>UICC stage (n (%))</i></td></tr><tr><td> <i>IIB</i></td><td>6 (12%)</td></tr><tr><td> <i>IIIA + IIIB</i></td><td>11 (22%)</td></tr><tr><td> <i>IV</i></td><td>32 (65%)</td></tr><tr><td colspan="2"><i>ER status (n (%))</i></td></tr><tr><td> <i>positive</i></td><td>49 (100%)</td></tr><tr><td> <i>negative</i></td><td>0 (0%)</td></tr><tr><td colspan="2"><i>PR status(n (%))</i></td></tr><tr><td> <i>positive</i></td><td>33 (67%)</td></tr><tr><td> <i>negative</i></td><td>16 (33%)</td></tr><tr><td colspan="2"><i>HER2 status (n(%))</i></td></tr><tr><td> <i>positive</i></td><td>8 (16%)</td></tr><tr><td> <i>negative</i></td><td>41 (84%)</td></tr></table>
aaf470ea4a62c907560ecfb4ebef0931cb8634ce746c26371adac10afa76d901.png
complex
<table><tr><td colspan="6">Univariate Analysis of log(MIF) over Time</td></tr><tr><td></td><td>Den DF</td><td><i>F</i> Value </td><td><i>P</i>-Value</td><td>Slope Estimator</td><td>SD (Estimator)</td></tr><tr><td colspan="6">Continuous variable</td></tr><tr><td>Age</td><td>47.7</td><td>0.03</td><td>0.8604</td><td>&#8722;0.00239</td><td>0.01351</td></tr><tr><td>BMI</td><td>47.8</td><td>0.34</td><td>0.5605</td><td>&#8722;0.02082</td><td>0.03551</td></tr><tr><td>Baseline MIF, logarithmized</td><td>42.2</td><td>11.44</td><td>0.0016 *</td><td>0.4456</td><td>0.1317</td></tr><tr><td colspan="6">Categorical variable</td></tr><tr><td>Gender (male)</td><td>48</td><td>0.07</td><td>0.7942</td><td>&#8722;0.0857</td><td>0.3267</td></tr><tr><td>Endovascular repair</td><td>48.2</td><td>0.01</td><td>0.9172</td><td>&#8722;0.02937</td><td>0.2809</td></tr><tr><td colspan="6">Continuous variable (repeated measurements)</td></tr><tr><td>Serum creatinine</td><td>171</td><td>3.11</td><td>0.0796</td><td>0.2094</td><td>0.1187</td></tr><tr><td>Apache II</td><td>137</td><td>12.92</td><td>0.0005 *</td><td>0.04273</td><td>0.01189</td></tr></table>
1313f725e2784f51092886823d2e949d01b149400b41c8eef24843feafee61cf.png
complex
<table><tr><td rowspan="3"></td><td colspan="4">Men/Boys</td><td colspan="4">Women/Girls</td></tr><tr><td colspan="2">Caritas population</td><td colspan="2">Barcelona residents</td><td colspan="2">Caritas population</td><td colspan="2">Barcelona residents</td></tr><tr><td>Direct Assistance Services</td><td>Housing Mediation Service</td><td>Overall</td><td>Deprived social classes (IV and V)</td><td>Direct Assistance Services</td><td>Housing Mediation Service</td><td>Overall</td><td>Deprived social classes (IV and V)</td></tr><tr><td>Adults</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Regular or poor self-reported health</td><td>24.4</td><td>45.8</td><td>11.2</td><td>12.8</td><td>53.1</td><td>60.3</td><td>15.3</td><td>20.5</td></tr><tr><td> Quality of life, below the median score in Ca&#769;ritas</td><td>35.6</td><td>51.4</td><td>5.6</td><td>4.4</td><td>47.7</td><td>58.9</td><td>8.3</td><td>13.1</td></tr><tr><td> Poor mental health (Goldberg-12)</td><td>62.2</td><td>75.0</td><td>11.5</td><td>12.1</td><td>66.9</td><td>72.6</td><td>15.2</td><td>17.4</td></tr><tr><td> Self-reported depression or anxiety the previous year</td><td>57.8</td><td>70.8</td><td>5.8</td><td>6.8</td><td>63.8</td><td>86.1</td><td>9.2</td><td>10.6</td></tr><tr><td> Consumption of tranquilizers, antidepressants, or sleeping pills the previous 2 days</td><td>6.7</td><td>18.1</td><td>6.7</td><td>8.3</td><td>15.4</td><td>30.1</td><td>15.7</td><td>13.8</td></tr><tr><td> Self-reported migraine or frequent headaches during the previous year</td><td>28.9</td><td>38.9</td><td>3.6</td><td>3.6</td><td>62.3</td><td>65.8</td><td>8.5</td><td>7.9</td></tr><tr><td> Self-reported backache during the previous year</td><td>37.8</td><td>63.4</td><td>12.0</td><td>15.8</td><td>73.9</td><td>83.6</td><td>19.2</td><td>18.9</td></tr><tr><td> 6 or less daily mean hours of sleep (working days)</td><td>45.5</td><td>56.9</td><td>22.1</td><td>22.1</td><td>53.1</td><td>61.1</td><td>24.9</td><td>30.6</td></tr><tr><td>Children</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Regular or poor health status</td><td>22.7</td><td>7.1</td><td>0.9</td><td>NE</td><td>22.9</td><td>22.0</td><td>1.7</td><td>NE</td></tr><tr><td> Poor mental health (SDQ questionnaire)</td><td>61.3</td><td>45.2</td><td>3.1</td><td>NE</td><td>37.5</td><td>25.0</td><td>5.1</td><td>NE</td></tr><tr><td> Recurrent otitis during the previous year</td><td>20.5</td><td>19.0</td><td>3.6</td><td>NE</td><td>31.9</td><td>19.5</td><td>1.6</td><td>NE</td></tr><tr><td> Not having had breakfast everyday before leaving home</td><td>15.9</td><td>26.2</td><td>6.4</td><td>15.4</td><td>20.8</td><td>22.0</td><td>8.4</td><td>14.5</td></tr></table>
60d4493932654c6124434518290e9e39082e9c15ed3e8d0d340e68e0159bb3c9.png
simple
<table><tr><td>GENE</td><td>Sense</td><td>Anti-sense</td><td>Product</td></tr><tr><td>ABCA1</td><td>5&#8217;-AGGCCCAGACCTGTAAATGC-3&#8217;</td><td>5&#8217;-CTCACCAACCTTGCCAACTTC-3&#8217;</td><td>450 bp</td></tr><tr><td>SREBP2</td><td>5&#8217;-CAGACGCCAAGATGCACAAG-3&#8217;</td><td>5&#8217;-TGGCTCATCTTTGACCTTTGC-3&#8217;</td><td>323 bp</td></tr><tr><td>CYP7A1</td><td>5&#8217;-CATTTGGGCACAGAAGCATTG-3&#8217;</td><td>5&#8217;-AGGCAGCGGTCTTTGAGTTAG-3&#8217;</td><td>174 bp</td></tr><tr><td>NR1H3 (LXR &#945;)</td><td>5&#8217;-AAGAAACTGAAGCGGCAAGA-3&#8217;</td><td>5&#8217;-AGCAATGAGCAAGGCAAACT-3&#8217;</td><td>555 bp</td></tr><tr><td>PRKAA2 (AMPK &#945;2)</td><td>5&#8217;-TCAATCGTTCTGTCGCCAC-3&#8217;</td><td>5&#8217;-ATACGGTTTGCTCTGACTTCG-3&#8217;</td><td>530 bp</td></tr><tr><td>HMGCR</td><td>5&#8217;-CTCCGCAGGCTATTTGTTCAG-3&#8217;</td><td>5&#8217;-GCTAAGAGCGTTCGTGGGTC-3&#8217;</td><td>620 bp</td></tr><tr><td>GAPDH</td><td>5&#8217;-ACTCCTCCACCTTTGACGCTG-3&#8217;</td><td>5&#8217;-CTCTCTTCCTCTTGTGCTCTTGC-3&#8217;</td><td>182 bp</td></tr></table>
cc20c14192693553cc876e9af53cf18e3bfb9fcdd44eb3af131a6f1c1d7d5fff.png
complex
<table><tr><td rowspan="2">District</td><td colspan="7">Percentage (%) scores of:</td></tr><tr><td>Total points</td><td>Reports</td><td>Management of supplies</td><td>Information management</td><td>Meetings</td><td>Technical support</td><td>Referrals</td></tr><tr><td>Nadowli</td><td>58.9</td><td>77.4</td><td>71.7</td><td>69.7</td><td>33.6</td><td>42.5</td><td>58.6</td></tr><tr><td>Wa Municipal</td><td>73.3</td><td>90.3</td><td>87.5</td><td>88.5</td><td>51.0</td><td>61.1</td><td>61.6</td></tr><tr><td>Wa East</td><td>54.1</td><td>74.5</td><td>78.9</td><td>74.8</td><td>39.2</td><td>0.0</td><td>57.2</td></tr><tr><td>Wa West</td><td>60.1</td><td>64.1</td><td>66.8</td><td>74.0</td><td>43.1</td><td>0.0</td><td>52.6</td></tr><tr><td>Lawra</td><td>30.0</td><td>46.6</td><td>30.6</td><td>28.8</td><td>26.0</td><td>12.9</td><td>35.2</td></tr></table>
a6246d7d834288580d860748e292faef70496dfcff3e77abce6735f401687f17.png
simple
<table><tr><td>Parameter</td><td>Estimate</td><td>Std. error</td><td><i>p</i>-Value</td></tr><tr><td>Intercept</td><td>&#8722;3.96</td><td>2.90</td><td>0.18</td></tr><tr><td>Stimulation</td><td>1.46</td><td>0.74</td><td>0.05</td></tr><tr><td>Time</td><td>0.39</td><td>0.10</td><td>&lt;0.01</td></tr><tr><td>Quadrant</td><td>3.27</td><td>0.74</td><td>&lt;0.01</td></tr><tr><td>Sequence</td><td>5.99</td><td>0.98</td><td>&lt;0.01</td></tr><tr><td>Time &#215; sequence</td><td>&#8722;0.18</td><td>0.07</td><td>0.01</td></tr><tr><td>Variance components</td><td></td><td>SD</td><td></td></tr><tr><td>Subjects</td><td></td><td>6.72</td><td></td></tr></table>
af44567ac0b03eeff603ea6b874d2ecb0f3e01c3899d60dcd239881db822f3f5.png
simple
<table><tr><td></td><td>Total</td><td>Cases</td><td>Controls</td><td><i>p<sup>a</sup></i></td></tr><tr><td>Number of participants (%)<sup>b</sup></td><td>2,042 (100)</td><td>681 (33.4)</td><td>1361 (66.7)</td><td></td></tr><tr><td>Sex (%)</td><td></td><td></td><td></td><td>0.955</td></tr><tr><td> Male</td><td>1,390 (68.1)</td><td>463 (68.0)</td><td>927 (68.1)</td><td></td></tr><tr><td> Female</td><td>652 (31.9)</td><td>218 (32.0)</td><td>434 (31.9)</td><td></td></tr><tr><td>Age (mean, year)</td><td>56.1 &#177; 9.3</td><td>56.5 &#177; 9.6</td><td>56.0 &#177; 9.1</td><td>0.258</td></tr><tr><td>Body mass index (kg/m<sup>2</sup>)</td><td></td><td></td><td></td><td>0.437</td></tr><tr><td> &lt; 25</td><td>1,374 (67.3)</td><td>466 (68.4)</td><td>908 (66.7)</td><td></td></tr><tr><td> &#8805; 25</td><td>668 (32.7)</td><td>215 (31.6)</td><td>453 (33.3)</td><td></td></tr><tr><td>Tobacco smoking (%)</td><td></td><td></td><td></td><td>0.088</td></tr><tr><td> Never</td><td>909 (44.5)</td><td>308 (45.2)</td><td>601 (44.2)</td><td></td></tr><tr><td> Former</td><td>742 (36.3)</td><td>228 (33.5)</td><td>514 (37.8)</td><td></td></tr><tr><td> Current</td><td>391 (19.15)</td><td>145 (21.3)</td><td>246 (18.1)</td><td></td></tr><tr><td>Alcohol drinking (%)</td><td></td><td></td><td></td><td>0.001</td></tr><tr><td> Never</td><td>619 (30.3)</td><td>208 (30.5)</td><td>411 (30.2)</td><td></td></tr><tr><td> Former</td><td>220 (10.8)</td><td>97 (14.2)</td><td>123 (9.0)</td><td></td></tr><tr><td>Current</td><td>1,203 (58.9)</td><td>376 (55.2)</td><td>827 (60.76)</td><td></td></tr><tr><td>Regular exercise (%)</td><td></td><td></td><td></td><td>&lt; .001</td></tr><tr><td> Yes</td><td>1,029 (50.4)</td><td>217 (31.9)</td><td>812 (59.6)</td><td></td></tr><tr><td> No</td><td>1,006 (49.3)</td><td>646 (68.1)</td><td>542 (39.8)</td><td></td></tr><tr><td> Missing</td><td>7 (0.3)</td><td>-</td><td>7 (0.5)</td><td></td></tr><tr><td>First-degree family history of colorectal cancer (%)</td><td></td><td></td><td></td><td>0.039</td></tr><tr><td> Yes</td><td>127 (6.2)</td><td>53 (7.8)</td><td>74 (5.4)</td><td></td></tr><tr><td> No</td><td>1,915 (93.8)</td><td>628 (92.2)</td><td>1,287 (94.6)</td><td></td></tr><tr><td>Marital status (%)</td><td></td><td></td><td></td><td>&lt; .001</td></tr><tr><td> Married or with a partner</td><td>1,800 (88.2)</td><td>576 (84.6)</td><td>1,224 (89.9)</td><td></td></tr><tr><td> Single</td><td>171 (8.4)</td><td>82 (12.0)</td><td>89 (6.5)</td><td></td></tr><tr><td> Never married</td><td>65 (3.2)</td><td>21 (3.1)</td><td>44 (3.2)</td><td></td></tr><tr><td> Missing</td><td>6 (0.3)</td><td>2 (0.3)</td><td>4 (0.3)</td><td></td></tr><tr><td>Education level (%)</td><td></td><td></td><td></td><td>&lt; .001</td></tr><tr><td> Middle school graduate or less</td><td>439 (21.5)</td><td>249 (36.6)</td><td>190 (14.0)</td><td></td></tr><tr><td> High school graduate</td><td>855 (41.9)</td><td>261 (38.3)</td><td>594 (43.6)</td><td></td></tr><tr><td> College graduate or more</td><td>739 (36.2)</td><td>171 (25.1)</td><td>568 (41.7)</td><td></td></tr><tr><td> Missing</td><td>9 (0.4)</td><td>-</td><td>9 (0.7)</td><td></td></tr><tr><td>Household income (10,000 won/month)</td><td></td><td></td><td></td><td>&lt; .001</td></tr><tr><td> &lt; 100</td><td>176 (8.6)</td><td>91 (13.4)</td><td>85 (6.3)</td><td></td></tr><tr><td> 100&#8211;200</td><td>373 (18.3)</td><td>143 (21.0)</td><td>230 (16.9)</td><td></td></tr><tr><td> 201&#8211;400</td><td>883 (43.2)</td><td>301 (44.2)</td><td>582 (42.8)</td><td></td></tr><tr><td> &gt; 400</td><td>570 (28.0)</td><td>146 (21.4)</td><td>424 (31.2)</td><td></td></tr><tr><td> Missing</td><td>40 (2.0)</td><td>-</td><td>40 (2.9)</td><td></td></tr><tr><td>Dietary zinc intake (mg/day)</td><td>8.4 &#177; 1.6</td><td>8.1 &#177; 1.4</td><td>8.5 &#177; 1.6</td><td>&lt; .001</td></tr></table>
f7db0643b1a67f4a74d23d2adbfdeab4140b464bad6c80a0c41e8adfe8b71506.png
complex
<table><tr><td colspan="5">Time I</td><td colspan="4">Time II</td></tr><tr><td>As range (&#956;g/dL)</td><td>Freq</td><td>Freq%</td><td>CumulFreq</td><td>CumulFreq%</td><td>Freq</td><td>Freq%</td><td>CumulFreq</td><td>CumulFreq%</td></tr><tr><td>2.800&#8211;2.999</td><td>0</td><td>0.0</td><td>204</td><td>100.0</td><td>0</td><td>0.0</td><td>204</td><td>100.0</td></tr><tr><td>2.600&#8211;2.799</td><td>1</td><td>0.5</td><td>204</td><td>100.0</td><td>0</td><td>0.0</td><td>204</td><td>100.0</td></tr><tr><td>2.400&#8211;2.599</td><td>1</td><td>0.5</td><td>203</td><td>99.5</td><td>0</td><td>0.0</td><td>204</td><td>100.0</td></tr><tr><td>2.200&#8211;2.399</td><td>2</td><td>1.0</td><td>202</td><td>99.0</td><td>0</td><td>0.0</td><td>204</td><td>100.0</td></tr><tr><td>2.000&#8211;2.199</td><td>0</td><td>0.0</td><td>200</td><td>98.0</td><td>1</td><td>0.5</td><td>204</td><td>100.0</td></tr><tr><td>1.800&#8211;1.999</td><td>7</td><td>3.4</td><td>200</td><td>98.0</td><td>0</td><td>0.0</td><td>203</td><td>99.5</td></tr><tr><td>1.600&#8211;1.799</td><td>7</td><td>3.4</td><td>193</td><td>94.6</td><td>0</td><td>0.0</td><td>203</td><td>99.5</td></tr><tr><td>1.400&#8211;1.599</td><td>14</td><td>6.9</td><td>186</td><td>91.2</td><td>0</td><td>0.0</td><td>203</td><td>99.5</td></tr><tr><td>1.200&#8211;1.399<sup>a</sup></td><td>26</td><td>12.7</td><td>172</td><td>84.3</td><td>1</td><td>0.5</td><td>203</td><td>99.5</td></tr><tr><td>1.000&#8211;1.199</td><td>23</td><td>11.3</td><td>146</td><td>71.6</td><td>4</td><td>2.0</td><td>202</td><td>99.0</td></tr><tr><td>0.800&#8211;0.999</td><td>28</td><td>13.7</td><td>123</td><td>60.3</td><td>11</td><td>5.4</td><td>198</td><td>97.1</td></tr><tr><td>0.600&#8211;0.799</td><td>42</td><td>20.6</td><td>95</td><td>46.6</td><td>14</td><td>6.9</td><td>187</td><td>91.7</td></tr><tr><td>0.400&#8211;0.599</td><td>34</td><td>16.7</td><td>53</td><td>26.0</td><td>66</td><td>32.4</td><td>173</td><td>84.8</td></tr><tr><td>0.200&#8211;0.399</td><td>13</td><td>6.4</td><td>19</td><td>9.3</td><td>81</td><td>39.7</td><td>107</td><td>52.5</td></tr><tr><td>0.000&#8211;0.199</td><td>6</td><td>2.9</td><td>6</td><td>2.9</td><td>26</td><td>12.7</td><td>26</td><td>12.7</td></tr><tr><td>Total</td><td>204</td><td>100.0</td><td>204</td><td>100.0</td><td>204</td><td>100.0</td><td>204</td><td>100.0</td></tr></table>
08567b14928e412f189d4a9b25f2c5f42caecbad9b700ed454e40a555eca9e62.png
simple
<table><tr><td>Manufacturer</td><td>Name of Product</td><td>Vaccine Type</td><td>Adjuvant</td><td>Produced in</td><td>Age Recommended</td></tr><tr><td>Abbot healthcare</td><td>Trivalent: Influvac Imuvac</td><td>Inactivated</td><td>None</td><td>Egg</td><td>From 6 months</td></tr><tr><td>AstraZeneca</td><td>Quadrivalent: Fluenz Tetra (Flumist quadrivalent) Trivalent: Fluarix Alpharix Influsplit</td><td>Live attenuated</td><td>None</td><td>Egg</td><td>From 24 months to 17 years Trivalent: From 6 months</td></tr><tr><td>GlaxoSmithKline</td><td>Quadrivalent: Fluarix Tetra Alpharix Tetra Influsplit Tetra</td><td>Inactivated/split</td><td>None</td><td>Egg</td><td>From 3 years</td></tr><tr><td>Novartis</td><td>Trivalent: Agrippal Fluvirin Fluad</td><td>Inactivated/subunit</td><td>None None Squalene (MF59)</td><td>Egg</td><td>From 6 years From 4 years From 65 years</td></tr><tr><td>Pfizer/CSl Australia</td><td>Trivalent: Afluria Enzira</td><td>Inactivated</td><td>None</td><td>Egg</td><td>From 5 years</td></tr><tr><td>Sanofi Pasteur</td><td>Trivalent: Vaxigrip Intanza 9 &#956;g Intanza 15&#956;g</td><td>Inactivated</td><td>None</td><td>Egg</td><td>From 6 months From 18-59 years From 60 years</td></tr></table>
83cf2b681da281391e654a6b22df7a1ae4a84df0aaccd95a1e5ee6b05084d3ef.png
simple
<table><tr><td>Stimuli</td><td><i>P1</i></td><td><i>N1</i></td><td><i>P2</i></td><td><i>N2</i></td><td><i>P3</i></td><td>LPP</td></tr><tr><td>FSS, RSS</td><td>100&#8211;140 ms</td><td>130&#8211;150 ms</td><td>150&#8211;220 ms</td><td>150&#8211;250 ms</td><td>250&#8211;500 ms</td><td></td></tr><tr><td>AA, RA, IA</td><td>100&#8211;180 ms</td><td>170&#8211;220 ms</td><td>190&#8211;330 ms</td><td>275&#8211;350 ms</td><td>340&#8211;590 ms</td><td>500&#8211;1000 ms</td></tr></table>
5adb3ffa6640fad0ea8753e5847c4fa39a0e48506d2b072b249f6bdcba21e654.png
complex
<table><tr><td rowspan="2">Variable</td><td>Bacteremic</td><td>Non-bacteremic</td><td rowspan="2"><i>p</i> value</td></tr><tr><td>(<i>n</i> = 38)</td><td>(<i>n</i> = 106)</td></tr><tr><td>Age under 50 years</td><td>9 (23.7)</td><td>25 (23.6)</td><td>1.00</td></tr><tr><td>Age 50&#8211;64 years</td><td>13 (34.2)</td><td>31 (29.2)</td><td>0.68</td></tr><tr><td>Age 65&#8211;74 years</td><td>6 (15.8)</td><td>27 (25.5)</td><td>0.27</td></tr><tr><td>Age over 75 years</td><td>10 (26.3)</td><td>23 (21.7)</td><td>0.65</td></tr><tr><td>Immunocompromised</td><td>7 (18.4)</td><td>11 (10.4)</td><td>0.25</td></tr><tr><td>Shock at ICU admission</td><td>23 (60.5)</td><td>63 (59.4)</td><td>1.00</td></tr><tr><td>Invasive mechanical ventilation</td><td>28 (73.7)</td><td>78 (73.6)</td><td>1.00</td></tr><tr><td>Acute kidney injury</td><td>17 (44.7)</td><td>43 (40.6)</td><td>0.70</td></tr><tr><td>Rapid radiographic spread</td><td>24 (63.2)</td><td>53 (50.0)</td><td>0.19</td></tr><tr><td>Combined therapy</td><td>34 (89.5)</td><td>86 (81.1)</td><td>0.31</td></tr><tr><td>Antibiotic initiated 0 to 3 hours</td><td>18 (47.4)</td><td>55 (51.9)</td><td>0.71</td></tr><tr><td>ICU mortality</td><td>11 (28.9)</td><td>26 (24.5)</td><td>0.67</td></tr></table>
8e4dbfd1470eb3ec1efeac9e87715e15990f62bbe1c59ed03ce8171bf9352c26.png
complex
<table><tr><td>Monitoring dates</td><td colspan="4">Albendazole treated risk cattle cohort</td><td colspan="4">Placebo treated risk cattle cohort</td></tr><tr><td> </td><td>Trypanosome cases</td><td>Cattle-months</td><td>IDR</td><td>95 % CI<sup>5</sup></td><td>Trypanosome cases</td><td>Cattle-months</td><td>IDR</td><td>95 % CI<sup>5</sup></td></tr><tr><td>Intervention area</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Jun - Nov 2008</td><td>1</td><td>247.6</td><td>0.004</td><td>0.000-0.020</td><td>8</td><td>293.6</td><td>0.031</td><td>0.010-0.050</td></tr><tr><td>Nov 2008 &#8211; Feb 2009</td><td>1</td><td>192.8</td><td>0.005</td><td>0.000-0.026</td><td>0</td><td>209.2</td><td>0</td><td>0</td></tr><tr><td>Feb &#8211; Jun 2009</td><td>1</td><td>240.3</td><td>0.004</td><td>0.000-0.021</td><td>1</td><td>256.3</td><td>0.004</td><td>0.000-0.019</td></tr><tr><td>Jun &#8211; Nov 2009</td><td>0</td><td>517.5</td><td>0</td><td>0</td><td>0</td><td>493.1</td><td>0</td><td>0</td></tr><tr><td>Total</td><td>3<sup>1</sup></td><td>1198.2</td><td>0.003</td><td>0.001-0.007</td><td>9<sup>2</sup></td><td>1252.2</td><td>0.007</td><td>0.004-0.013</td></tr><tr><td>Control area</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Jun - Nov 2008</td><td>3</td><td>56.7</td><td>0.053</td><td>0.013-0.144</td><td>4</td><td>65.2</td><td>0.061</td><td>0.019-0.148</td></tr><tr><td>Nov 2008 &#8211; Feb 2009</td><td>3</td><td>52.8</td><td>0.057</td><td>0.014-0.155</td><td>2</td><td>48.6</td><td>0.041</td><td>0.007-0.136</td></tr><tr><td>Feb &#8211; Jun 2009</td><td>7</td><td>45.2</td><td>0.155</td><td>0.068-0.306</td><td>5</td><td>49.7</td><td>0.10</td><td>0.037-0.223</td></tr><tr><td>Jun &#8211; Nov 2009</td><td>2</td><td>73.8</td><td>0.027</td><td>0.005-0.090</td><td>2</td><td>108.2</td><td>0.002</td><td>0.003-0.061</td></tr><tr><td>Total</td><td>15<sup>3</sup></td><td>228.5</td><td>0.066</td><td>0.038-0.106</td><td>13<sup>4</sup></td><td>272.3</td><td>0.048</td><td>0.027-0.080</td></tr></table>
bf0eaefa3e97937dad30f08242fc7b85906288e5df0fd435676d531e866f9222.png
simple
<table><tr><td> </td><td>Method 1</td><td>Method 2</td><td>Method 3</td><td>Method 4</td><td>Method 5</td></tr><tr><td>Mean</td><td>0.20</td><td>0.10</td><td>0.10</td><td>0.23</td><td>0.45</td></tr><tr><td>SD</td><td>0.24</td><td>0.22</td><td>0.21</td><td>0.24</td><td>0.15</td></tr><tr><td>Method 1</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Method 2</td><td>0.93</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Method 3</td><td>0.93</td><td>0.99</td><td> </td><td> </td><td> </td></tr><tr><td>Method 4</td><td>0.98</td><td>0.90</td><td>0.92</td><td> </td><td> </td></tr><tr><td>Method 5</td><td>0.29</td><td>0.14</td><td>0.19</td><td>0.38</td><td> </td></tr></table>
4e4334c84aab8478e5f337b7e2923a0a80d222e874ad8395b66f47befb480de6.png
complex
<table><tr><td></td><td>% (N)</td></tr><tr><td colspan="2">Histological subtype</td></tr><tr><td> Epidermoid carcinoma</td><td>100 (392/392)</td></tr><tr><td colspan="2">Initial anatomic site</td></tr><tr><td> Glans</td><td>74.0(216/392)</td></tr><tr><td> Undetermined<sup>a</sup></td><td>15.0 (44/392)</td></tr><tr><td> Foreskin</td><td>11.0 (32/392)</td></tr><tr><td colspan="2">Histologic grade</td></tr><tr><td> Grade 1</td><td>38.9 (123/316)</td></tr><tr><td> Grade 2</td><td>54.1 (171/316)</td></tr><tr><td> Grade 3</td><td>7.0 (22/316)</td></tr><tr><td colspan="2">Primary tumor (T stage)</td></tr><tr><td> Tis</td><td>0.6 (2/335)</td></tr><tr><td> T1(a, b)</td><td>33.0 (107/335)</td></tr><tr><td> T2</td><td>44.6 (145/335)</td></tr><tr><td> T3</td><td>17.5 (57/335)</td></tr><tr><td> T4</td><td>4.3 (14/335)</td></tr><tr><td colspan="2">Regional lymph nodes (N stage)</td></tr><tr><td> N0</td><td>46.0 (107/233)</td></tr><tr><td> N1</td><td>8.6 (20/233)</td></tr><tr><td> N2</td><td>28.7 (67/233)</td></tr><tr><td> N3</td><td>16.7 (39/233)</td></tr><tr><td colspan="2">Distant meta&#769;stasis</td></tr><tr><td> M0</td><td>45.9 (180/392)</td></tr><tr><td> M1</td><td>2.3 (9/392)</td></tr><tr><td> Mx</td><td>51.8 (203/392)</td></tr><tr><td colspan="2">Staging</td></tr><tr><td> Stage 0</td><td>26.0 (95/366)</td></tr><tr><td> Stage 1</td><td>30.0 (110/366)</td></tr><tr><td> Stage 2</td><td>26.5 (97/366)</td></tr><tr><td> Stage 3</td><td>15.3 (56/366)</td></tr><tr><td> Stage 4</td><td>2.2 (8/366)</td></tr></table>
8eb9a821eba2ca39ee7988c8b764c7a121665b757e36185f14c80e5dd70a715c.png
complex
<table><tr><td>Study</td><td>Measure</td><td>Assessed variable</td><td>Time of assessment</td></tr><tr><td>Study 1 cultural validity</td><td>Cultural Relevance Questionnaire (CRQ)</td><td>Culturally adapted internet-delivered treatment</td><td>Completed by experts and users before the trial.</td></tr><tr><td rowspan="5">Study 2 efficacy trial</td><td>Patient Health Questionnaire (PHQ-9)</td><td>Depression symptoms</td><td>Baseline, post-treatment and follow- up</td></tr><tr><td>Generalised Anxiety Disorder 7 (GAD-7).</td><td>Anxiety symptoms</td><td>Baseline, post-treatment and follow- up</td></tr><tr><td>Sociodemographic &amp; Clinical History Questionnaire</td><td>Gender, age, marital status, education, occupation, socioeconomic status and clinical history</td><td>Baseline</td></tr><tr><td>Helpful and Hindering Aspects of Treatment (HAT)</td><td>Helpful and hindering aspects of treatment</td><td>After each session</td></tr><tr><td>Satisfaction with Treatment (SAT)</td><td>Satisfaction with therapy</td><td>Post-treatment</td></tr></table>
c82df6135a76ba28de2644f83dc4af6e166c1e663617f6c431b5b9d501c4fb29.png
simple
<table><tr><td>Author, date</td><td>Conclusions</td><td>Contributions</td></tr><tr><td>Levy et al., 2009 [1]</td><td>AUT is not a monogenic disorder, in many individuals may be the result of a complex amalgam of multiple simultaneous genetic variations, and present morphological and functional brain abnormalities.</td><td>Highlights the importance of understanding biological markers, patterns of cortical organization and connectivity in advancing the treatment of AUT.</td></tr><tr><td>Baron-Cohen et al., 2000 [19]</td><td>Unlike those with TD in ToM tests, patients with AS or AUT do not show activation of the amygdala when making mentalistic inferences from the eyes. The amygdala may be one of many abnormal neural regions in AUT.</td><td>Highlights the role of the amygdala in the symptoms of ASD.</td></tr><tr><td>Castelli et al., 2002 [20]</td><td>The physiological cause for the mentalizing dysfunction in AUT can be a bottleneck in the interaction between perceptual processes of higher and lower order.</td><td>Relates the difficulties in understanding socially relevant movements in AUT to information processing in the visual cortex.</td></tr><tr><td>Brunet et al., 2000 [21]</td><td>Attribution of intentions to others is associated with a complex brain activity involving the right medial prefrontal cortex when a nonverbal task is used.</td><td>Presents data that validate hypothesis of abnormal brain activation in patients with impaired mentalizing.</td></tr><tr><td>Castelli et al., 2000 [22]</td><td>The regions responsible for processing information about intentions and the ability to make inferences about the mental states of others may have evolved from the ability to make inferences about the actions of other creatures.</td><td>Suggests evolutionary history for the abilities that make ToM.</td></tr><tr><td>Pierce et al., 2001 [23]</td><td>Compared to typical individuals, autistic "see" faces using different neural systems, unique to each individual.</td><td>Experiential factors play an important role in the development of the fusiform facial area, related to the processing faces.</td></tr><tr><td>Scholz et al., 2009 [24]</td><td>There are neighboring but distinct regions in the right temporo-parietal junction involved in ToM and orientation of attention.</td><td>Identifies difficulties in the investigation of brain functions that occupy regions close to each other or overlapping.</td></tr><tr><td>Johnson et al., 2007 [25]</td><td>There is involvement of frontal and parietal attentional networks and sub-cortical excitatory systems in ADHD and a prefrontal cortex dysfunction in children with HFA.</td><td>Provides detailed evidence of dysfunction in sustained attention in ADHD significantly higher than in HFA.</td></tr><tr><td>Kana et al., 2007 [26]</td><td>The neural circuit linked to inhibition in individuals with ASD is atypically activated and is less synchronized, leaving inhibition to be accomplished by strategic control rather than automatically.</td><td>Identifies dysfunction in inhibitory cortical level, being disorganized and desynchronized.</td></tr><tr><td>Schultz et al., 2000 [27]</td><td>Individuals with ASD demonstrate during facial discrimination, a pattern of brain activity consistent with strategies based on characteristics or traits more typical of the perception of non-facial objects.</td><td>Highlights possible dysfunction in processing stimuli related to biological and inanimate objects in ASD.</td></tr><tr><td>Dapretto et al., 2006 [28]</td><td>A dysfunctional mirror neuron system may underlie the social deficits of autism.</td><td>Substantiates hypothesis of the importance of mirror neurons in the development of social functions.</td></tr><tr><td>Jones et al., 2008 [29]</td><td>The behavior of eye contact is already noticeably compromised in children two years of age with ASD, accompanying the person with autism for life.</td><td>Subsidizes and highlights the importance of early diagnosis of ASD.</td></tr></table>
e134c2b4c5e80ad103830c67e02ff61fad77f105749180fb3e4da05d92e83c46.png
simple
<table><tr><td><i>Manufacturer</i></td><td><i>Diameter (mm)</i></td><td><i>Mean Life</i></td><td><i>St. Dev</i></td></tr><tr><td>Ace</td><td>4.5</td><td>10115</td><td>4426</td></tr><tr><td>Biomet</td><td>4.0</td><td>1502</td><td>615</td></tr><tr><td></td><td>5.0</td><td>360881</td><td>469213</td></tr><tr><td>Synthes</td><td>3.9</td><td>1413</td><td>490</td></tr><tr><td></td><td>4.9</td><td>16121</td><td>3426</td></tr><tr><td>Howmedica &#8211; Alta</td><td>3.7</td><td>888</td><td>608</td></tr><tr><td></td><td>5.0</td><td>1000000</td><td>-<sup>1</sup></td></tr><tr><td>Russell-Taylor</td><td>4.5</td><td>18238</td><td>4009</td></tr><tr><td></td><td>5.0</td><td>46736</td><td>13702</td></tr><tr><td>S&amp;N &#8211; Trigen</td><td>5.0</td><td>436248</td><td>487507</td></tr></table>
fc0cee67fd38f859dae03dcd8c22c91a028be1f537605e67aeae3adf07c05070.png
simple
<table><tr><td>Study</td><td>Parameter estimate</td><td>Standard error</td><td>Weight in fixed effects model</td><td>Weight in random effects model</td></tr><tr><td>ACT</td><td>&#8722;0.01220</td><td>0.01223</td><td>0.03788</td><td>0.11078</td></tr><tr><td>LRC</td><td>0.01437</td><td>0.01063</td><td>0.05015</td><td>0.11780</td></tr><tr><td>DASH</td><td>&#8722;0.01362</td><td>0.02348</td><td>0.01028</td><td>0.06695</td></tr><tr><td>DISC</td><td>0.18181</td><td>0.25408</td><td>0.00009</td><td>0.00105</td></tr><tr><td>DPP</td><td>&#8722;0.02086</td><td>0.00964</td><td>0.06098</td><td>0.12205</td></tr><tr><td>MRFIT</td><td>0.00043</td><td>0.00608</td><td>0.15329</td><td>0.13568</td></tr><tr><td>PREMIER</td><td>&#8722;0.01004</td><td>0.01002</td><td>0.05644</td><td>0.12043</td></tr><tr><td>TOHP I</td><td>&#8722;0.02998</td><td>0.01887</td><td>0.01591</td><td>0.08289</td></tr><tr><td>TOHP II</td><td>&#8722;0.00820</td><td>0.01495</td><td>0.02535</td><td>0.09887</td></tr><tr><td>WHI</td><td>0.02844</td><td>0.00310</td><td>0.58964</td><td>0.14351</td></tr></table>
a2478cce2a95d5661516a22750d5d84e474b7416426b2e7dddfec500af78e214.png
complex
<table><tr><td rowspan="2">Outcome</td><td colspan="2">Per 10 &#956;g/m<sup>3</sup> PM<sub>2.5</sub> exposure</td><td colspan="2">Per 10 ppb NO<sub>2</sub> exposure</td></tr><tr><td>mmHg (95% CI)</td><td><i>p</i>-Value</td><td>mmHg (95% CI)</td><td><i>p</i>-Value</td></tr><tr><td>Systolic blood pressure</td></tr><tr><td>Model 1</td><td>0.8 (0.3, 1.3)</td><td>0.002</td><td>&#8211;0.4 (&#8211;0.6, &#8211;0.1)</td><td>0.003</td></tr><tr><td>Model 2</td><td>0.9 (0.4, 1.4)</td><td>&lt; 0.001</td><td>0.2 (&#8211;0.1, 0.4)</td><td>0.17</td></tr><tr><td>Model 3</td><td>1.9 (1.0, 2.8)</td><td>&lt; 0.001</td><td>0.3 (0.0, 0.6)</td><td>0.07</td></tr><tr><td>Model 4</td><td>1.5 (0.7, 2.4)</td><td>&lt; 0.001</td><td>0.2 (0.0, 0.5)</td><td>0.09</td></tr><tr><td>Model 5</td><td>1.4 (0.6, 2.3)</td><td>&lt; 0.001</td><td>0.2 (0.0, 0.5)</td><td>0.10</td></tr><tr><td>Diastolic blood pressure</td></tr><tr><td>Model 1</td><td>0.8 (0.4, 1.1)</td><td>&lt; 0.001</td><td>&#8211;0.3 (&#8211;0.5, &#8211;0.2)</td><td>&lt; 0.001</td></tr><tr><td>Model 2</td><td>0.7 (0.4, 1.1)</td><td>&lt; 0.001</td><td>&#8211;0.1 (&#8211;0.3, 0.0)</td><td>0.11</td></tr><tr><td>Model 3</td><td>0.7 (0.1, 1.3)</td><td>0.03</td><td>&#8211;0.2 (&#8211;0.4, 0.0)</td><td>0.10</td></tr><tr><td>Model 4</td><td>0.5 (&#8211;0.1, 1.0)</td><td>0.12</td><td>&#8211;0.2 (&#8211;0.4, 0.0)</td><td>0.06</td></tr><tr><td>Model 5</td><td>0.4 (&#8211;0.2, 1.0)</td><td>0.15</td><td>&#8211;0.2 (&#8211;0.4, 0.0)</td><td>0.05</td></tr><tr><td>Mean arterial pressure</td></tr><tr><td>Model 1</td><td>0.8 (0.4, 1.2)</td><td>&lt; 0.001</td><td>&#8211;0.3 (&#8211;0.5, &#8211;0.2)</td><td>&lt; 0.001</td></tr><tr><td>Model 2</td><td>0.8 (0.4, 1.2)</td><td>&lt; 0.001</td><td>0.0 (&#8211;0.2, 0.1)</td><td>0.72</td></tr><tr><td>Model 3</td><td>1.1 (0.4, 1.7)</td><td>0.001</td><td>0.0 (&#8211;0.2, 0.2)</td><td>0.84</td></tr><tr><td>Model 4</td><td>0.8 (0.2, 1.4)</td><td>0.01</td><td>0.0 (&#8211;0.2, 0.2)</td><td>0.67</td></tr><tr><td>Model 5</td><td>0.8 (0.2, 1.4)</td><td>0.01</td><td>&#8211;0.1 (&#8211;0.2, 0.2)</td><td>0.63</td></tr><tr><td>Pulse pressure</td></tr><tr><td>Model 1</td><td>0.1 (&#8211;0.3, 0.4)</td><td>0.73</td><td>&#8211;0.1 (&#8211;0.2, 0.1)</td><td>0.59</td></tr><tr><td>Model 2</td><td>0.2 (&#8211;0.2, 0.5)</td><td>0.42</td><td>0.3 (0.1, 0.5)</td><td>&lt; 0.001</td></tr><tr><td>Model 3</td><td>1.2 (0.6, 1.9)</td><td>&lt; 0.001</td><td>0.4 (0.2, 0.6)</td><td>&lt; 0.001</td></tr><tr><td>Model 4</td><td>1.1 (0.4, 1.7)</td><td>&lt; 0.001</td><td>0.4 (0.2, 0.6)</td><td>&lt; 0.001</td></tr><tr><td>Model 5</td><td>1.0 (0.4, 1.7)</td><td>0.001</td><td>0.4 (0.2, 0.6)</td><td>&lt; 0.001</td></tr><tr><td colspan="5">Model 1: Included age and race/ethnicity. Model 2: Model 1 + household income, education, marital status, working &#8805; 20 hr per week outside the home, perceived stress score, and socioeconomic status <i>z</i>-score. Model 3: Model 2 + Rural-Urban Continuum Codes and unpenalized thin-plate regression splines for latitude and longitude. Model 4: Model 3 + body mass index, waist-to-hip ratio, smoking status, alcohol use, history of diabetes, and history of hypercholesterolemia. Model 5: Model 4 + blood pressure medication use. </td></tr></table>
4f90cde2798352f9850700d626ce3401ec07bc69d9b00ae45fc4c0ffcb12d6e0.png
complex
<table><tr><td><i>Data collection</i></td><td><i>Measurement tool</i></td><td><i>Data collected method</i></td><td><i>Timeframe</i></td></tr><tr><td rowspan="2"><i>Measurement of total ulcer area</i></td><td><i>Centimetres squared;</i></td><td rowspan="2"><i>Research assistant</i></td><td rowspan="2"><i>Weekly: Post-treatment until healed or at 6 months</i></td></tr><tr><td><i>Tracing from photographs and counting squares</i></td></tr><tr><td rowspan="2"><i>Measurement of ulcer depth</i></td><td><i>Centimetres;</i></td><td rowspan="2"><i>Treating podiatrist</i></td><td rowspan="2"><i>Weekly: post-treatment until healed or at 6 months</i></td></tr><tr><td><i>Using sterile probe</i></td></tr><tr><td><i>Ulcer pain</i></td><td><i>Visual analogue pain scale 100 mm</i></td><td><i>Treating podiatrist</i></td><td><i>Weekly: Pre-treatment, during treatment, post-treatment until healed or 6 months</i></td></tr><tr><td><i>Quality of life</i></td><td><i>EQ-5D-5 L tool</i></td><td><i>Participant questionnaire</i></td><td><i>Initial treatment, at 3 months, at 6 months</i></td></tr><tr><td colspan="4"><i>Direct health costs</i></td></tr><tr><td><i>Consumable costs for treatments</i></td><td><i>In dollars for each treatment</i></td><td><i>Treating podiatrist</i></td><td><i>Weekly, per participant until healed or at 6 months</i></td></tr><tr><td><i>Medicare Benefit Scheme (MBS)</i></td><td><i>MBS Care database, in dollars</i></td><td><i>Extraction from MBS database</i></td><td><i>End of project for each participant from initial to final treatment</i></td></tr><tr><td><i>Pharmaceutical Benefit Scheme (PBS)</i></td><td><i>PBS Care database, in dollars</i></td><td><i>Extraction from PBS database</i></td><td><i>End of project for each participant from initial to final treatment</i></td></tr><tr><td rowspan="4"><i>Inpatient data</i></td><td><i>Monash Health:</i></td><td rowspan="4"><i>Hospitalisation costs</i></td><td><i>Monash Health:</i></td></tr><tr><td rowspan="2"><i>Admission duration, reason for admission, imaging and interventions, obtained from the patient record and from the Victorian Admitted Episodes Database</i></td><td><i>End of project</i></td></tr><tr><td rowspan="2"><i>External organisation: End of project</i></td></tr><tr><td><i>External organisation: Admission duration, reason for admission, costs of any surgery for diabetes-related foot ulcers will be estimated using WEISS funding</i></td></tr><tr><td><i>Hospital based services (outpatient data)</i></td><td><i>Hours &#8211; time spent</i></td><td><i>Treating podiatrist</i></td><td><i>Weekly per participant until healed or at 6 months</i></td></tr><tr><td><i>Medical imaging and pathology for outpatients</i></td><td><i>Dollars &#8211; hospital based costs</i></td><td><i>Treating podiatrist</i></td><td><i>Monthly per participant until healed or at 6 months</i></td></tr><tr><td><i>Community based services</i></td><td><i>Number and cost of appointments</i></td><td><i>Participant interview</i></td><td><i>Monthly until healed or at 6 months</i></td></tr><tr><td><i>Private health appointments</i></td><td><i>Number and cost of appointments, eligibility for private health subsidies</i></td><td><i>Participant interview</i></td><td><i>Monthly until healed or at 6 months</i></td></tr><tr><td><i>Royal District Nursing Service for ulcer management</i></td><td><i>Frequency and cost of service</i></td><td><i>Participant interview</i></td><td><i>Monthly until healed or at 6 months</i></td></tr><tr><td><i>Ongoing ulcer care products</i></td><td><i>Valued using market prices</i></td><td><i>Participant interview</i></td><td><i>Monthly until healed or at 6 months</i></td></tr><tr><td><i>Parking costs for appointments</i></td><td><i>Dollars</i></td><td><i>Participant interview</i></td><td><i>Monthly until healed or at 6 months</i></td></tr><tr><td><i>Transportation costs to travel to appointments</i></td><td><i>Estimated through Australian Tax Office car rate cents per km</i></td><td><i>Participant interview</i></td><td><i>Monthly until healed or at 6 months</i></td></tr><tr><td colspan="4"><i>Productivity costs</i></td></tr><tr><td><i>Time taken from work for participant and/or any family member</i></td><td><i>Salary and hours taken from work</i></td><td><i>Participant/family interview</i></td><td><i>Monthly until healed or at 6 months</i></td></tr></table>
b43dd7f555cee5d5fc4a012fe4cca9c61b26dc3566838416e03f232abc816915.png
simple
<table><tr><td>RI of interest</td><td>Tc-99m</td><td></td><td></td><td>I-123</td><td></td><td></td></tr><tr><td>Acquisition (photopeak count ratio)</td><td>None</td><td>FiveEW-woDR</td><td>FiveEW</td><td>None</td><td>FiveEW-woDR</td><td>FiveEW</td></tr><tr><td>Single (%)</td><td>25.6</td><td>4.1</td><td>2.4</td><td>14.3</td><td>72.6</td><td>39.9</td></tr><tr><td>Dual (Tc:I = 1:9) (%)</td><td>700.4</td><td>27.0</td><td>35.5</td><td>14.3</td><td>72.6</td><td>39.9</td></tr><tr><td>Dual (Tc:I = 2:8) (%)</td><td>325.5</td><td>9.7</td><td>17.1</td><td>14.3</td><td>72.6</td><td>39.9</td></tr><tr><td>Dual (Tc:I = 3:7) (%)</td><td>200.5</td><td>4.0</td><td>11.0</td><td>14.3</td><td>72.6</td><td>40.0</td></tr><tr><td>Dual (Tc:I = 4:6) (%)</td><td>138.1</td><td>1.1</td><td>7.9</td><td>14.3</td><td>72.6</td><td>40.0</td></tr><tr><td>Dual (Tc:I = 5:5) (%)</td><td>100.6</td><td>0.6</td><td>6.1</td><td>14.3</td><td>72.6</td><td>40.0</td></tr><tr><td>Dual (Tc:I = 6:4) (%)</td><td>75.6</td><td>1.8</td><td>4.8</td><td>14.3</td><td>72.7</td><td>40.1</td></tr><tr><td>Dual (Tc:I = 7:3) (%)</td><td>57.7</td><td>2.6</td><td>4.0</td><td>14.3</td><td>72.7</td><td>40.2</td></tr><tr><td>Dual (Tc:I = 8:2) (%)</td><td>44.3</td><td>3.2</td><td>3.3</td><td>14.3</td><td>72.8</td><td>40.5</td></tr><tr><td>Dual (Tc:I = 9:1) (%)</td><td>33.9</td><td>3.7</td><td>2.8</td><td>14.3</td><td>73.1</td><td>41.2</td></tr><tr><td>Dual (mean &#177; SD) (%)</td><td>186.3 &#177; 213.8</td><td>6.0 &#177; 8.3</td><td>10.3 &#177; 10.5</td><td>14.3 &#177; 0</td><td>72.7 &#177; 0.2</td><td>40.2 &#177; 0.4</td></tr></table>
459fe837ca75064b579fda70549eee69b7480b91d75e6941033589d431a55af7.png
simple
<table><tr><td>6MWD (m)</td><td>Overall</td><td>GROC &lt; 2</td><td>GROC &#8805; 2</td><td><i>P </i>value</td></tr><tr><td>Pre-intervention</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Mean (SD)</td><td>294.7 (78.4)</td><td>269.2 (93.9)</td><td>297.0 (77.3)</td><td>0.41</td></tr><tr><td>Post-intervention</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Mean (SD)</td><td>330.0 (77.6)</td><td>278.4 (91.9)</td><td>334.3 (75.3)</td><td>0.091</td></tr><tr><td>Change from baseline</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Mean (SD)</td><td>35.0 (45.2) *</td><td>9.3 (18.2)</td><td>37.3 (46.2)</td><td>0.011 <sup>&#8224;</sup></td></tr></table>
ae44977bf54ce0f848a585d3ac7a9300004a227e4ebac450a76d3796f7f4cc96.png
simple
<table><tr><td>Explanatory variable</td><td><i>d.f.</i></td><td>Mean square</td><td><i>F</i>-value</td><td><i>P</i></td></tr><tr><td>TREATMENT</td><td>2</td><td>0.4168</td><td>5.08</td><td>0.0302</td></tr><tr><td>LARVAE</td><td>1</td><td>0.2237</td><td>3.44</td><td>0.0670</td></tr><tr><td>TREATMENT (DAY)</td><td>9</td><td>0.0831</td><td>1.28</td><td>0.2603</td></tr><tr><td>Error</td><td>92</td><td>0.0651</td><td></td><td></td></tr></table>
c800c337893951d4df94edb3fdd8fd35c30e88b357d08ab0f3fc7f5764da7aef.png
simple
<table><tr><td>Variable (units)</td><td>Men</td><td>Women</td><td><i>P</i> value</td></tr><tr><td>N</td><td>141</td><td>16</td><td>-</td></tr><tr><td>Age (y)</td><td>41.9 &#177; 9.7</td><td>42.0 &#177; 6.1</td><td>0.98</td></tr><tr><td>Body mass (kg)</td><td>75.0 &#177; 9.2</td><td>56.6 &#177; 7.1</td><td>&lt;0.01</td></tr><tr><td>Body surface area (m<sup>2</sup>)</td><td>1.9 &#177; 0.1</td><td>1.6 &#177; 0.1</td><td>&lt;0.01</td></tr><tr><td>Height (m)</td><td>176 &#177; 7</td><td>161 &#177; 5</td><td>&lt;0.01</td></tr><tr><td>Body mass index (kg &#183; m<sup>&#8722;2</sup>)</td><td>24.1 &#177; 2.2</td><td>20.9 &#177; 1.2</td><td>&lt;0.01</td></tr><tr><td>Best race time (min)</td><td>217 &#177; 34</td><td>240 &#177; 32</td><td>0.03</td></tr><tr><td>Running experience (yr)</td><td>10.7 &#177; 9.8</td><td>9.5 &#177; 5.9</td><td>0.67</td></tr><tr><td>Completed marathons (number)</td><td>7 &#177; 3</td><td>5 &#177; 2</td><td>0.42</td></tr><tr><td>Average training distance &#183; week<sup>&#8722;1</sup> (km)</td><td>62.7 &#177; 27.8</td><td>59.5 &#177; 26.6</td><td>0.69</td></tr><tr><td>Training sessions of running &#183; week<sup>&#8722;1</sup> (number)</td><td>4.3 &#177; 1.0</td><td>4.4 &#177; 1.0</td><td>0.68</td></tr></table>
1984ca90a11435591b8b8f9897905a0dddce601c1449e7c0e99cb71e3a287c9f.png
simple
<table><tr><td>Murine models of infection</td><td>Immune outcome</td><td>Reference</td></tr><tr><td>FrCasE virus (MLV)</td><td>Enhanced memory cellular CD8+ responses</td><td><sup>43</sup></td></tr><tr><td>Influenza</td><td>Prolonged Ag presentation by DC; enhanced proliferation of CD8+ T cells</td><td><sup>64</sup></td></tr><tr><td>RSV</td><td>Modification of CD4+/CD8+ T-cell balance</td><td><sup>65</sup></td></tr><tr><td>LCMV</td><td>Innate immune activation;induction of virus-specific CD8+ T-cell response</td><td><sup>66</sup></td></tr></table>
6649ed5f10f28514d7a35c5ac4a81c4b656aff95822fe5ab7c444d9393900b5a.png
complex
<table><tr><td>N test group=23N control group=23</td><td>Baseline</td><td>3 months</td><td>6 months</td><td>Difference t0-t3</td><td>Difference t0-t6</td></tr><tr><td colspan="6">BoP (%)</td></tr><tr><td>TestControl</td><td>17.0 (13.0, 19.0) ***16.0 (13.0, 19.0) ***</td><td>6.0 (4.0, 9.0) *** &#8224;&#8224;9.0 (5.0, 12.0) ***</td><td>12.0 (9.0, 14.0) ***11.0 (8.0, 17.0) ***</td><td>10.0 (8.0, 12.0) *** &#8224;9.0 (6.0, 11.0) ***</td><td>5.0 (3.0, 8.0) ***4.0 (2.0, 7.0) ***</td></tr><tr><td>TestControl</td><td>16.5 &#177; 4.016.7 &#177; 5.5</td><td>6.2 &#177; 3.08.7 &#177; 3.7</td><td>11.5 &#177; 4.913.0 &#177; 6.7</td><td>10.3 &#177; 3.18.0 &#177; 4.0</td><td>5.0 &#177; 4.03.7 &#177; 5.6</td></tr><tr><td colspan="6">SBI (%)</td></tr><tr><td>Test groupControl group</td><td>18.0 (14.0, 23.0) ***16.0 (14.0, 21.0) ***</td><td>12.0 (8.0, 15.0) ***11.0 (7.0, 15.0) ***</td><td>13.0 (11.0, 18.0) ***13.0 (11.0, 15.0) ***</td><td>7.0 (4.0, 11.0) ***8.0 (4.0, 12.0) ***</td><td>4.0 (0.0, 8.0) **4.0 (3.0, 8.0) **</td></tr><tr><td>TestControl</td><td>18.7 &#177; 6.518.1 &#177; 5.6</td><td>11.8 &#177; 4.410.3 &#177; 4.3</td><td>13.4 &#177; 5.213.4 &#177; 3.8</td><td>6.8 &#177; 5.27.8 &#177; 5.4</td><td>5.2 &#177; 5.74.7 &#177; 5.9</td></tr><tr><td colspan="6">Mean PD (mm)</td></tr><tr><td>TestControl</td><td>3.3 (3.1, 3.6) ***3.2 (3.1, 3.5) ***</td><td>2.1 (2.0, 2.2) *** &#8224;&#8224;2.2 (2.0, 2.5) ***</td><td>2.2 (2.0, 2.3) *** &#8224;&#8224;2.3 (2.1, 2.5) ***</td><td>1.2 (0.8, 1.2) *** &#8224;1.0 (0.9, 1.5) ***</td><td>1.1 (0.8, 1.2) ***1.0 (0.8, 1.5) ***</td></tr><tr><td>TestControl</td><td>3.3 &#177; 0.43.3 &#177; 0.3</td><td>2.1 &#177; 0.32.3 &#177; 0.2</td><td>2.2 &#177; 0.22.3 &#177; 0.3</td><td>1.2 &#177; 0.31.0 &#177; 0.3</td><td>1.1 &#177; 0.31.0 &#177; 0.3</td></tr><tr><td colspan="6">Mean AL (mm)</td></tr><tr><td>Test groupControl group</td><td>3.5 (3.3, 3.7) ***3.5 (3.3, 3.7) ***</td><td>2.5 (2.4, 2.6) *** &#8224;&#8224;2.8 (2.5, 2.9) ***</td><td>2.6 (2.5, 2.7) *** &#8224;&#8224;2.8 (2.7, 3.0) ***</td><td>0.9 (0.8, 1.1) *** &#8224;&#8224;&#8224;0.7 (0.6, 0.8) ***</td><td>0.9 (0.7, 1.0) *** &#8224;&#8224;&#8224;0.6 (0.5, 0.7) ***</td></tr><tr><td>TestControl</td><td>3.5 &#177; 0.23.4 &#177; 0.3</td><td>2.5 &#177; 0.32.7 &#177; 0.3</td><td>2.6 &#177; 0.22.8 &#177; 0.3</td><td>1.0 &#177; 0.30.7 &#177; 0.2</td><td>0.9 &#177; 0.20.6 &#177; 0.2</td></tr><tr><td colspan="6">Sites PD &gt; 5 mm (n)</td></tr><tr><td>TestControl</td><td>18.0 (13.0,27.0)19.0 (9.0, 25.0)</td><td>0.0 (0.0, 2.0)1.0 (0.0, 5.0)</td><td>0.0 (0.0, 2.0)2.0 (0.0, 6.0)</td><td>17.0 (13.0, 26.0)17.0 (8.0, 22.0)</td><td>18.0 (13.0, 25.0)16.0 (7.0, 22.0)</td></tr><tr><td>TestControl</td><td>18.7 &#177; 10.319.4 &#177; 13.0</td><td>1.1 &#177; 1.72.7 &#177; 3.3</td><td>1.3 &#177; 2.23.4 &#177; 4.2</td><td>17.6 &#177; 9.216.7 &#177; 10.2</td><td>17.4 &#177; 8.716.0 &#177; 9.9</td></tr><tr><td colspan="6">Mean sites PD&gt;5 mm (n)</td></tr><tr><td>TestControl</td><td>5.3 (5.0, 5.5)5.3 (5.0, 5.5)</td><td>3.0 (2.8, 3.3)3,0 (2.8, 3.3)</td><td>3.0 (2.8, 3.5)3.0 (2.8, 3.3)</td><td>2.5 (2.3, 2.5)2.3 (2.0, 2.5)</td><td>2.3 (2.0, 2.5)2.3 (2.0, 2.3)</td></tr><tr><td>TestControl</td><td>5.3 &#177; 0.45.3 &#177; 0.4</td><td>3.0 &#177; 0.43.0 &#177; 0.3</td><td>3.1 &#177; 0.43.1 &#177; 0.3</td><td>2.3 &#177; 0.22.3 &#177; 0.3</td><td>2.2 &#177; 0.32.2 &#177; 0.4</td></tr><tr><td colspan="6">Sites AL &gt; 5 mm (n)</td></tr><tr><td>TestControl</td><td>21.0 (14.0, 31.0)21.0 (12.0, 27.0)</td><td>2.0 (0.0, 3.0)2.0 (0.0, 6.0)</td><td>1.0 (0.0, 3.0)3.0 (0.0, 8.0)</td><td>21.0 (14.0, 27.0)16.0 (12.0, 24.0)</td><td>21.0 (14.0, 27.0)16.0 (9.0, 23.0)</td></tr><tr><td>Test Control</td><td>21.3 &#177; 11.522.3 &#177; 14.7</td><td>2.1 &#177; 3.33.4 &#177; 4.2</td><td>2.4 &#177; 3.74.3 &#177; 4.4</td><td>19.2 &#177; 9.518.9 &#177; 11.7</td><td>18.9 &#177; 9.118.0 &#177; 11.7</td></tr><tr><td colspan="6">Mean sites AL &gt; 5 mm (n)</td></tr><tr><td>TestControl</td><td>4.0 (4.0, 4.3)4.0 (4.0, 4.3)</td><td>2.8 (2.8, 3.0)3.0 (2.8, 3.0)</td><td>3.0 (3.0, 3.0)3.0 (3.0, 3.3)</td><td>1.3 (1.3, 1.5)1.3 (1.0, 1.5)</td><td>1.0 (1.0, 1.3)1.0 (0.8, 1.3)</td></tr><tr><td>TestControl</td><td>4.2 &#177; 0.34.1 &#177; 0.2</td><td>2.9 &#177; 0.22.9 &#177; 0.3</td><td>3.1 &#177; 0.23.1 &#177; 0.2</td><td>1.3 &#177; 0.21.2 &#177; 0.3</td><td>1.1 &#177; 0.31.0 &#177; 0.2</td></tr></table>
e81e51086e51987d098b2ae83650ce85dd42abef966cdf1123e391cdefc7bbe5.png
complex
<table><tr><td></td><td colspan="4">Fungi</td><td colspan="4">Bacteria</td></tr><tr><td></td><td colspan="2">Endorhiza</td><td colspan="2">Rhizosphere</td><td colspan="2">Endorhiza</td><td colspan="2">Rhizosphere</td></tr><tr><td></td><td><i>P</i></td><td><i>D</i></td><td><i>P</i></td><td><i>D</i></td><td><i>P</i></td><td><i>D</i></td><td><i>P</i></td><td><i>D</i></td></tr><tr><td>C/W</td><td>0.3</td><td>0.8</td><td>0.5</td><td>0.3</td><td>0.03</td><td>8.2</td><td>0.03</td><td>7.8</td></tr><tr><td>C/G</td><td>0.03</td><td>8.7</td><td>0.06</td><td>2.9</td><td>0.03</td><td>5.2</td><td>0.03</td><td>7.1</td></tr><tr><td>C/GW</td><td>0.03</td><td>12.4</td><td>0.17</td><td>1.2</td><td>0.03</td><td>8.4</td><td>0.03</td><td>22.1</td></tr><tr><td>W/G</td><td>0.03</td><td>14.7</td><td>0.3</td><td>1.3</td><td>0.06</td><td>5.2</td><td>0.03</td><td>12.4</td></tr><tr><td>W/GW</td><td>0.03</td><td>23</td><td>0.08</td><td>1.3</td><td>0.1</td><td>5.1</td><td>0.03</td><td>13.4</td></tr><tr><td>G/GW</td><td>0.2</td><td>3.6</td><td>0.03</td><td>2.1</td><td>0.06</td><td>2.4</td><td>0.03</td><td>14.4</td></tr></table>